

28 October 2020 EMA/CHMP/558121/2020 Human Medicines Division

#### Committee for medicinal products for human use (CHMP)

Final Minutes for the meeting on 20-23 July 2020

Chair: Harald Enzmann - Vice-Chair: Bruno Sepodes

#### **Disclaimers**

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the <a href="CHMP meeting highlights">CHMP meeting highlights</a> once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

#### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



### **Table of contents**

1.	Introduction 8
1.1.	Welcome and declarations of interest of members, alternates and experts8
1.2.	Adoption of agenda8
1.3.	Adoption of the minutes8
2.	Oral Explanations 9
2.1.	Pre-authorisation procedure oral explanations9
2.1.1.	Arikayce liposomal - amikacin - Orphan - EMEA/H/C/0052649
2.1.2.	Gamifant - emapalumab - Orphan - EMEA/H/C/0043869
2.1.3.	Jyseleca - filgotinib - EMEA/H/C/0051139
2.1.4.	Zynrelef - bupivacaine / meloxicam - EMEA/H/C/00520510
2.2.	Re-examination procedure oral explanations10
2.3.	Post-authorisation procedure oral explanations10
2.4.	Referral procedure oral explanations10
2.4.1.	Ibuprofen Kabi – EMEA/H/A-29(4)/1498
3.	Initial applications 11
3.1.	Initial applications; Opinions11
3.1.1.	Adakveo - crizanlizumab - Orphan - EMEA/H/C/00487411
3.1.2.	Arikayce liposomal - amikacin - Orphan - EMEA/H/C/005264
3.1.3.	Arsenic trioxide medac - arsenic trioxide - EMEA/H/C/005218 12
3.1.4.	Ayvakyt - avapritinib - Orphan - EMEA/H/C/00520812
3.1.5.	Blenrep - belantamab mafodotin - Orphan - EMEA/H/C/004935
3.1.6.	Calquence - acalabrutinib - Orphan - EMEA/H/C/005299
3.1.7.	Dapivirine Vaginal Ring 25 mg - dapivirine - Article 58 - EMEA/H/W/002168 14
3.1.8.	Elzonris - tagraxofusp - Orphan - EMEA/H/C/00503114
3.1.9.	Equidacent - bevacizumab - EMEA/H/C/00518115
3.1.10.	Fampridine Accord - fampridine - EMEA/H/C/005359
3.1.11.	Gamifant - emapalumab - Orphan - EMEA/H/C/004386
3.1.12.	Jyseleca - filgotinib - EMEA/H/C/00511316
3.1.13.	Zynrelef - bupivacaine / meloxicam - EMEA/H/C/00520517
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)
3.2.1.	meningococcal group A, C, W135 and Y conjugate vaccine - Article 28 - EMEA/H/C/00508417
3.2.2.	melphalan - EMEA/H/C/005173
3.2.3.	rilpivirine - EMEA/H/C/005060
3.2.4.	influenza quadrivalent vaccine (rDNA) - EMEA/H/C/005159
3.2.5.	cabotegravir - EMEA/H/C/004976

3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)19	
3.3.1.	bevacizumab - EMEA/H/C/005327	
3.3.2.	abiraterone acetate - EMEA/H/C/005368	
3.3.3.	bevacizumab - EMEA/H/C/005611	
3.3.4.	leuprorelin - EMEA/H/C/00503420	
3.3.5.	cenobamate - EMEA/H/C/00537720	
3.3.6.	hydrocortisone - Orphan - EMEA/H/C/005105	
3.3.7.	insulin human (rDNA) - EMEA/H/C/00533121	
3.3.8.	selumetinib - Orphan - EMEA/H/C/005244	
3.3.9.	lonafarnib - Orphan - EMEA/H/C/00527121	
3.3.10.	berotralstat - Orphan - EMEA/H/C/00513821	
3.3.11.	lumasiran - Orphan - EMEA/H/C/00504021	
3.3.12.	tanezumab - EMEA/H/C/00518922	
3.3.13.	relugolix / estradiol / norethisterone acetate - EMEA/H/C/00526722	
3.3.14.	ponesimod - EMEA/H/C/005163	
3.3.15.	adalimumab - EMEA/H/C/005188	
3.4.	Update on on-going initial applications for Centralised procedure23	
3.4.1.	dasatinib - EMEA/H/C/00544623	
3.4.2.	dasatinib - EMEA/H/C/00531723	
3.4.3.	dostarlimab - EMEA/H/C/005204	
3.4.4.	istradefylline - EMEA/H/C/00530824	
3.4.5.	ofatumumab - EMEA/H/C/00541024	
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/200424	
3.6.	Initial applications in the decision-making phase24	
3.6.1.	Cabazitaxel Accord - cabazitaxel - EMEA/H/C/00517824	
3.6.2.	Kaftrio - elexacaftor / tezacaftor / ivacaftor - Orphan - EMEA/H/C/00526924	
3.7.	Withdrawals of initial marketing authorisation application25	
3.7.1.	Rayoqta - abicipar pegol - EMEA/H/C/00510325	
3.7.2.	Abilify MyCite - aripiprazole - EMEA/H/C/005062	
4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 25	
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulatio (EC) No 1234/2008; Opinion25	'n
4.1.1.	Pemetrexed Hospira - pemetrexed - EMEA/H/C/003970/X/0021	
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulatio (EC) No 1234/2008; Day 180 list of outstanding issues26	'n
4.2.1.	Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G	
4.2.2.	Trulicity - dulaglutide - EMEA/H/C/002825/X/004527	

4.2.3.	Ultomíris - ravulizumab - EMEA/H/C/004954/X/0004/G
4.2.4.	Xarelto - rivaroxaban - EMEA/H/C/000944/X/0074/G27
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question
4.3.1.	Hulio - adalimumab - EMEA/H/C/004429/X/0016
4.3.2.	Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0012
4.3.3.	Tysabri - natalizumab - EMEA/H/C/000603/X/0116
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/200829
4.4.1.	Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008
5.	Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 30
5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information
5.1.1.	Crysvita - burosumab - Orphan - EMEA/H/C/004275/II/0010/G
5.1.2.	Dupixent - dupilumab - EMEA/H/C/004390/II/0027
5.1.3.	Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/000531
5.1.4.	Humira - adalimumab - EMEA/H/C/000481/II/0198
5.1.5.	HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/005632
5.1.6.	Imbruvica - ibrutinib - Orphan - EMEA/H/C/003791/II/0059
5.1.7.	Imfinzi - durvalumab - EMEA/H/C/004771/II/0014/G
5.1.8.	Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0085
5.1.9.	Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0086
5.1.10.	Latuda - lurasidone - EMEA/H/C/002713/II/002934
5.1.11.	NovoThirteen - catridecacog - EMEA/H/C/002284/II/0026/G35
5.1.12.	Olumiant - baricitinib - EMEA/H/C/004085/II/0016
5.1.13.	Opdivo - nivolumab - EMEA/H/C/003985/II/0080
5.1.14.	Prezista - darunavir - EMEA/H/C/000707/II/0107
5.1.15.	Recarbrio - imipenem / cilastatin / relebactam - EMEA/H/C/004808/II/000137
5.1.16.	Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0022 37
5.1.17.	Votubia - everolimus - Orphan - EMEA/H/C/002311/II/0061
5.1.18.	Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0015
5.1.19.	Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0048
5.1.20.	WS1782 Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS1782/0006 Vimpat - lacosamide - EMEA/H/C/000863/WS1782/0088

5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/200840
5.2.1.	Spravato - esketamine - EMEA/H/C/004535/II/0001/G
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/200840
6.	Ancillary medicinal substances in medical devices 41
6.1.	Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions41
6.2.	Update of Ancillary medicinal substances in medical devices41
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 41
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)41
7.1.1.	Remdesivir - EMEA/H/K/5622/CU
7.1.2.	Sofosbuvir - EMEA/H/K/003891/CU41
7.1.3.	Sofosbuvir/Ledipasvir - EMEA/H/K/003892/CU
7.1.4.	Daclatasvir – EMEA/H/K/003867/CU
8.	Pre-submission issues 42
8.1.	Pre-submission issue42
8.1.1.	artesunate - H0005550
8.1.2.	autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub family D (ALD), member 1, (ABCD1) cDNA - Orphan - H0003690
8.2.	Priority Medicines (PRIME)43
8.2.1.	List of applications received43
8.2.2.	Recommendation for PRIME eligibility43
9.	Post-authorisation issues 43
9.1.	Post-authorisation issues43
9.1.1.	Desloratadine ratiopharm - desloratadine - EMEA/H/C/002404/II/0023/G 43
9.1.2.	Duzallo - allopurinol/lesinurad - EMEA/H/C/00441244
9.1.3.	Edistride - dapagliflozin - EMEA/H/C/004161/R/0038
9.1.4.	Erleada - apalutamide - EMEA/H/C/004452/II/0006
9.1.5.	Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0030
9.1.6.	Juluca - dolutegravir / rilpivirine - EMEA/H/C/004427/II/0016 Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0001 Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0069 Tivicay - dolutegravir - EMEA/H/C/002753/II/0052
9.1.7.	Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0026/G, Orphan
9.1.8.	Qutenza - capsaicin - EMEA/H/C/000909/II/0048
9.1.9.	Tecentriq - atezolizumab - EMEA/H/C/004143/II/0036

9.1.10.	WS1587/G Abasaglar-EMEA/H/C/002835/WS1587/0028/G Humalog- EMEA/H/C/000088/WS1587/0178/G	
9.1.11.	Zurampic - lesinurad - EMEA/H/C/003932	
9.1.12.	Forxiga/Edistride (dapagliflozin) - EMEA/H/C/002322 / EMEA/H/C/004161/WS1844 48	
10.	Referral procedures 48	
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/200448	
10.1.1.	Yondelis - EMEA/H/C/0773/A-20/0060	
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 . 49	
10.2.1.	Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490	
10.2.2.	Dexamethasone EMEA/H/A-5(3)/1500	
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/200449	
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) -under Article 29(4) of Directive 2001/83/EC50	
10.4.1.	Ibuprofen Kabi – EMEA/H/A-29(4)/149850	
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC 50	
10.5.1.	Varilrix - EMEA/H/A-30/1499 50	
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC51	
10.6.1.	Panexcell Clinical Laboratories Priv. Ltd - Multiple NAPs (EMEA/H/A-31/1494) 51	
10.6.2.	Ranitidine - EMEA/H/A-31/1491	
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC52	
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC52	
10.9.	Disagreement between Member States on Type II variation— Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	
10.10.	Procedure under Article 29 of Regulation (EC) 1901/200652	
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	
11.	Pharmacovigilance issue 52	
11.1.	Early Notification System52	
12.	Inspections 52	
12.1.	GMP inspections	
12.2.	GCP inspections52	
12.3.	Pharmacovigilance inspections53	
124	GIP inspections	

13.	Innovation Task Force 53
13.1.	Minutes of Innovation Task Force53
13.2.	Innovation Task Force briefing meetings53
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/200453
13.4.	Nanomedicines activities53
14.	Organisational, regulatory and methodological matters 53
14.1.	Mandate and organisation of the CHMP53
14.2.	Coordination with EMA Scientific Committees53
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)
14.2.2.	Committee for Orphan Medicinal Products (COMP)
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups54
14.3.1.	Biologics Working Party (BWP)
14.3.2.	Name Review Group (NRG)54
14.3.3.	Quality Working Party (QWP)54
14.3.4.	Scientific Advice Working Party (SAWP)55
14.4.	Cooperation within the EU regulatory network55
14.5.	Cooperation with International Regulators55
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee55
14.7.	CHMP work plan55
14.8.	Planning and reporting55
14.9.	Others55
15.	Any other business 55
15.1.	AOB topic55
15.1.1.	Update on COVID-1955
15.1.2.	Online public consultation on the Pharmaceutical Strategy for Europe
16.	List of participants 57
17	Explanatory notes 62

#### 1. Introduction

### **1.1.** Welcome and declarations of interest of members, alternates and experts

The participants had no objection to hold the meeting remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See (current) July 2020 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 20 – 23 July 2020.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

#### 1.2. Adoption of agenda

CHMP agenda for 20-23 July 2020.

The CHMP adopted the agenda.

#### 1.3. Adoption of the minutes

CHMP minutes for 22-25 June 2020.

The CHMP adopted the minutes.

ORGAM minutes for 13 July 2020.

The Minutes of the July 2020 CHMP ORGAM meeting held on 13 July 2020, together with all decisions taken at that meeting, were adopted.

#### 2. Oral Explanations

#### 2.1. Pre-authorisation procedure oral explanations

#### 2.1.1. Arikayce liposomal - amikacin - Orphan - EMEA/H/C/005264

Insmed Netherlands B.V.; treatment of lung infection as part of combination antibacterial drug regiment in adults.

Scope: Oral explanation,

Updated list of experts for the SAG on Anti-Infectives meeting adopted via written procedure on 3 July 2020, Report from the SAG on Anti-Infectives meeting held on 10 July 2020

**Action**: Oral explanation to be held on Tuesday, 21 July 2020 at 14:00

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2020, 30.04.2020. List of Questions adopted on 14.11.2019.

Participation of a patient representative.

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application.

See 3.1

#### 2.1.2. Gamifant - emapalumab - Orphan - EMEA/H/C/004386

Swedish Orphan Biovitrum AB (publ); treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH).

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 21 July 2020 at 09:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2020, 27.06.2019. List of Questions adopted on 13.12.2018.

Participation of a patient representative.

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application.

See 3.1

#### 2.1.3. Jyseleca - filgotinib - EMEA/H/C/005113

Gilead Sciences Ireland UC; treatment of adult patients with moderately to severely active rheumatoid arthritis.

Scope: Possible oral explanation/ Opinion

Action: Oral explanation to be held on Tuesday, 21 July 2020 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 12.12.2019.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

#### 2.1.4. Zynrelef - bupivacaine / meloxicam - EMEA/H/C/005205

Heron Therapeutics, B.V.; for application into the surgical site to reduce postoperative pain.

Scope: Oral explanation

Action: Oral explanation to be held on Monday, 20 July 2020 at 16:00

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.04.2020, 27.02.2020. List of Questions adopted on 25.07.2019.

An oral explanation was held on Monday, 20 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application with specific focus on the fixed dose combination.

See 3.1

#### 2.2. Re-examination procedure oral explanations

No items

#### 2.3. Post-authorisation procedure oral explanations

No items

#### 2.4. Referral procedure oral explanations

#### 2.4.1. Ibuprofen Kabi – EMEA/H/A-29(4)/1498

Fresenius Kabi Deutschland GmbH

Referral Rapporteur: Janet Koenig, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 21 July 2020 at time 11:00

Summary: Decentralised Procedure number: DE/H/6040/001/DC, notification by the German Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the data for the bridging to the reference medicinal product.

#### 3. Initial applications

#### 3.1. Initial applications; Opinions

#### 3.1.1. Adakveo - crizanlizumab - Orphan - EMEA/H/C/004874

Novartis Europharm Limited; treatment of sickle cell disease.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.04.2020. List of Questions adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that crizanlizumab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 16.07.2020.

The summary of opinion was circulated for information.

#### 3.1.2. Arikayce liposomal - amikacin - Orphan - EMEA/H/C/005264

Insmed Netherlands B.V.; treatment of lung infection as part of combination antibacterial drug regiment in adults.

Scope: Opinion,

Updated list of experts for the SAG on Anti-Infectives meeting adopted via written procedure on 3 July 2020, Report from the SAG on Anti-Infectives meeting held on 10 July 2020

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2020, 30.04.2020. List of Questions adopted on 14.11.2019.

Participation of a patient representative.

#### See 2.1

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

#### 3.1.3. Arsenic trioxide medac - arsenic trioxide - EMEA/H/C/005218

medac Gesellschaft fur klinische Spezialpraparate mbH; treatment of relapsed acute promyelocytic leukaemia (APL).

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TRISENOX

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 12.12.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

#### 3.1.4. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208

Blueprint Medicines (Netherlands) B.V.; treatment of gastrointestinal stromal tumours.

Scope: Opinion

**Action**: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.04.2020. List of Questions adopted on 14.11.2019.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that Avapritinib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 21.07.2020.

The summary of opinion was circulated for information.

#### 3.1.5. Blenrep - belantamab mafodotin - Orphan - EMEA/H/C/004935

GlaxoSmithKline (Ireland) Limited; treatment of patients with relapsed or refractory multiple myeloma.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2020. List of Questions adopted on 28.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that belantamab mafodotin is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

#### 3.1.6. Calquence - acalabrutinib - Orphan - EMEA/H/C/005299

AstraZeneca AB; treatment of adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on

27.02.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that acalabrutinib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 21.07.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

#### 3.1.7. Dapivirine Vaginal Ring 25 mg - dapivirine - Article 58 - EMEA/H/W/002168

International Partnership for Microbicides Belgium AISBL; reducing the risk of HIV-1 infection via vaginal intercourse in sexually active HIV-uninfected women.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2020, 25.07.2019, 26.04.2019, 18.10.2018. List of Questions adopted on 09.11.2017.

The CHMP was reminded of previous discussions.

The Committee adopted a positive scientific opinion by majority (25 positive out of 28 votes) together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The divergent position (Johann Lodewijk Hillege, Simona Badoi, Kristina Dunder) was appended to the opinion.

The summary of opinion was circulated for information.

#### 3.1.8. Elzonris - tagraxofusp - Orphan - EMEA/H/C/005031

Stemline Therapeutics B.V.; treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.03.2020, 25.06.2019. List of Questions adopted on 24.04.2019.

The CHMP was reminded of previous discussions.

The CHMP adopted a negative opinion by majority, recommending the refusal of the granting of the marketing authorisation. The CHMP adopted the assessment report.

The divergent position was appended to the opinion.

The refusal question and answer document was circulated for information.

#### 3.1.9. Equidacent - bevacizumab - EMEA/H/C/005181

Centus Biotherapeutics Europe Limited; Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 30.01.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

#### 3.1.10. Fampridine Accord - fampridine - EMEA/H/C/005359

Accord Healthcare S.L.U.; treatment of multiple sclerosis.

Scope: Opinion

**Action**: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Fampyra

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 12.12.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation

timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

#### 3.1.11. Gamifant - emapalumab - Orphan - EMEA/H/C/004386

Swedish Orphan Biovitrum AB (publ); treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2020, 27.06.2019. List of Questions adopted on 13.12.2018.

Participation of a patient representative.

See 2.1

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application.

The CHMP adopted a negative opinion by majority recommending the refusal of the granting of the marketing authorisation. The CHMP adopted the assessment report.

The divergent position was appended to the opinion.

The refusal question and answer document was circulated for information.

#### 3.1.12. Jyseleca - filgotinib - EMEA/H/C/005113

Gilead Sciences Ireland UC; treatment of adult patients with moderately to severely active rheumatoid arthritis.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 12.12.2019.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that filgotinib is a new active substance, as claimed by

the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

#### 3.1.13. Zynrelef - bupivacaine / meloxicam - EMEA/H/C/005205

Heron Therapeutics, B.V.; for application into the surgical site to reduce postoperative pain.

Scope: Opinion

Action: For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.04.2020, 27.02.2020. List of Questions adopted on 25.07.2019.

See 2.1

An oral explanation was held on Monday, 20 July 2020. The presentation by the applicant focused on the clinical data in support of the marketing authorisation application with specific focus on the fixed dose combination.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

### 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

### 3.2.1. meningococcal group A, C, W135 and Y conjugate vaccine - Article 28 - EMEA/H/C/005084

immunisation against Neisseria meningitidis serogroups A, C, W-135 and Y.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.02.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

#### 3.2.2. melphalan - EMEA/H/C/005173

high-dose used alone or in combination with other cytotoxic drugs and/or total body irradiation is indicated in the treatment of: multiple myeloma, malignant lymphoma (Hodgkin, non-Hodgkin lymphoma), acute lymphoblastic and myeloblastic leukaemia, childhood neuroblastoma, ovarian adenocarcinoma, mammary adenocarcinoma.

in combination with other cytotoxic drugs and/or total body irradiation, in adult and paediatric population, is indicated as conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (HSCT) in haematological diseases.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 26.03.2020. List of Questions adopted on 25.07.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

#### 3.2.3. rilpivirine - EMEA/H/C/005060

treatment of human immunodeficiency virus type 1 (HIV-1).

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 12.12.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SAG HIV/viral diseases and adopted a list of questions to this group.

#### 3.2.4. influenza quadrivalent vaccine (rDNA) - EMEA/H/C/005159

prevention of influenza disease.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.02.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

#### 3.2.5. cabotegravir - EMEA/H/C/004976

treatment of human immunodeficiency virus type 1 (HIV-1).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 12.12.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SAG HIV/viral diseases and adopted a list of questions to this group.

### 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

#### 3.3.1. bevacizumab - EMEA/H/C/005327

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent nonsmall cell lung cancer.

First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.2. abiraterone acetate - EMEA/H/C/005368

treatment of metastatic castration resistant prostate cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.3. bevacizumab - EMEA/H/C/005611

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal

cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent nonsmall cell lung cancer.

First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.4. leuprorelin - EMEA/H/C/005034

indicated for the treatment of hormone dependent advanced prostate cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.5. cenobamate - EMEA/H/C/005377

for the adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.6. hydrocortisone - Orphan - EMEA/H/C/005105

Diurnal Europe BV; replacement therapy for congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.7. insulin human (rDNA) - EMEA/H/C/005331

treatment of patients with diabetes mellitus who require intravenous insulin.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.8. selumetinib - Orphan - EMEA/H/C/005244

AstraZeneca AB; treatment of neurofibromatosis type 1 (NF1).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.9. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.10. berotralstat - Orphan - EMEA/H/C/005138

BioCryst Ireland Limited; prevention of hereditary angioedema (HAE).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.11. lumasiran - Orphan - EMEA/H/C/005040

#### **Accelerated assessment**

Alnylam Netherlands B.V.; primary hyperoxaluria type 1 (PH1).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.12. tanezumab - EMEA/H/C/005189

treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.13. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267

treatment of uterine fibroids.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.14. ponesimod - EMEA/H/C/005163

treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.15. adalimumab - EMEA/H/C/005188

treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.4. Update on on-going initial applications for Centralised procedure

#### 3.4.1. dasatinib - EMEA/H/C/005446

treatment of leukaemia.

Scope: Letter from the applicant dated 14 July 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in June 2020.

Action: For adoption

List of Outstanding Issues adopted on 25.06.2020. List of Questions adopted on 17.10.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in June 2020.

#### 3.4.2. dasatinib - EMEA/H/C/005317

treatment of leukaemia.

Scope: Letter from the applicant dated 14 July 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in June 2020.

Action: For adoption

List of Outstanding Issues adopted on 25.06.2020. List of Questions adopted on 17.10.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in June 2020.

#### 3.4.3. dostarlimab - EMEA/H/C/005204

treatment of mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC).

Scope: Letter from the applicant dated 16 July 2020 requesting an extension of clock-stop to respond to the list of questions adopted in June 2020.

Action: For adoption

List of questions adopted on 25.06.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in June 2020.

#### 3.4.4. istradefylline - EMEA/H/C/005308

indicated as an adjunctive treatment to levodopa-based regimens in patients with Parkinson's disease.

Scope: Letter from the applicant dated 6 July 2020 requesting an extension of clock-stop to respond to the list of questions adopted in April 2020.

Action: For adoption

List of questions adopted on 30.04.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in April 2020.

#### 3.4.5. ofatumumab - EMEA/H/C/005410

treatment of relapsing forms of multiple sclerosis.

Scope: Request to Biostatistics Working Party (BSWP)

**Action**: For adoption

List of Questions adopted on 28.05.2020.

The CHMP adopted the list of questions to the BSWP.

### 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

#### 3.6. Initial applications in the decision-making phase

#### 3.6.1. Cabazitaxel Accord - cabazitaxel - EMEA/H/C/005178

Accord Healthcare S.L.U.; treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen.

Scope: Letter from the EC on the opinion adopted in April 2020.

Action: For discussion

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Opinion adopted on 30.04.2020. List of Outstanding Issues adopted on 26.03.2020, 27.02.2020. List of Questions adopted on 19.09.2019.

The CHMP noted the letter from the European Commission. A response letter will be sent to the European Commission.

#### 3.6.2. Kaftrio - elexacaftor / tezacaftor / ivacaftor - Orphan - EMEA/H/C/005269

Vertex Pharmaceuticals (Ireland) Limited; treatment of cystic fibrosis.

Scope: Update on Kaftrio

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 25.06.2020. Oral explanation held on 23.06.2020. List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 28.01.2020.

The CHMP noted the update.

#### 3.7. Withdrawals of initial marketing authorisation application

#### 3.7.1. Rayogta - abicipar pegol - EMEA/H/C/005103

Allergan Pharmaceuticals International Limited; treatment of neovascular (wet) age-related macular degeneration (AMD).

Scope: Withdrawal of initial marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 14.11.2019.

The CHMP noted the withdrawal of initial marketing authorisation application.

#### 3.7.2. Abilify MyCite - aripiprazole - EMEA/H/C/005062

Otsuka Pharmaceutical Netherlands B.V.; treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence.

Scope: Withdrawal of initial marketing authorisation application

Action: For information

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.03.2020. List of Questions adopted on 25.07.2019.

The CHMP noted the withdrawal of the initial marketing authorisation application.

### 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Pemetrexed Hospira - pemetrexed - EMEA/H/C/003970/X/0021

Pfizer Europe MA EEIG

Rapporteur: Alar Irs

Scope: "Extension application to introduce a new pharmaceutical form with its associated strength (25 mg/ml concentrate for solution for infusion)."

Action: For adoption

List of Outstanding Issues adopted on 25.06.2020. List of Questions adopted on 27.02.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

## 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

#### 4.2.1. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G

Boehringer Ingelheim International GmbH

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension application to add two new pharmaceutical forms for Pradaxa (coated granules (20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg) and powder and solvent for oral solution (6.25 mg/ml)), grouped with:

-A type II variation (C.I.6.a) - Extension of indication to include new indication for Pradaxa 75 mg, 110 mg, 150 mg capsules based on the paediatric trials 1160.106 and 1160.108. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and labelling are updated in accordance. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet. The RMP version 37.0 has also been submitted.

```
-Type IB (B.I.b.1.c)
```

<sup>-</sup>Type IA (B.I.b.1.b)

<sup>-</sup>Type IB (B.I.b.1.d

<sup>-</sup>Type IA (B.I.b.2.a)

<sup>-</sup>Type IA (B.I.b.1.d)

<sup>-</sup>Type IA (B.I.d.1.a.1)

<sup>-</sup>Type IA (B.II.d.1.a)

<sup>-</sup>Type IB (B.II.d.1.d)

<sup>-</sup>Type IA (B.II.d.2.a)

<sup>-</sup>Type IA (B.II.c.1.c)"

Action: For adoption

List of Questions adopted on 27.02.2020.

The Committee discussed the issues identified in this application, mainly concerning the clinical data in specific sub-groups and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension of the clock stop to respond to the list of outstanding issues.

The CHMP agreed to consult a SAG and adopted a list of questions to this group.

#### 4.2.2. Trulicity - dulaglutide - EMEA/H/C/002825/X/0045

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to introduce two new strengths of 3 mg and 4.5 mg solution

for injection."

Action: For adoption

List of Questions adopted on 26.03.2020.

The Committee discussed the issues identified in this application, mainly relating to some clinical aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

#### 4.2.3. Ultomiris - ravulizumab - EMEA/H/C/004954/X/0004/G

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Agnes Gyurasics

Scope: "Extension application to add a new strength (1100 mg in 11 ml vial, concentration 100 mg/ml) for Ultomiris concentrate for solution for infusion, grouped with a Type II application (B.II.z) for a new presentation (300 mg in 3 ml vial, concentration 100 mg/ml) including changes in the active substance concentration, excipients composition and concentrations, and minor differences in the last two steps of the manufacturing process."

Action: For adoption

List of Questions adopted on 30.04.2020.

The Committee discussed the issues identified in this application, mainly relating to some clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

#### 4.2.4. Xarelto - rivaroxaban - EMEA/H/C/000944/X/0074/G

Bayer AG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form, granules for oral suspension, 1 mg/ml.

Extension of indication to include treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years following initiation of standard anticoagulation treatment for Xarelto 15 and 20 mg tablets.

As a consequence, sections 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated accordingly.

In addition, sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC is updated for all other dose strengths (2.5/10/ and 15/20 mg initiation packs) of Xarelto and corresponding sections of the package leaflet. Section 4.4 has been updated with regard to sodium content according to Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668).

The RMP version 12.1 has also been submitted."

Action: For adoption

List of Questions adopted on 30.04.2020.

The Committee discussed the issues identified in this application, mainly concerning the clinical data in some sub-groups.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of guestions to this group.

## 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

#### 4.3.1. Hulio - adalimumab - EMEA/H/C/004429/X/0016

Mylan S.A.S

Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength of 20 mg solution for injection.

The RMP (version 3.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning some questions in relation to the quality part, the SmPC and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 4.3.2. Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0012

Chiesi Farmaceutici S.p.A.

Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to add a new pharmaceutical form (inhalation powder) associated with new strength (88µg / 5µg / 9µg).

The RMP (version 6.2) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality, preclinical and clinical aspects of the dossier as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.3. Tysabri - natalizumab - EMEA/H/C/000603/X/0116

Biogen Netherlands B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection), associated with a new strength (150 mg) and a new route of administration (subcutaneous use). The RMP (version 26.1) is updated accordingly."

**Action**: For adoption

The Committee discussed the issues identified in this application, concerning quality and clinical aspects of the dossier as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

#### 4.4.1. Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007

Accord Healthcare S.L.U.

Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form (solution for infusion), a new strength (10 mg/ml) and a new route of administration (intravenous use).",

Letter from the applicant dated 16 July 2020 requesting an extension of clock-stop to respond to the list of questions adopted in March 2020.

Action: For adoption

List of guestions adopted on 26.03.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in March 2020.

### 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

# 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

## 5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

#### 5.1.1. Crysvita - burosumab - Orphan - EMEA/H/C/004275/II/0010/G

Kyowa Kirin Holdings B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adults with X-linked hypophosphataemia (XLH), and modification of the currently approved indication in children and adolescents, by removing the qualification 'with growing skeletons', in order to include treatment in all children with radiographic evidence of bone disease.

The application provides new week-48 data from study UX023-CL304; a randomised, double-blind, placebo-controlled, phase 3 study with open-label extension to assess the efficacy and safety of KRN23 in adults with XLH.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated and the package leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.1.

The updated RMP version 2.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2020, 30.01.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.2. Dupixent - dupilumab - EMEA/H/C/004390/II/0027

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include atopic dermatitis patients from 6 years to 11 years. Consequently, the sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The package leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The Committee discussed the issues identified in this application, concerning some clarifications on clinical aspects and the RMP.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.3. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0005

GW Pharma (International) B.V.

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 1 year of age and older. As a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated accordingly. The updated RMP version 1.1 has been submitted. The marketing authorisation holder (MAH) also took the opportunity to correct typographic errors and implement editorial updates as well as implement the updated ethanol statement in compliance with the EC Guideline on Excipient." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning clinical data in subgroups as well as in relation to the posology and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.4. Humira - adalimumab - EMEA/H/C/000481/II/0198

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of moderately to severely active ulcerative colitis in paediatric patients for Humira; as a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC for 40mg/0.8ml, 40mg/0.4ml and 80mg/0.8ml presentations are updated. Furthermore, sections 5.1 and 5.2 of the SmPC for 20mg/0.2ml are updated. The package leaflet is updated in accordance. Version 15.0 of the RMP has also been submitted."

**Action**: For adoption

The Committee discussed the issues identified in this application, concerning some clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.5. HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0056

Baxalta Innovations GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication for HyQvia in order to align the wording for the already approved secondary immunodeficiencies indications in the HyQvia SmPC with the wording of the Guideline on core SmPC for human normal immunoglobulin for intravenous administration (EMA/CHMP/BPWP/94038/ 2007 Rev 5; CHMP, 2018).

As a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP is also agreed.

Furthermore, the PI is brought in line with the latest QRD template version 10.1. As a consequence, sections 1, 2, 3, 4.2, 4.4, 4.7, 4.8, 5.2 and 6.5 of the SmPC, labelling and package leaflet are updated.

The conditions or restrictions with regard to the safe and effective use of the medicinal product are also updated to include the ongoing non-interventional post-authorisation safety study on the long-term safety of HyQvia in subjects treated with HyQvia, which is a Category 1 study in the agreed RMP.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.6. Imbruvica - ibrutinib - Orphan - EMEA/H/C/003791/II/0059

Janssen-Cilag International NV

Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL.

This extension of the approved CLL indication is based on results from the phase 3 Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG ACRIN) study E1912 (also referred to as PCYC-1126e-CA).

The SmPC is revised to include information related to the new indication. The package leaflet has been revised accordingly. Minor editorial changes have been implemented in Annex II and Annex IIIA. An updated RMP has been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.7. Imfinzi - durvalumab - EMEA/H/C/004771/II/0014/G

#### AstraZeneca AB

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include the use of Imfinzi in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The proposed indication is supported by study D419QC00001 (CASPIAN), an ongoing phase III randomised, multicentre, open-label, comparative study designed to determine the efficacy and safety of durvalumab, or durvalumab and tremelimumab, in combination with etoposide and platinum-based chemotherapy (EP) for the first-line treatment of patients with ES-SCLC. In addition, the marketing authorisation holder (MAH) proposes to update sections 4.4 and 4.8 of the SmPC to update the safety information based on the Durvalumab Pan-Tumour Pool, a safety dataset comprising of 9 clinical studies building on the existing safety database and summarising the safety information for durvalumab monotherapy characterised across tumour types in the durvalumab clinical program to date. The package leaflet is updated in accordance. The RMP version 2S1 has also been submitted."

#### Action: For adoption

Request for Supplementary Information adopted on 28.05.2020, 27.02.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.8. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0085

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to include the combination regimen of the ivacaftor 150 mg

tablets with elexacaftor/tezacaftor/ivacaftor fixed dose combination (FDC) tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis who are homozygous for F508del mutation in the CFTR gene or heterozygous for F508del in the CFTR gene with a minimal function (MF) mutation; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP is updated to version 8.8. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.9. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0086

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC

Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to extend the indication of Kalydeco (ivacaftor) granules in the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 8.9 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning some clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.10. Latuda - lurasidone - EMEA/H/C/002713/II/0029

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication for the treatment of schizophrenia in adolescent from 13 to less than 18 years. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly. In addition, the marketing authorisation holder (MAH) takes the opportunity to update the PI according to the excipient guideline and update the list of local representatives in the package leaflet. The RMP version 8 has also been submitted." Request for 1 year of market protection for a new

indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.06.2020, 26.03.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.11. NovoThirteen - catridecacog - EMEA/H/C/002284/II/0026/G

Novo Nordisk A/S

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of bleeding episodes in patients with congenital factor XIII A-subunit deficiency as well as minor surgery based on the results of study NN1841-3868 and the PRO-RBDD registry. As a consequence, sections 4.1, 4.2, 4.4, 4.6, 5.1 and 5.2 of the SmPC and the RMP version 15 has been submitted. Annex IID and the package leaflet have been updated accordingly.

Furthermore, the PI is brought in line with the latest QRD template version. Minor editorial updates have also been made."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The CHMP was informed that the applicant withdrew the request for 1 year market protection.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.12. Olumiant - baricitinib - EMEA/H/C/004085/II/0016

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bart Van der Schueren, PRAC

Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include a new indication in the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are

updated.

The package leaflet is updated in accordance. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet.

Minor editorial changes were brought to the labelling. Furthermore, the Annex II is brought in line with the latest QRD template version 10.1.

The RMP version 8.1 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020, 26.03.2020.

The Committee discussed the issues identified in this application concerning some SmPC wordings.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.13. Opdivo - nivolumab - EMEA/H/C/003985/II/0080

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC

Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) after prior fluoropyrimidine- and platinum-based chemotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 16.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The Committee discussed the issues identified in this application, mainly concerning clinical aspects with regard to the European/non-Asian patient population.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

The CHMP agreed to consult the SAG Oncology and adopted a list of guestions to this group.

#### 5.1.14. Prezista - darunavir - EMEA/H/C/000707/II/0107

Janssen-Cilag International NV

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication for Prezista (darunavir) in combination with cobicistat for the treatment of HIV-1 infection in adolescents aged 12 years and older with body weight at least 40 kg. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 of the SmPC and section 3 of the Package Leaflet are being updated accordingly. The updated RMP version 27.2 has been submitted.

In addition, in order to align the SmPC with recommendations for other HIV products, the MAH has also taken the opportunity to update section 4.2 throughout with regards to the

administration of Prezista in case of vomiting. The MAH has also implemented some editorial changes in Annex II and IIIA. The package leaflet is updated accordingly."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.15. Recarbrio - imipenem / cilastatin / relebactam - EMEA/H/C/004808/II/0001

Merck Sharp & Dohme B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include the treatment of hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), with or without concurrent bacteraemia in adults for Recarbrio; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Furthermore, the marketing authorisation holder (MAH) made editorial corrections and brought the PI in line with the latest QRD template version 10.1. Version 1.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application concerning some clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

## 5.1.16. Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0022

GlaxoSmithkline Biologicals SA

Rapporteur: Christophe Focke, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension of indication to include a new population for Shingrix: adults 18 years of age or older at increased risk of Herpes Zoster supported by the clinical studies ZOSTER-002 (MEA 001), ZOSTER-039 (MEA 002), ZOSTER-041 (MEA 003), ZOSTER-028 (MEA 004), ZOSTER-001 and ZOSTER-015.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated in order to delete a warning and to add new safety and efficacy information. The Package Leaflet is updated in accordance. The RMP version 2.2 has also been approved.

In addition, the list of excipients has been updated in section 6 of the SmPC.

Furthermore, the MAH took this opportunity to implement some editorial changes in Annex II and IIIA."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.17. Votubia - everolimus - Orphan - EMEA/H/C/002311/II/0061

Novartis Europharm Limited

Rapporteur: Janet Koenig

Scope: "Update of sections 4.2, 5.1, and 5.2 of the SmPC based on results from a modelling and simulation study of patients from 6 months to less than 2 years of age whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020, 12.12.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.18. Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0015

Pfizer Ireland Pharmaceuticals

Rapporteur: Bjorg Bolstad, Co-Rapporteur: Simona Stankeviciute, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to include paediatric patients aged 3 months to less than 18 years for Zavicefta (for the treatment of cIAI and cUTI), based on data from paediatric studies D4280C00014, C3591004 and C3591005 and the population PK modelling/simulation analyses (CAZ-MS-PED-01 and CAZ-MS-PED-02).

As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 6.3 and 6.6 of the SmPC are updated in order to reflect this additional population, the paediatric posology, paediatric safety information, the description of the clinical trials and handling instructions for paediatric dosing. The package leaflet is updated in accordance. In addition, the marketing authorisation holder (MAH) took the opportunity to correct the sodium content to SmPC sections 2 and 4.4 and PL section 2 and the volumes of distribution of ceftazidime and

avibactam in SmPC section 5.2. Furthermore, the MAH is also introducing a correction in the Czech SmPC to add missing values in the table in SmPC section 5.1.

The RMP version 3.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 26.03.2020, 25.07.2019.

The Committee discussed the issues identified in this application concerning the SmPC and the RMP.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.19. Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0048

Pfizer Ireland Pharmaceuticals

Rapporteur: Alar Irs

Scope: "Extension of indication for the treatment of community acquired pneumonia (CAP) to include concurrent bacteraemia due to Streptococcus pneumoniae (SP) for all age groups, based on the results of previously submitted studies: FOCUS 1 (study P903-08) and FOCUS 2 (study P903-09), paediatric CAP study (study P903-31) and relevant postmarketing safety experience with ceftaroline for bacteraemic Streptococcus pneumoniae CAP. As a consequence, sections 4.1 and 5.1 of the SmPC are updated accordingly. No RMP has been provided within this application."

**Action**: For adoption

Request for Supplementary Information adopted on 12.12.2019.

The Committee discussed the issues identified in this application relating to the wording of the indication.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.20. WS1782

Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS1782/0006 Vimpat - lacosamide - EMEA/H/C/000863/WS1782/0088

UCB Pharma S.A.

Lead Rapporteur: Filip Josephson, Lead Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include the treatment as adjunctive therapy of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy for Lacosamide UCB and Vimpat; consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. The RMP version 15.0 has also been submitted.

Furthermore, the PI is brought in line with the latest QRD template version 10.1. The marketing authorisation holder (MAH) also takes the opportunity to align the PI of Lacosamide UCB with the PI of Vimpat and to implement some corrections in BG, CS, DA, FR, DE, HU, PL and ES."

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The Committee discussed the issues identified in this application concerning some clinical aspects, the SmPC and the RMP.

The Committee adopted a  $2^{nd}$  request for supplementary information with a specific timetable.

# 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

#### 5.2.1. Spravato - esketamine - EMEA/H/C/004535/II/0001/G

Janssen-Cilag International N.V.

Rapporteur: Martina Weise, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "C.I.6(a): Extension of indication to include a new indication for Spravato for the rapid reduction of depressive symptoms in adult patients with a moderate to severe depressive episode of MDD who have current suicidal ideation with intent. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 the SmPC are updated. The RMP version 2.1 has also been submitted.

B.II.e.5.a.2: Addition of a new pack size corresponding to 4 weeks of treatment in the new indication.

The Package Leaflet and labelling are updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to clarify the wording in Annex II.D."

Request by the applicant for an extension to the clock stop to respond to the Request for Supplementary Information adopted on 30.04.2020.

**Action**: For adoption

Request for Supplementary Information adopted on 30.04.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the Request for Supplementary Information adopted on 30.04.2020.

# 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

### 6. Ancillary medicinal substances in medical devices

# 6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

#### 6.2. Update of Ancillary medicinal substances in medical devices

No items

# 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

# 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

#### 7.1.1. Remdesivir - EMEA/H/K/5622/CU

Gilead Sciences Ireland UC

Scope: Update on the compassionate use programme

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 25.06.2020.

The CHMP noted that the compassionate use opinion is no longer updated following the granting of a marketing authorisation.

#### 7.1.2. Sofosbuvir - EMEA/H/K/003891/CU

Gilead Sciences International

Scope: Update on the compassionate use programme

Action: For information

Opinion adopted on 24.10.2013.

The CHMP noted that the compassionate use opinion is no longer updated following the granting of a marketing authorisation.

#### 7.1.3. Sofosbuvir/Ledipasvir - EMEA/H/K/003892/CU

Gilead Sciences International

Scope: Update on the compassionate use programme

Action: For information

Opinion adopted on 20.02.2014.

The CHMP noted that the compassionate use opinion is no longer updated following the granting of a marketing authorisation.

#### 7.1.4. Daclatasvir – EMEA/H/K/003867/CU

Bristol-Myers Squibb

Scope: Update on the compassionate use programme

Action: For information

Opinion adopted on 21.11.2013.

The CHMP noted that the compassionate use opinion is no longer updated following the granting of a marketing authorisation.

#### 8. Pre-submission issues

#### 8.1. Pre-submission issue

#### 8.1.1. artesunate - H0005550

initial treatment of severe or complicated malaria, in adults and children.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

# 8.1.2. autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub family D (ALD), member 1, (ABCD1) cDNA - Orphan - H0003690

bluebird bio (Netherlands) B.V; treatment of patients less than 18 years of age with early cerebral adrenoleukodystrophy for whom a human leukocyte antigen (HLA) - matched sibling haematopoietic stem cell (HSC) donor is not available.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

#### 8.2.1. List of applications received

Action: For information

The CHMP noted the information.

#### 8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 7 recommendations for eligibility to PRIME: 2 were accepted and 5 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

### 9. Post-authorisation issues

#### 9.1. Post-authorisation issues

#### 9.1.1. Desloratadine ratiopharm - desloratadine - EMEA/H/C/002404/II/0023/G

ratiopharm GmbH

Rapporteur: Koenraad Norga, Co-Rapp: Peter Kiely, PRAC Rapporteur: Jean-Michel Dogné

Scope: "C.I.5.b - Change in the legal status of desloratedine ratiopharm from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' in view of the safety profile of desloratedine ratiopharm and the post-marketing experience already available with other medicinal products containing similar long acting histamine antagonists. The RMP version 1.0 has also been submitted. In addition, the marketing authorisation holder (MAH) also took the opportunity to bring the PI in line with the latest QRD template (version 10.1), to update the list of local representatives in the package leaflet and to make editorial changes.

C.I.6.b - To delete the therapeutic indication in adolescents aged 12 years and older for the relief of symptoms associated with allergic rhinitis and urticaria. Section 4.1 of the SmPC and section 1 of the package leaflet are updated accordingly."

Action: For discussion

Request for Supplementary Information adopted on 26.03.2020.

The Committee discussed the issues identified in this application concerning the pack size, some SmPC wordings and a user testing.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 9.1.2. Duzallo - allopurinol/lesinurad - EMEA/H/C/004412

Grunenthal GmbH

Rapporteur: Kristina Dunder, Co-Rapporteur: Tomas Radimersky

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

#### 9.1.3. Edistride - dapagliflozin - EMEA/H/C/004161/R/0038

AstraZeneca AB

Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Annika Folin

Scope: Renewal of marketing authorisations for unlimited validity

Action: For adoption

Request for Supplementary Information adopted on 25.06.2020, 28.05.2020.

The CHMP adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### 9.1.4. Erleada - apalutamide - EMEA/H/C/004452/II/0006

Janssen-Cilag International N.V.

Rapporteur: Blanca Garcia-Ochoa

Scope: "Update of section 4.8 of the SmPC to add interstitial lung disease to the list of adverse drug reactions (ADRs) with frequency unknown based on a safety review; the package leaflet is updated accordingly."

Action: For discussion

Request for Supplementary Information adopted on 05.06.2020.

The Committee discussed the issues identified in this application. The members considered that the evidence provided is not deemed sufficient to justify the addition of interstitial lung disease to the list of adverse drug reactions in the SmPC.

The CHMP adopted a negative opinion by consensus recommending the refusal of the variation to the terms of the marketing authorisation. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

Recordati Ireland Ltd

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Change in the legal status of Fortacin from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription'. As a consequence, sections 4.4, 4.8 and 4.9 of the SmPC are updated. The package leaflet and labelling are updated accordingly. Furthermore, the PI is being brought in line with the latest QRD template (version 10.1). The RMP is updated to version 4.0."

Action: For discussion

Request for Supplementary Information adopted on 26.03.2020, 12.12.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

9.1.6. Juluca - dolutegravir / rilpivirine - EMEA/H/C/004427/II/0016
Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0001
Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0069
Tivicay - dolutegravir - EMEA/H/C/002753/II/0052

ViiV Healthcare B.V.

Lead Rapporteur: Filip Josephson

Scope: "Update of section 4.6 of the SmPC in order to update the safety information regarding the occurrence of neural tube defects with the dolutegravir -containing regimens based on the interim analysis from the Tsepamo study. This is a birth outcomes surveillance study being conducted in Botswana that was designed to evaluate adverse birth outcomes by HIV status and antiretroviral regimen, and to determine if there is an increased risk of neural tube defects among infants exposed to efavirenz at conception. This surveillance system captures all antiretroviral exposure including dolutegravir. The PL is updated accordingly."

PRAC advice

**Action**: For adoption

The CHMP noted the PRAC advice.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP

#### 9.1.7. Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0026/G, Orphan

Alexion Europe SAS

Rapporteur: Bart Van der Schueren, Co-Rapporteur: Fátima Ventura

Scope: Grouped variations consisting of

1) update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the clinical information based on the pooled safety and efficacy analysis of already submitted studies (namely study LAL-CL04: an open label multicentre extension study to evaluate the long-term safety, tolerability, and efficacy of sebelipase alfa (SBC-102) in adult subjects with liver dysfunction due to lysosomal acid lipase deficiency (LAL-D) who previously received treatment in study LAL-CL01; study LAL-CL03: an open label, multicentre, dose escalation study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of SBC-102 in children with growth failure due to LAL-D; study LAL-CL06: a multicentre, open-label study of sebelipase alfa in patients with LAL-D; study LAL-CL08: a phase 2, open label, multicentre study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of sebelipase alfa in infants with rapidly progressive LAL-D; study LAL-CL02: a multicentre, randomised, placebo-controlled study of SBC-102 in patients with LAL-D) and updated population pharmacokinetic (PK) analyses in children and adults. The package leaflet and the RMP (version 4.0) are updated accordingly. Annex II is also updated to remove the obligation related to the provision of study LAL-CL08;

2) submission of the final report from study LAL-EA01: an open-label study with sebelipase alfa 1 mg/kg every other week for up to 78 weeks or until drug commercialisation in the United States (US) patients who did not otherwise qualify for an active sebelipase alfa trial (expanded access protocol).

Action: For adoption

Request for supplementary information adopted on 26.03.2020.

The Committee discussed the issues identified in this application concerning some clinical aspects.

The Committee adopted a  $2^{nd}$  request for supplementary information with a specific timetable.

#### 9.1.8. Qutenza - capsaicin - EMEA/H/C/000909/II/0048

Grunenthal GmbH

Rapporteur: Bruno Sepodes

Scope: "Update of sections 4.2 and 5.1 of the SmPC in order to amend the posology based on PACE and STRIDE studies. The package leaflet is updated accordingly.",

Correction of opinion

Action: For information

Opinion adopted on 30.04.2020. Request for Supplementary Information adopted on 27.02.2020, 12.12.2019.

The CHMP noted the corrected opinion.

#### 9.1.9. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0036

Roche Registration GmbH

Rapporteur: Sinan B. Sarac

Scope: "Submission of the final report from study GO28915 (OAK) listed as a category 3 study in the RMP. This is a Phase III, open-label multicenter, randomised study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with docetaxel in patients with NSCLC after failure with platinum-containing chemotherapy. In addition, the marketing authorisation holder (MAH) submitted integrated analyses of the potential relationship of ADA and safety were based on studies IMvigor210, IMvigor211, OAK, POPLAR, IMpower150, IMpower130, IMpower131, IMpower132, IMpower133 and IMpassion130 as recommended by the CHMP."

Action: For adoption

Request for Supplementary Information adopted on 12.03.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

#### 9.1.10. WS1587/G

Abasaglar-EMEA/H/C/002835/WS1587/0028/G Humalog-EMEA/H/C/000088/WS1587/0178/G

Eli Lilly Nederland B.V.

Lead Rapporteur: Kristina Dunder

Scope: "Type II variation. B.IV.z.,

Type IAIN B. II.e.5.a.1"

Action: For adoption

Request for Supplementary Information adopted on 30.04.2020, 14.11.2019, 19.09.2019

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

#### 9.1.11. Zurampic - lesinurad - EMEA/H/C/003932

Grunenthal GmbH

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

#### 9.1.12. Forxiga/Edistride (dapagliflozin) – EMEA/H/C/002322 / EMEA/H/C/004161/WS1844

Astra Zeneca AB

Rapporteur: Kristina Dunder

Scope: MAH's intention to re-classify the imposed cat 1 PASS in the T1DM indication, PRAC

advice to CHMP, Request for supplementary information

Action: For adoption

The Committee discussed the issues identified in this application concerning the request for PASS re-classification.

The Committee adopted a request for supplementary information with a specific timetable.

### 10. Referral procedures

# 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

#### 10.1.1. Yondelis - EMEA/H/C/0773/A-20/0060

MAH: Pharma Mar S.A.

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa

Scope: Opinion

**Action**: For adoption

European Commission triggered a referral procedure under Article 20 of Regulation (EC) No 726/2004 to request CHMP to assess study OVC-3006, which failed to meet its endpoints in the indication of ovarian cancer, and its impact on the benefit risk balance for the centrally authorised medicinal product(s) Yondelis (trabectedin).

The CHMP adopted an opinion by consensus recommending that the marketing authorisations for Yondelis should be varied, to include the results from study OVC-3006 in the SmPC.

The CHMP adopted the assessment report together with the translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The public health communication was circulated for information.

# 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

### 10.2.1. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Scope: Implementation of the Nitrosamine Art. 5.3 referral outcome

Action: For information

The CHMP was updated on the implementation of the CHMP opinion. It was noted that processes will be developed to address the detection of nitrosamines. The members noted the timelines of the call for review for chemical and biological medicines. A dedicated group should be put in place for overseeing the implementation (the Nitrosamine Implementation Oversight Group (NIOG)).

#### 10.2.2. Dexamethasone EMEA/H/A-5(3)/1500

MAHs: various

Referral Rapporteur: Peter Kiely, Referral Co-Rapporteur: Ewa Balkowiec Iskra

Scope: Start of procedure, List of Questions, Timetable, Appointment of Rapporteurs

**Action**: For adoption

Dexamethasone for the treatment of COVID-19 in hospitalised adult patients. Assessment of the recovery study arm based on preliminary results (Horby et al 2020)

The CHMP noted the start of procedure and appointed Peter Kiely as Rapporteur and Ewa Balkowiec Iskra as Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Start of procedure (CHMP): July 2020 CHMP

CHMP LoQs to Authors of study: 23.07.2020

Authors' responses to the CHMP LoQs by: 12.08.2020

Rapporteur / co-rapporteur assessment reports circulated to CHMP: 01.09.2020

CHMP comments: 07.09.2020

Updated rapporteur/co-rapporteur assessment reports circulated to CHMP: 11.09.2020

CHMP opinion/LoOIs: September 2020 CHMP

# 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

# 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

#### 10.4.1. Ibuprofen Kabi – EMEA/H/A-29(4)/1498

MAH: Fresenius Kabi Deutschland GmbH

Referral Rapporteur: Janet Koenig, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation

Action: For adoption

Summary: Decentralised procedure number: DE/H/6040/001/DC, notification by the German Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

See 2.4

An oral explanation was held on Tuesday, 21 July 2020. The presentation by the applicant focused on the data for the bridging to the reference medicinal product.

The CHMP adopted an opinion by consensus recommending that the marketing authorisation(s) should be granted.

The CHMP adopted the assessment report together with the translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The guestion-and-answer document was circulated for information.

# **10.5.** Harmonisation - Referral procedure under Article 30 of Directive **2001/83/EC**

#### 10.5.1. Varilrix - EMEA/H/A-30/1499

MAH: GlaxoSmithKline Biologicals

Referral Rapporteur: Jan Mueller-Berghaus, Referral Co-Rapporteur: Sol Ruiz

Scope: List of questions

Action: For adoption

Harmonisation exercise for Varilrix and associated names. Product information harmonisation was triggered by the MAH.

The CHMP adopted a list of questions with a specific timetable.

Submission of responses: 22.10.2020 Re-start of the procedure: 12.11.2020

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 20.11.2020

Comments: 27.11.2020

Updated Rapporteur / co-rapporteur joint AR circulated to CHMP: 03.12.2020

CHMP list of questions/CHMP opinion: December 2020 CHMP

## 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

#### 10.6.1. Panexcell Clinical Laboratories Priv. Ltd - Multiple NAPs (EMEA/H/A-31/1494)

MAH: various

Referral Rapporteur: Janet Koenig, Referral Co-Rapporteur: Jayne Crowe

Scope: Opinion

Action: For adoption

Article 31 procedure triggered by the German Federal Institute of Drugs and Medical Devices (BfArM) concerning the contract research organisation (CRO) Panexcell Clinical Laboratories Priv. Ltd. located in Navi Mumbai 400 701, India.

The CHMP was informed that none of the MAHs requested an oral explanation at the CHMP.

The CHMP adopted an opinion by consensus recommending the suspension of the marketing authorisations of generic medicines tested by Panexcell Clinical Laboratories Priv. Ltd at its site in Mumbai, India.

The CHMP adopted the assessment report together with the translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The public health communication was circulated for information.

#### 10.6.2. Ranitidine - EMEA/H/A-31/1491

MAHs: various

Re-examination Rapporteur: John Joseph Borg, Re-examination Co-Rapporteur: Blanka

Hirschlerova

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Melchiorri

Scope: Appointment of re-examination rapporteurs

**Action:** For information

Tests performed in a random selection of ranitidine API batches and finished products available in the EU have shown levels of NDMA which raise concerns.

European Commission triggered on 12 September 2019 a referral procedure under Article 31 of Directive 2001/83/EC to evaluate the relevance of these findings, the potential root causes and their impact on the benefit-risk balance of medicinal products containing ranitidine.

The CHMP appointed John Joseph Borg as Re-examination Rapporteur and Blanka Hirschlerova as Re-examination Co-Rapporteur.

# 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

### 10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

### 10.9. Disagreement between Member States on Type II variation— Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

### 10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

# 10.11. Referral under Article 13 Disagreement between Member States on Type II variation – Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

### 11. Pharmacovigilance issue

#### 11.1. Early Notification System

July 2020 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

### 12. Inspections

### 12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

#### 12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

### 12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

#### 12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

#### 13. Innovation Task Force

#### 13.1. Minutes of Innovation Task Force

Action: For information

The CHMP noted the minutes.

### 13.2. Innovation Task Force briefing meetings

No items

# 13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

#### 13.4. Nanomedicines activities

No items

### 14. Organisational, regulatory and methodological matters

### 14.1. Mandate and organisation of the CHMP

No items

#### 14.2. Coordination with EMA Scientific Committees

#### 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 6-9 July 2020

Action: For information

The CHMP noted the Summary of recommendations and advice.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for July 2020

Action: For adoption

The CHMP adopted the EURD list.

#### 14.2.2. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 14-16 July 2020

Action: For information

The CHMP noted the information.

## **14.3.** Coordination with EMA Working Parties/Working Groups/Drafting Groups

#### 14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP July 2020 meeting to CHMP for adoption:

- 15 reports on products in scientific advice and protocol assistance
- 12 reports on products in pre-authorisation procedures
- 1 report on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

#### 14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 2-3 June 2020

Table of Decisions of the NRG meeting held on 30 June - 1 July 2020

Action: For adoption

The CHMP adopted the table of decisions.

#### 14.3.3. Quality Working Party (QWP)

Chair(s): Blanka Hirschlerova

QWP response to questions from CMDh on acceptability of the proposed in-use period of 3 months for TAPTIQOM 15 micrograms/ml + 5 mg/ml eye drops, solution

Action: For adoption

The CHMP adopted the QWP response.

#### 14.3.4. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 06-09 July 2020. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

### 14.4. Cooperation within the EU regulatory network

No items

### 14.5. Cooperation with International Regulators

No items

### 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

### 14.7. CHMP work plan

No items

### 14.8. Planning and reporting

No items

#### 14.9. Others

No items

### 15. Any other business

#### 15.1. AOB topic

#### 15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

### 15.1.2. Online public consultation on the Pharmaceutical Strategy for Europe

#### https://ec.europa.eu/health/human-use/strategy\_en

Action: For information

The CHMP noted the update. Coming in the wake of the COVID-19 pandemic, the Strategy will aim to ensure Europe's supply of safe and affordable medicines to meet patients' needs and support the European pharmaceutical industry to remain an innovator and world leader.

The aim of the consultation is to allow the public, experts and stakeholders to contribute and voice their opinion on the best ways to address pharmaceutical related issues in the EU. The results of the public consultation will contribute to the preparation, in the autumn, of the Pharmaceutical Strategy, which is expected to be adopted by the end of the year.

### 16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 20-23 July 2020 CHMP meeting.

Name	Role	Member	Outcome	Topics on agenda for
rame	Roic	State or	restriction	which restrictions apply
		affiliation	following	
			evaluation of	
			e-DoI	
			No interests	
Harald Enzmann	Chair	Germany	declared	
			No interests	
Andrea Laslop	Member	Austria	declared	
Milena Stain	Alternate	Austria	No interests declared	
Bart Van der	Aiterriate	Austria	No interests	
Schueren	Alternate	Belgium	declared	
			No interests	
Mila Vlaskovska	Member	Bulgaria	declared	
Margareta Dege	Manahau	Crostis	No interests	
Margareta Bego Selma Arapovic	Member	Croatia	declared No interests	
Dzakula	Alternate	Croatia	declared	
Emilia			No interests	
Mavrokordatou	Alternate	Cyprus	declared	
0 17 1 Cl Y		Czech	No interests	
Ondřej Slanař Tomas	Member	Republic Czech	declared No interests	
Radimersky	Alternate	Republic	declared	
radifficiony	Aucernace	Керивне	No interests	
Sinan B. Sarac	Member	Denmark	declared	
Kirstine Moll			No interests	
Harboe	Alternate	Denmark	declared	
			No restrictions applicable to	
Alar Irs	Member	Estonia	this meeting	
			No restrictions	
			applicable to	
Outi Mäki-Ikola	Member	Finland	this meeting	
Tuomo Lapveteläinen	Alternate	Finland	No interests declared	
Lapvetelainen	Alternate	Tillalla	No interests	
Alexandre Moreau	Member	France	declared	
			No interests	
Jean-Michel Race	Alternate	France	declared	
Martina Weise	Member	Germany	No restrictions	
			applicable to this meeting	
			No interests	
Janet Koenig	Alternate	Germany	declared	
Konstantinos			No interests	
Markopoulos	Member	Greece	declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Mikulalal	Alternate	JI CCCE	ucciai ca	

Name	Role	Member	Outcome	Tonics on agonda for
Name	Kole		Outcome	Topics on agenda for which restrictions apply
		State or	restriction	which restrictions apply
		affiliation	following	
			evaluation of	
Melinda Sobor	Member	Hungary	e-DoI No part in	Dupixent
Melifida Sobol	меттрет	Tiurigary	discussions,	EMEA/H/C/004390/II/0027
			final	, , , , , , , , , , , , , , , , , , , ,
			deliberations	
			and voting as appropriate	
			No interests	
Agnes Gyurasics	Alternate	Hungary	declared	
Hrefna	A.I.		No interests	
Gudmundsdottir	Alternate	Iceland	declared No interests	
Jayne Crowe	Member	Ireland	declared	
·			No interests	
Peter Kiely	Alternate	Ireland	declared	
Daniela Melchiorri	Member	Italy	No restrictions applicable to	
			this meeting	
			No interests	
Giuseppa Pistritto	Alternate	Italy	declared	
Elita Poplavska	Alternate	Latvia	No interests declared	
Romaldas	Aiternate	Latvia	No interests	
Mačiulaitis	Member	Lithuania	declared	
Simona			No interests	
Stankeviciute	Alternate	Lithuania	declared No interests	
Martine Trauffler	Member	Luxembourg	declared	
			No interests	
John Joseph Borg	Member	Malta	declared	
Johann Lodewijk			No interests	
Hillege	Member	Netherlands	declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions	
, ,		,	applicable to	
			this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec			No interests	
Iskra	Member	Poland	declared	
Bruno Sepodes	Member (Vice- Chair)	Portugal	No interests declared	
bruno Sepodes	Citaii)	Portugal	No restrictions	
			applicable to	
Fatima Ventura	Alternate	Portugal	this meeting	
Simona Badoi	Member	Romania	No interests declared	
Dana	HEITIDEI	Nomania	No interests	
Gabriela Marin	Alternate	Romania	declared	
		a	No interests	
Francisek Drafi Nevenka Trsinar	Member	Slovakia	declared	
Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion			No interests	
Prieto Yerro	Member	Spain	declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Blanca Garcia- Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner Koenraad Norga	Co-opted member Co-opted	Austria Belgium	No restrictions applicable to this meeting No	Blenrep - belantamab
	member		participation in final deliberations and voting on	mafodotin - EMEA/H/C/004935
Jan Mueller- Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czech Republic	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Beate Maichel	Expert - via telephone*	Austria	No interests declared	
Eskild Colding- Jørgensen	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	
Nikica Mirosevic Skvrce	Expert - via telephone*	Croatia	No interests declared	
Stephanie Hueber	Expert - via Adobe*	France	No interests declared	
Nathalie Dumarcet	Expert - via Adobe*	France	No interests declared	
Mogens Westergaard	Expert - via Adobe*	Denmark	No interests declared	
Tomas Boran	Expert - via Adobe*	Czech Republic	No interests declared	
Karel Ulrych	Expert - via Adobe*	Czech Republic	No restrictions applicable to this meeting	
Mario Miguel Coelho da Silva Rosa	Expert - via Adobe*	Portugal	No interests declared	
Pertti Pellinen	Expert - via Adobe*	Finland	No restrictions applicable to this meeting	
Augustin Portela	Expert - via Adobe*	Spain	No interests declared	
Cecile Dop	Expert - via Adobe*	France	No interests declared	
Nicolas Glasser	Expert - via Adobe*	France	No interests declared	
Mair Powell	Expert - via Adobe*	Ireland	No interests declared	
Nuala Kelly	Expert - via Adobe*	Ireland	No interests declared	

Name	Role	Member State or	Outcome restriction	Topics on agenda for which restrictions apply
		affiliation	following	
			evaluation of	
Ebru Karakoc Madsen	Expert - via Adobe*	Denmark	e-DoI  No restrictions applicable to this meeting	
Claudia Reichmann	Expert - via Adobe*	Germany	No interests declared	
Uta Buckpesch- Heberer	Expert - via Adobe*	Germany	No interests declared	
Anja Schiel	Expert - via Adobe*	Norway	No interests declared	
Miki Hew	Expert - via Adobe*	Netherlands	No interests declared	
Rou-Afza Gunput	Expert - via Adobe*	Netherlands	No interests declared	
Andre Elferink	Expert - via Adobe*	Netherlands	No interests declared	
Helene Blok	Expert - via Adobe*	Netherlands	No interests declared	
Michel Kooijman	Expert - via Adobe*	Netherlands	No interests declared	
Johannus Theodorus Span	Expert - via Adobe*	Netherlands	No interests declared	
Jacqueline van Kuijk	Expert - via Adobe*	Netherlands	No interests declared	
Johanna Henriksnas	Expert - via Adobe*	Sweden	No restrictions applicable to this meeting	
Peter Theunissen	Expert - via Adobe*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via Adobe*	Netherlands	No interests declared	
Lieke Sandberg	Expert - via Adobe*	Netherlands	No interests declared	
Elisabeth Johanne Rook	Expert - via Adobe*	Netherlands	No interests declared	
Sanna Gevers	Expert - via Adobe*	Netherlands	No interests declared	
Hinke Johanna van der Woude	Expert - via Adobe*	Netherlands	No interests declared	
Miriam Fuers- Wilmes	Expert - via Adobe*	Germany	No interests declared	
Elmer Schable	Expert - via Adobe*	Germany	No interests declared	
Sofia Kapanadze	Expert - via Adobe*	Germany	No restrictions applicable to this meeting	
Katalina Mettke	Expert - via Adobe*	Germany	No interests declared	
Irena Rogovska	Expert - via Adobe*	Latvia	No interests declared	
Ilze Kalve	Expert - via Adobe*	Latvia	No interests declared	
Kristine Supe	Expert - via Adobe*	Latvia	No interests declared	
Anouk Neuteboom	Expert - via Adobe*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lies van Vlijmen	Expert - via Adobe*	Netherlands	No interests declared	
Emmely de Vries	Expert - via Adobe*	Netherlands	No interests declared	
Jan Welink	Expert - via Adobe*	Netherlands	No interests declared	
Alicia Perez Gonzalez	Expert - via Adobe*	Spain	No interests declared	
		·		
Meeting run with th	e help of EMA staff			

<sup>\*</sup>Experts were only evaluated against the product(s) they have been invited to talk about.

### 17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

#### **Oral explanations** (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

#### **Initial applications** (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (Day 180 List of outstanding issues) and 3.3 (Day 120 list of questions).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

#### Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

#### **Type II variations - Extension of indication procedures** (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

#### **Ancillary medicinal substances in medical devices** (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

### Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

#### **Re-examination procedures** (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

#### Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

#### Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

#### **Pre-submission issues** (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

#### Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

#### **Referral procedures** (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found <a href="https://example.com/here">here.</a>

#### Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

#### **Inspections Issues** (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

#### **Innovation task force** (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

#### Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found <a href="here">here</a>.

#### **Satellite groups / other committees** (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

#### **Invented name issues** (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found <a href="https://example.com/here-new medicines">here</a>.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



28 October 2020 EMA/CHMP/566439/2020

### Annex to 20-23 July 2020 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES	. З
A.1. ELIGIBILITY REQUESTS	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	. 3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity	4
B.2.3. Renewals of Conditional Marketing Authorisations	7
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES	8
B.4. EPARs / WPARs	
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	14
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	14
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	23
B.5.3. CHMP-PRAC assessed procedures	
B.5.4. PRAC assessed procedures	
B.5.5. CHMP-CAT assessed procedures	
B.5.6. CHMP-PRAC-CAT assessed procedures	
B.5.7. PRAC assessed ATMP procedures	
B.5.8. Unclassified procedures and worksharing procedures of type I variations	
B.5.9. Information on withdrawn type II variation / WS procedure	
B.5.10. Information on type II variation / WS procedure with revised timetable	
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	
B.6.1. Start of procedure for New Applications: timetables for information	59
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	60
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information	



B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	ne .
·	
B.6.6. VARIATIONS – START OF THE PROCEDURE	
B.6.7. Type II Variations scope of the Variations: Extension of indication	
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	
B.6.10. CHMP-PRAC assessed procedures	
B.6.11. PRAC assessed procedures	86
B.6.12. CHMP-CAT assessed procedures	90
B.6.13. CHMP-PRAC-CAT assessed procedures	91
B.6.14. PRAC assessed ATMP procedures	91
B.6.15. Unclassified procedures and worksharing procedures of type I variations	91
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY	96
B.7.1. Yearly Line listing for Type I and II variations	96
B.7.2. Monthly Line listing for Type I variations	96
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (Monly)	
B.7.5. Request for supplementary information relating to Notification of Type I variation	
(MMD only)	
B.7.6. Notifications of Type I Variations (MMD only)	96
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures start in that given month with assessment timetabled)	_
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs	
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by	У
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)	y . 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	y . 96 . 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)	y . <b>96</b> . <b>96</b>
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update	<b>y</b> . <b>96</b> 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update  E.1.2. Variations:	. <b>96</b> 96 96 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update  E.1.2. Variations:  E.1.3. Initial PMF Certification:	. 96 96 96 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update  E.1.2. Variations:  E.1.3. Initial PMF Certification:  E.2. Timetables - starting & ongoing procedures: For information	. 96 96 96 96 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update  E.1.2. Variations:  E.1.3. Initial PMF Certification:  E.2. Timetables - starting & ongoing procedures: For information  F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver  F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98	y . 96 96 96 96 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES	y . 96 96 96 96 96
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES	y . 96 96 96 96 96 97
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES	y . 96 96 96 96 97 97
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES	y . 96 96 96 96 97 of 97
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	y . 96 96 96 96 97 97 97
including description and conclusion, for adoption by CHMP in that give month, or finalised ones with PRAC recommendation and no adoption be CHMP needed)  E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES  E.1. PMF Certification Dossiers:  E.1.1. Annual Update  E.1.2. Variations:  E.1.3. Initial PMF Certification:  E.2. Timetables - starting & ongoing procedures: For information  F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver  F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 14 December 1998, as amended  F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health  G. ANNEX G.  G.1. Final Scientific Advice (Reports and Scientific Advice letters):	y . 96 96 96 96 97 97 97

EMA/CHMP/566439/2020 Page 2/98

G.3.2. List of procedures starting in July 2020 for September 2020 CHMP adoption of outcomes	98
H. ANNEX H - Product Shared Mailboxes - e-mail address	98
A. PRE-SUBMISSION ISSUES	
A.1. ELIGIBILITY REQUESTS	
Report on Eligibility to Centralised Procedure for Adopted.  July 2020: For adoption	

#### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for

Adopted.

July 2020: For adoption

#### **A.3. PRE-SUBMISSION ISSUES FOR INFORMATION**

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

#### **B. POST-AUTHORISATION PROCEDURES OUTCOMES**

#### **B.1.** Annual re-assessment outcomes

#### B.1.1. Annual reassessment for products authorised under exceptional circumstances

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid -	Positive Opinion adopted by consensus together with the CHMP assessment report.	
EMEA/H/C/004061/S/0014, Orphan Leadiant GmbH, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Adam	The Marketing Authorisation remains under exceptional circumstances.	
Przybylkowski	The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.	
Elaprase - idursulfase - EMEA/H/C/000700/S/0087	Positive Opinion adopted by consensus together with the CHMP assessment report.	
Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan	The Marketing Authorisation remains under exceptional circumstances.	
,	The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.	

EMA/CHMP/566439/2020 Page 3/98

#### **B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES**

#### **B.2.1.** Renewals of Marketing Authorisations requiring 2nd Renewal

### Episalvan - birch bark extract - EMEA/H/C/003938/R/0018

Amryt GmbH, Rapporteur: Kristina Dunder, Co-Rapporteur: Natalja Karpova, PRAC Rapporteur:

Zane Neikena

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that an additional five-year renewal was required.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

#### **B.2.2.** Renewals of Marketing Authorisations for unlimited validity

## Aripiprazole Accord - aripiprazole - EMEA/H/C/004021/R/0019

Accord Healthcare S.L.U., Generic of Abilify, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ana Sofia Diniz Martins

Request for Supplementary Information adopted

on 28.05.2020.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

## Briviact - brivaracetam - EMEA/H/C/003898/R/0025

UCB Pharma S.A., Rapporteur: Filip Josephson, Co-Rapporteur: Daniela Melchiorri, PRAC

Rapporteur: Adam Przybylkowski

 $\label{lem:lementary Information adopted} Request for Supplementary Information adopted$ 

on 28.05.2020.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

### Cinacalcet Mylan - cinacalcet - EMEA/H/C/004014/R/0011

Mylan S.A.S, Generic, Generic of Mimpara, Rapporteur: Tomas Radimersky, PRAC

Rapporteur: Ulla Wändel Liminga

Request for Supplementary Information adopted

on 28.05.2020.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

### Edistride - dapagliflozin - EMEA/H/C/004161/R/0038

AstraZeneca AB, Rapporteur: Kristina Dunder,

See agenda 9.1

Positive Opinion adopted by consensus together

EMA/CHMP/566439/2020 Page 4/98

Co-Rapporteur: Martina Weise, PRAC

Rapporteur: Annika Folin

Request for Supplementary Information adopted

on 25.06.2020, 28.05.2020.

with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

## Eptifibatide Accord - eptifibatide - EMEA/H/C/004104/R/0010

Accord Healthcare S.L.U., Generic of Integrilin, Rapporteur: Jayne Crowe, PRAC Rapporteur: Adrien Inoubli Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

# Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/R/0069

Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ilaria Baldelli Request for Supplementary Information adopted Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

### Jevtana - cabazitaxel - EMEA/H/C/002018/R/0042

on 28.05.2020.

sanofi-aventis groupe, Rapporteur: Alexandre Moreau, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 23.07.2020. Request for supplementary information adopted with a specific timetable.

### Kovaltry - octocog alfa -EMEA/H/C/003825/R/0030

Bayer AG, Rapporteur: Kristina Dunder, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur:

Brigitte Keller-Stanislawski

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Lopinavir/Ritonavir Mylan - lopinavir / ritonavir - EMEA/H/C/004025/R/0014

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 5/98

Mylan S.A.S, Generic, Generic of Kaletra, Rapporteur: John Joseph Borg, PRAC

Rapporteur: Adrien Inoubli

Request for Supplementary Information adopted

on 23.07.2020.

### Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/R/0056

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald Request for Supplementary Information adopted

on 23.07.2020, 28.05.2020.

Request for supplementary information adopted with a specific timetable.

### Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/R/0012

Accord Healthcare S.L.U., Generic of Alimta, Rapporteur: John Joseph Borg, PRAC

Rapporteur: Tiphaine Vaillant

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

### Rasagiline Mylan - rasagiline - EMEA/H/C/004064/R/0006

Mylan S.A.S, Generic, Generic of AZILECT, Rapporteur: Kolbeinn Gudmundsson, PRAC

Rapporteur: Ana Sofia Diniz Martins

Request for Supplementary Information adopted

on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

### Spectrila - asparaginase - EMEA/H/C/002661/R/0018

medac Gesellschaft fur klinische

Spezialpraparate mbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Daniela Melchiorri, PRAC

Rapporteur: Jan Neuhauser

Request for Supplementary Information adopted

on 25.06.2020.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/R/0065

MCM Vaccine B.V., Rapporteur: Christophe Focke, Co-Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Brigitte Keller-Stanislawski Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members

EMA/CHMP/566439/2020 Page 6/98

were in agreement with the CHMP Opinion.

## Zalviso - sufentanil - EMEA/H/C/002784/R/0016

Grunenthal GmbH, Rapporteur: Milena Stain, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted

on 26.03.2020.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

#### **B.2.3.** Renewals of Conditional Marketing Authorisations

## Adcetris - brentuximab vedotin - EMEA/H/C/002455/R/0079, Orphan

Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

# Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/R/0004

Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

## NINLARO - ixazomib - EMEA/H/C/003844/R/0021, Orphan

Takeda Pharma A/S, Rapporteur: Daniela Melchiorri, Co-Rapporteur: Kristina Dunder,

PRAC Rapporteur: Annika Folin

Request for Supplementary Information adopted

on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 7/98

#### **B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES**

#### Signal detection

# PRAC recommendations on signals adopted at the PRAC meeting held on 06-09 July 2020:

#### Signal of Kaposi's sarcoma

AMGEVITA, AMSPARITY, HALIMATOZ, HEFIYA, HULIO, HUMIRA, HYRIMOZ, IDACIO, IMRALDI, CIMZIA, BENEPALI, ENBREL, ERELZI, SIMPONI, FLIXABI, INFLECTRA, REMICADE, REMSIMA, ZESSLY (CAP) – tumour necrosis factor (TNF) inhibitors

Rapporteur: various, Co-Rapporteur: various

PRAC recommendation on a variation

Action: For adoption

Adopted.

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its July 2020 meeting:

# **EMEA/H/C/PSUSA/00000805/201912** (clofarabine)

CAPS:

**Evoltra** (EMEA/H/C/000613) (clofarabine), Genzyme Europe BV, Rapporteur: Alexandre Moreau

**Ivozall** (EMEA/H/C/005039) (clofarabine), ORPHELIA Pharma SAS, Rapporteur: Simona Badoi

NAPS:

**CLOFARABINE NEON HEALTHCARE** - NEON HEALTHCARE LIMITED

PRAC Rapporteur: Tiphaine Vaillant, "Period Covered From: 14/11/2019 To: 28/12/2019"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of section 4.2 of the SmPC to add the step of filtration in sub-section "Method of administration". Updated of Annex IIIa, section 5 "Method and route(s) of administration" of "Particulars to appear on the outer packaging outer carton" to include the need of filtration. Addition of a dedicated section in the package leaflet "Instructions for Use for Healthcare Professionals Handling clofarabine". The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00001838/201912

(lenalidomide)

CAPS:

**Lenalidomide Accord** (EMEA/H/C/004857) (lenalidomide), Accord Healthcare S.L.U.,

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended,

EMA/CHMP/566439/2020 Page 8/98

Rapporteur: Ewa Balkowiec Iskra

**Revlimid** (EMEA/H/C/000717) (lenalidomide), Celgene Europe BV, Rapporteur: Alexandre

Moreau NAPS:

NAPs - EU

PRAC Rapporteur: Tiphaine Vaillant, "Period Covered From: 26/12/2018 To: 26/12/2019"

recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following changes:

#### For all MAHs:

Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction pulmonary hypertension with a frequency "uncommon" for all grades and "rare" for grade 3-4, and a warning on the risk of pulmonary hypertension. The Package leaflet is updated accordingly.

#### For Lenalidomide Accord:

Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction pulmonary hypertension with a frequency "uncommon" for all grades and "rare" for grade 3-4, and a warning on the risk of pulmonary hypertension. The Package leaflet is updated accordingly. In addition, removal of the black triangle and additional monitoring statements from the product information.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

### **EMEA/H/C/PSUSA/00001892/201912** (liraglutide)

CAPS:

**Saxenda** (EMEA/H/C/003780) (liraglutide), Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege

**Victoza** (EMEA/H/C/001026) (liraglutide), Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "Period Covered From: 01/01/2019 To: 31/12/2019" The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.9 of the SmPC to inform HCP's that hypoglycaemia has occurred in cases of liraglutide overdose. The Package Leaflet has been updated accordingly. In addition, for Victoza the MAH took the opportunity to add a paragraph regarding traceability to section 4.4 of the SmPC and to align the Annex II to the latest QRD template. The Icelandic and the Norwegian CHMP

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010020/201911

(aflibercept (ophthalmological indication(s))) CAPS:

**Eylea** (EMEA/H/C/002392) (aflibercept), Bayer AG, Rapporteur: Alexandre Moreau, PRAC

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the

EMA/CHMP/566439/2020 Page 9/98

Rapporteur: Tiphaine Vaillant, "Period Covered

From: 01/12/2018 To: 30/11/2019"

terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction "retinal haemorrhage" with a "very common" frequency. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010322/201912

(olaparib)

CAPS:

**Lynparza** (EMEA/H/C/003726) (olaparib), AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, "Period Covered From: 16/12/2018 To: 15/12/2019" The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:

Update of section 4.8 of the SmPC to add "Erythema Nodosum" and "Angioedema" with a frequency "rare" and "uncommon" respectively. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010341/201912

(secukinumab)

CAPS:

**Cosentyx** (EMEA/H/C/003729) (secukinumab), Novartis Europharm Limited, Rapporteur: Tuomo Lapveteläinen, PRAC Rapporteur: Eva A. Segovia, "Period Covered From: 26/12/2018 To: 25/12/2019" The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction fatigue, nausea and headache with a frequency common. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010391/201912

(lutetium (177Lu) chloride)

CAPS:

**EndolucinBeta** (EMEA/H/C/003999) (lutetium (177Lu) chloride), ITM Medical Isotopes GmbH, Rapporteur: Peter Kiely

**Lumark** (EMEA/H/C/002749) (lutetium (177Lu) chloride), I.D.B. Holland B.V., Rapporteur: Jean-Michel Race

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following

EMA/CHMP/566439/2020 Page 10/98

NAPS:

NAPs - EU

PRAC Rapporteur: Ronan Grimes

, "Period Covered From: 19/12/2018 To:

19/12/2019"

change(s):

Update of section 4.4 of the SmPC to amend a warning on renal irradiation; of sections 4.4 and 4.8 of the SmPC to amend a warning on myelosuppression and to add the adverse reaction pancytopenia with a frequency not known; of section 4.8 of the SmPC to add the adverse reaction neutropenia with a frequency common and dry mouth with a frequency not known. The package leaflet is updated accordingly. Section 2 of the package leaflet is also updated to add a warning on extravasation. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010647/201912

(dimethyl fumarate (psoriasis))

CAPS:

**Skilarence** (EMEA/H/C/002157) (dimethyl fumarate), Almirall S.A, Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin, "Period Covered From: 24/06/2019 To: 23/12/2019"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change:

The term « herpes zoster » under SOC "Infections and infestations" should be included in Table 1 section 4.8 of the SmPC of Skilarence. At present marked with frequency "Not known" and a footnote below the Table stating that "Adverse reactions derived only during post marketing experience". An asterisk to other reported reactions has also been removed. The term « Shingles » should be included in section 4. Possible side effects, under frequency «Not known: frequency cannot be estimated from the available data » in order to reflect SmPC.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00010671/201911

(semaglutide)

CAPS:

**Ozempic** (EMEA/H/C/004174) (semaglutide), Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Annika Folin, "Period Covered From: 01/06/2019 To: 30/11/2019" The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to introduce the grouped term 'hypersensitivity', covering adverse events related to hypersensitivity, rash

EMA/CHMP/566439/2020 Page 11/98

and urticaria, to the list of adverse drug reactions with a frequency 'uncommon'. The Package Leaflet is updated accordingly. The MAH also took the opportunity to add a paragraph on traceability in line with the latest QRD template to section 4.4 of the SmPC. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### EMEA/H/C/PSUSA/00107800/201912 (levodopa)

CAPS:

**Inbrija** (EMEA/H/C/004786) (levodopa), Acorda Therapeutics Ireland Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Nikica Mirošević Skvrce, "Period Covered From: 21/12/2018 To: 20/12/2019" The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction 'sensation of choking' with a frequency 'not known'. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### **B.4. EPARs / WPARs**

### Abicipar Pegol Allergan (WD) - abicipar pegol - EMEA/H/C/005103

Allergan Pharmaceuticals International Limited, treatment of neovascular (wet) age-related macular degeneration (AMD), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### **WPAR**

### ABILIFY MYCITE - aripiprazole - EMEA/H/C/005062

Otsuka Pharmaceutical Netherlands B.V., treatment: of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence, Hybrid application (Article 10(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### **WPAR**

## Aybintio - bevacizumab - EMEA/H/C/005106

Samsung Bioepis NL B.V., treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of

For information only. Comments can be sent to the PL in case necessary.

EMA/CHMP/566439/2020 Page 12/98

platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer - first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

- first line treatment of patients with advanced and/or metastatic renal cell cancer., Similar biological application (Article 10(4) of Directive No 2001/83/EC)

### Gencebok - caffeine citrate - EMEA/H/C/005435

Gennisium Pharma, treatment of primary apnoea, Hybrid application (Article 10(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### Idefirix - imlifidase - EMEA/H/C/004849, Orphan

Hansa Biopharma AB, Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor., New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

## Kaftrio - elexacaftor / tezacaftor / ivacaftor - EMEA/H/C/005269, Orphan

Vertex Pharmaceuticals (Ireland) Limited, treatment of cystic fibrosis, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### LIVOGIVA - teriparatide - EMEA/H/C/005087

Theramex Ireland Limited, treatment of osteoporosis, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

# Methylthioninium chloride Cosmo - methylthioninium chloride - EMEA/H/C/002776

Cosmo Technologies Ltd, is indicated as an aid for the enhanced visualisation and detection of colorectal lesions in adult patients undergoing screening / surveillance colonoscopy for colorectal cancer., Hybrid application (Article 10(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

### Pretomanid FGK - pretomanid - EMEA/H/C/005167, Orphan

FGK Representative Service GmbH, treatment of tuberculosis, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

EMA/CHMP/566439/2020 Page 13/98

### QUTAVINA - teriparatide - EMEA/H/C/005388

EuroGenerics Holdings B.V., treatment of osteoporosis, Duplicate of Livogiva, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

## Turalio - pexidartinib - EMEA/H/C/004832, Orphan

Daiichi Sankyo Europe GmbH, treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT), also referred to as giant cell tumour of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Veklury - remdesivir - EMEA/H/C/005622**Gilead Sciences Ireland UC, treatment of coronavirus disease 2019 (COVID-19), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### **B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES**

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

#### **B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects**

# Abilify Maintena - aripiprazole - EMEA/H/C/002755/II/0036/G

Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Bruno Sepodes Opinion adopted on 23.07.2020. Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Advate - octocog alfa - EMEA/H/C/000520/II/0107

Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 30.04.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0013

Baxalta Innovations GmbH, Rapporteur: Andrea Laslop

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

# ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0014/G

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 14/98

Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 23.07.2020. ADYNOVI - rurioctocog alfa pegol -Request for supplementary information adopted EMEA/H/C/004195/II/0015/G with a specific timetable. Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 23.07.2020. Cinacalcet Mylan - cinacalcet -Request for supplementary information adopted EMEA/H/C/004014/II/0009 with a specific timetable. Mylan S.A.S, Generic, Generic of Mimpara, Rapporteur: Tomas Radimersky Request for Supplementary Information adopted on 02.07.2020, 30.04.2020. Dupixent - dupilumab -Request for supplementary information adopted EMEA/H/C/004390/II/0031/G with a specific timetable. sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.07.2020. Epclusa - sofosbuvir / velpatasvir -Positive Opinion adopted by consensus on EMEA/H/C/004210/II/0049/G 16.07.2020. The Icelandic and Norwegian CHMP Gilead Sciences Ireland UC, Rapporteur: Filip Members were in agreement with the CHMP Josephson recommendation. Opinion adopted on 16.07.2020. Fasenra - benralizumab -Positive Opinion adopted by consensus on EMEA/H/C/004433/II/0028/G 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP AstraZeneca AB, Rapporteur: Fátima Ventura Opinion adopted on 16.07.2020. recommendation. Fasenra - benralizumab -Positive Opinion adopted by consensus on EMEA/H/C/004433/II/0029/G 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP AstraZeneca AB, Rapporteur: Fátima Ventura Opinion adopted on 23.07.2020. recommendation. Flucelvax Tetra - influenza vaccine surface Positive Opinion adopted by consensus on antigen inactivated prepared in cell 10.07.2020. The Icelandic and Norwegian CHMP cultures - EMEA/H/C/004814/II/0014 Members were in agreement with the CHMP Segirus Netherlands B.V., Rapporteur: Sol Ruiz recommendation. Opinion adopted on 10.07.2020. Positive Opinion adopted by consensus on Fluenz Tetra - influenza vaccine (live attenuated, nasal) -10.07.2020. The Icelandic and Norwegian CHMP EMEA/H/C/002617/II/0101 Members were in agreement with the CHMP AstraZeneca AB, Rapporteur: Christophe Focke recommendation.

EMA/CHMP/566439/2020 Page 15/98

Positive Opinion adopted by consensus on

Opinion adopted on 10.07.2020.

Gardasil 9 - human papillomavirus vaccine

#### [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) -EMEA/H/C/003852/II/0038/G

MSD Vaccins, Rapporteur: Kristina Dunder

Opinion adopted on 23.07.2020.

23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0111/G

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 19.03.2020, 12.12.2019.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0116

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 16.07.2020.

Request for supplementary information adopted with a specific timetable.

### IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0041/G, Orphan

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 16.07.2020.

Request for supplementary information adopted with a specific timetable.

## ILARIS - canakinumab - EMEA/H/C/001109/II/0069/G

Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 02.07.2020.

Request for supplementary information adopted with a specific timetable.

## Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0012/G

Almirall S.A, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 14.05.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0047/G

Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

# IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0049

Bavarian Nordic A/S, Rapporteur: Jan Mueller-

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 16/98

Berghaus Request for Supplementary Information adopted on 23.07.2020. Inflectra - infliximab -Positive Opinion adopted by consensus on EMEA/H/C/002778/II/0088/G 02.07.2020. The Icelandic and Norwegian CHMP Pfizer Europe MA EEIG, Duplicate, Duplicate of Members were in agreement with the CHMP Remsima, Rapporteur: Outi Mäki-Ikola recommendation. Opinion adopted on 02.07.2020. JETREA - ocriplasmin -Positive Opinion adopted by consensus on EMEA/H/C/002381/II/0050 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Oxurion NV, Rapporteur: Kristina Dunder Opinion adopted on 16.07.2020. recommendation. Keytruda - pembrolizumab -Positive Opinion adopted by consensus on EMEA/H/C/003820/II/0088 09.07.2020. The Icelandic and Norwegian CHMP Merck Sharp & Dohme B.V., Rapporteur: Members were in agreement with the CHMP Daniela Melchiorri recommendation. Opinion adopted on 09.07.2020. Lamzede - velmanase alfa -Request for supplementary information adopted EMEA/H/C/003922/II/0012/G, Orphan with a specific timetable. Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 09.07.2020. MabThera - rituximab -Request for supplementary information adopted with a specific timetable. EMEA/H/C/000165/II/0173/G Roche Registration GmbH, Rapporteur: Sinan B. Sarac Request for Supplementary Information adopted on 09.07.2020. Menveo - meningococcal group A, C, W135 Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP and Y conjugate vaccine -EMEA/H/C/001095/II/0094/G Members were in agreement with the CHMP GSK Vaccines S.r.I, Rapporteur: Johann recommendation. Lodewijk Hillege Opinion adopted on 16.07.2020. Mepsevii - vestronidase alfa -Positive Opinion adopted by consensus on EMEA/H/C/004438/II/0013/G, Orphan 23.07.2020. The Icelandic and Norwegian CHMP Ultragenyx Germany GmbH, Rapporteur: Members were in agreement with the CHMP Johann Lodewijk Hillege recommendation. Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 05.06.2020, 17.04.2020. Mysimba - naltrexone hydrochloride / Request for supplementary information adopted bupropion hydrochloride with a specific timetable. EMEA/H/C/003687/II/0042

EMA/CHMP/566439/2020 Page 17/98

Orexigen Therapeutics Ireland Limited,

Rapporteur: Kirstine Moll Harboe

Request for Supplementary Information adopted

on 23.07.2020.

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0098

Pfizer Europe MA EEIG, Rapporteur: Bjorg

**Bolstad** 

Opinion adopted on 09.07.2020.

Request for Supplementary Information adopted

on 14.05.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0099/G

Pfizer Europe MA EEIG, Rapporteur: Bjorg

**Bolstad** 

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Ongentys - opicapone - EMEA/H/C/002790/II/0028/G

Bial - Portela & Ca, S.A., Rapporteur: Martina Weise

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Ontruzant - trastuzumab - EMEA/H/C/004323/II/0024/G

Samsung Bioepis NL B.V., Rapporteur:

Koenraad Norga

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Orencia - abatacept - EMEA/H/C/000701/II/0140/G

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Outi Mäki-Ikola

Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

Pazenir - paclitaxel - EMEA/H/C/004441/II/0007

ratiopharm GmbH, Generic, Generic of Abraxane, Rapporteur: Milena Stain

Request for Supplementary Information adopted

on 16.07.2020.

Request for supplementary information adopted with a specific timetable.

Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0068

Merck Europe B.V., Rapporteur: Kirstine Moll

Harboe

Request for Supplementary Information adopted

on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

Perjeta - pertuzumab -

Request for supplementary information adopted

EMA/CHMP/566439/2020 Page 18/98

EMEA/H/C/002547/II/0049/G

Roche Registration GmbH, Rapporteur: Sinan B.

Sarac

Request for Supplementary Information adopted on 09.07.2020.

with a specific timetable.

POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0005/G, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Paula Boudewina van Hennik

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 07.05.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMEA/H/C/001104/II/0190

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0163

CSL Behring GmbH, Rapporteur: Jan Mueller-

Berghaus

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

ReFacto AF - moroctocog alfa - EMEA/H/C/000232/II/0153/G

Pfizer Europe MA EEIG, Rapporteur: Kirstine Moll Harboe

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Remsima - infliximab - EMEA/H/C/002576/II/0088/G

Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola

Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0041

CSL Behring GmbH, Rapporteur: Kristina Dunder

Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Revatio - sildenafil - EMEA/H/C/000638/II/0090/G

Upjohn EESV, Rapporteur: Johann Lodewijk Hillege

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Ritonavir Mylan - ritonavir -

Request for supplementary information adopted

EMA/CHMP/566439/2020 Page 19/98

EMEA/H/C/004549/II/0007/G with a specific timetable. Mylan S.A.S, Generic, Generic of Norvir, Rapporteur: John Joseph Borg Request for Supplementary Information adopted on 16.07.2020, 17.04.2020. Skyrizi - risankizumab -Request for supplementary information adopted EMEA/H/C/004759/II/0010/G with a specific timetable. AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely Request for Supplementary Information adopted on 23.07.2020. Somavert - pegvisomant -Positive Opinion adopted by consensus on EMEA/H/C/000409/II/0095 02.07.2020. The Icelandic and Norwegian CHMP Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Members were in agreement with the CHMP Race recommendation. Opinion adopted on 02.07.2020. Stelara - ustekinumab -Positive Opinion adopted by consensus on EMEA/H/C/000958/II/0080/G 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Janssen-Cilag International NV, Rapporteur: Jayne Crowe recommendation. Opinion adopted on 09.07.2020. Taltz - ixekizumab -Positive Opinion adopted by consensus on EMEA/H/C/003943/II/0034 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder recommendation. Opinion adopted on 02.07.2020. Trecondi - treosulfan -Positive Opinion adopted by consensus on EMEA/H/C/004751/II/0003/G 23.07.2020. The Icelandic and Norwegian CHMP medac Gesellschaft fur klinische Members were in agreement with the CHMP recommendation. Spezialpraparate mbH, Rapporteur: Fátima Ventura Opinion adopted on 23.07.2020. Trecondi - treosulfan -Request for supplementary information adopted EMEA/H/C/004751/II/0004/G with a specific timetable. medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Request for Supplementary Information adopted on 23.07.2020. Vosevi - sofosbuvir / velpatasvir / Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP voxilaprevir -EMEA/H/C/004350/II/0040/G Members were in agreement with the CHMP Gilead Sciences Ireland UC, Rapporteur: Filip recommendation. Josephson Opinion adopted on 16.07.2020.

EMA/CHMP/566439/2020 Page 20/98

Request for supplementary information adopted

Vyxeos liposomal - daunorubicin /

cytarabine -

#### EMEA/H/C/004282/II/0012/G, Orphan

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Tuomo Lapveteläinen

Request for Supplementary Information adopted

on 09.07.2020.

Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0052/G

Pfizer Ireland Pharmaceuticals, Rapporteur: Alar

Irs

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

with a specific timetable.

Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0022

Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS1587/G

Abasaglar-EMEA/H/C/002835/WS1587/ 0028/G

Humalog-EMEA/H/C/000088/WS1587/ 0178/G

Eli Lilly Nederland B.V., Lead Rapporteur:

Kristina Dunder

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 30.04.2020, 14.11.2019, 19.09.2019.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS1786

Hexacima-EMEA/H/C/002702/WS1786/ 0097

Hexaxim-EMEA/H/W/002495/WS1786/ 0102

Hexyon-EMEA/H/C/002796/WS1786/

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-

Berghaus

Opinion adopted on 02.07.2020.

Request for Supplementary Information adopted on 30.04.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS1815/G

Hexacima-EMEA/H/C/002702/WS1815/ 0102/G

Hexaxim-EMEA/H/W/002495/WS1815/ 0107/G

Hexyon-EMEA/H/C/002796/WS1815/ 0106/G

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-

Berghaus

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 21/98

Opinion adopted on 16.07.2020. WS1817/G Positive Opinion adopted by consensus on Infanrix hexa-EMEA/H/C/000296/ 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP WS1817/0276/G GlaxoSmithkline Biologicals SA, Lead recommendation. Rapporteur: Christophe Focke Opinion adopted on 09.07.2020. WS1823/G Positive Opinion adopted by consensus on Aflunov-EMEA/H/C/002094/WS1823/ 02.07.2020. The Icelandic and Norwegian CHMP 0060/G Members were in agreement with the CHMP Foclivia-EMEA/H/C/001208/WS1823/ recommendation. 0055/G Segirus S.r.I, Lead Rapporteur: Daniela Melchiorri Opinion adopted on 02.07.2020. WS1826 Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Ambirix-EMEA/H/C/000426/WS1826/ 0107 Members were in agreement with the CHMP recommendation. Twinrix Adult-EMEA/H/C/000112/ WS1826/0142 Twinrix Paediatric-EMEA/H/C/000129/ WS1826/0143 GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 23.07.2020. WS1870/G Request for supplementary information adopted Entresto-EMEA/H/C/004062/WS1870/ with a specific timetable. 0033/G Neparvis-EMEA/H/C/004343/WS1870/ Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 23.07.2020. WS1882 Request for supplementary information adopted HyQvia-EMEA/H/C/002491/WS1882/0060 with a specific timetable. Kiovig-EMEA/H/C/000628/WS1882/0102 Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 23.07.2020. Hexacima-EMEA/H/C/002702/WS1802/ Positive Opinion adopted by consensus on 0098 16.07.2020. The Icelandic and Norwegian CHMP Hexaxim-EMEA/H/W/002495/WS1802/ Members were in agreement with the CHMP

EMA/CHMP/566439/2020 Page 22/98

Hexyon-EMEA/H/C/002796/WS1802/

0102

recommendation.

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 16.07.2020.
Request for Supplementary Information adopted on 28.05.2020.

#### B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

#### Aptivus - tipranavir - EMEA/H/C/000631/II/0085

Boehringer Ingelheim International GmbH, Rapporteur: Jean-Michel Race, "Update of section 4.5 of the SmPC in order to include a new interaction with Dolutegravir. The Product Leaflet has been updated accordingly." Opinion adopted on 09.07.2020. Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0091

GSK Vaccines S.r.I, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to update the safety information and include Rash as Adverse Reaction in adolescents and adults. The Package Leaflet is updated accordingly." Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 02.07.2020.

# Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/II/0032

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update the efficacy and safety data in HIV-1 infected subjects aged ≥ 65 years based on week 48 interim results from study GS-US-380-4449, "A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir /Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years"." Opinion adopted on 23.07.2020. Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### Bosulif - bosutinib -EMEA/H/C/002373/II/0041

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP

EMA/CHMP/566439/2020 Page 23/98

Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, "Update of sections 4.4 and 5.2 of the SmPC with additional safety and PK data from the recently completed Phase 2 study (B1871048) following a commitment within variation EMEA/H/C/002373/II/0036 and a pooled safety data analysis performed to assess the clinical impact of reduced clearance in Asian population. The MAH takes also the opportunity to make editorial changes on the Package Leaflet"

Members were in agreement with the CHMP recommendation.

Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 30.04.2020.

# Cometriq - cabozantinib - EMEA/H/C/002640/II/0036, Orphan

Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, "Submission of PK results from the clinical study ADVL1211 (an open-label trial to evaluate toxicity, tolerability, pharmacokinetics and pharmacodynamics of cabozantinib in children with refractory or relapsed malignant solid tumours (MEA 019))."

Opinion adopted on 02.07.2020.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Cubicin - daptomycin - EMEA/H/C/000637/II/0075

on 12.03.2020.

on 28.05.2020.

Merck Sharp & Dohme B.V., Rapporteur: Bjorg Bolstad, "Update of sections 4.4 and 4.8 of the SmPC in order to include two new terms, tubulointerstitial nephritis (TIN) and drug reaction with eosinophilia and systemic symptoms (DRESS) to the Special warnings and precautions of the SmPC. TIN has also been added to the Adverse events section, based on a review of the cumulative post-marketing cases associated with the use of daptomycin. The Package Leaflet is updated accordingly. In addition, QRD-related, spelling, formatting and spacing corrections were implemented." Opinion adopted on 16.07.2020. Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Darzalex - daratumumab - EMEA/H/C/004077/II/0038, Orphan

Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC in order to add sepsis with frequency Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 24/98

common as an ADR and incidence data on fatal infections and adverse reactions in the elderly patients based on cross-programmatic review of data. The MAH also proposed minor corrections in section 4.8 of the SmPC. The Package Leaflet and labelling is updated accordingly." Opinion adopted on 09.07.2020. Request for Supplementary Information adopted on 07.05.2020.

## DaTSCAN - ioflupane (123I) - EMEA/H/C/000266/II/0059

GE Healthcare B.V., Rapporteur: Alexandre Moreau, "C.I.4, Update of sections 4.2 and 5.1 of the SmPC in order to describe the possibility of quantitative reading in line with current scientific knowledge."

Request for Supplementary Information adopted on 16.07.2020.

Request for supplementary information adopted with a specific timetable.

#### Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0001

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update the safety information regarding the occurrence of neural tube defects with the dolutegravir -containing regimens based on the interim analysis from the Tsepamo study. This is a birth outcomes surveillance study being conducted in Botswana that was designed to evaluate adverse birth outcomes by HIV status and antiretroviral regimen, and to determine if there is an increased risk of neural tube defects among infants exposed to efavirenz at conception. This surveillance system captures all antiretroviral exposure including dolutegravir. The PL is updated accordingly. The MAH has taken the opportunity to include a paragraph in section 4 of the PL regarding weight, blood lipid and blood glucose effects following the assessment of LEG004.1." Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 26.03.2020, 12.12.2019, 14.11.2019.

See agenda 9.1

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Dupixent - dupilumab - EMEA/H/C/004390/II/0032

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "Update of SmPC sections 4.8 and 5.1 based on results of a paediatric study report, LTS12551 to fulfil the article 46 requirement (Regulation EC No 1901/2006).

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 25/98

The LTS12551 study is an open–label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma."

Request for Supplementary Information adopted on 23.07.2020.

# Effentora - fentanyl - EMEA/H/C/000833/II/0054/G

Teva B.V., Rapporteur: Janet Koenig, "Update of the SmPC in line with the recent PSUSA evaluation outcome and to reflect the updated Company core safety information" Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 28.05.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Epidyolex - cannabidiol - EMEA/H/C/004675/II/0007, Orphan

GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe, "Update of section 4.2 of the SmPC in order to add information regarding enteral administration using nasogastric and gastrostomy tubes."

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

## Epidyolex - cannabidiol - EMEA/H/C/004675/II/0008/G, Orphan

GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe, "Update of section 4.5 of the SmPC to reflect the data of the rifampicin drug-drug interaction study GWEP17074. Update of section 4.5 of the SmPC to reflect the data of the CYP1A2 substrate (caffeine) drugdrug interaction study GWCP18056. Update of sections 4.5 and 5.2 of the SmPC to propose an additional statement regarding the stiripentol interaction based on the pharmacological study GWEP1447 (provided in eCTD sequence 018, P46 006). Update of section 5.2 of the SmPC to reflect the data of the pharmacokinetic study GWEP17076, exploring the impact of meal, milk and alcohol on cannabidiol exposure.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Erleada - apalutamide - EMEA/H/C/004452/II/0006

Opinion adopted on 23.07.2020.

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of

In addition, the MAH took the opportunity to correct the MAH address in the SmPC."

See agenda 9.1

Negative Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP

EMA/CHMP/566439/2020 Page 26/98

the SmPC to add interstitial lung disease to the list of adverse drug reactions (ADRs) with frequency unknown based on a safety review; the Package Leaflet is updated accordingly. The MAH also took the opportunity to update the PI in line with the QRD template 10.1." Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 05.06.2020.

Members were in agreement with the CHMP recommendation.

### Gliolan - 5-aminolevulinic acid - EMEA/H/C/000744/II/0018/G

medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Bruno Sepodes, "To update section 4.4 of the SmPC to add a warning (false positive and false negative fluorescence) following an analysis of the MAHs safety database.

To update section 4.2 of the SmPC to exclude re-administration if surgery is delayed by less than 12 hours."

Request for Supplementary Information adopted on 16.07.2020, 05.06.2020, 17.04.2020.

Request for supplementary information adopted with a specific timetable.

# Herceptin - trastuzumab - EMEA/H/C/000278/II/0160

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.7 of the SmPC in order to add "dizziness and somnolence" to the recommendations on the effects on the patient's ability to drive and use machines. Update of section 4.8 of the SmPC to remove Herpes zoster, Erysipelas, Cellulitis Common, Sepsis, Thinking abnormal, Ataxia, Paresis, Brain oedema, Pericarditis, Bradycardia and Hepatic failure as adverse drug reactions. An update of the frequencies of adverse reactions is proposed in accordance to a change in the company core datasheet (CDS) for Herceptin: Anaphylactic reaction and Anaphylactic shock is changed to frequency Rare, Wheezing is changed to frequency Uncommon, Pneumonitis is changed to frequency Uncommon and Palpitation is changed to frequency Common. The MAH is taking the opportunity to update section 2 of the Herceptin PL to ensure compliance with the guidance on Excipients in the Labelling and Package Leaflet of medicinal products for Human Use (SANTE 2017-11668). The Package Leaflet is updated accordingly."

Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 27/98

Request for Supplementary Information adopted on 17.04.2020.

Infanrix hexa - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/000296/II/0275

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of sections 4.8 and 5.1 of the SmPC in relation to the frequency of adverse reactions somnolence and fatigue and to update the safety and immunogenicity information in infants and toddlers born to mothers vaccinated with dTpa during pregnancy; based on data generated from DTPA-048 and DTPA-049; these are phase IV, open-label, non-randomised, multicentre studies aimed to provide immunological responses to Infanrix hexa in terms of seroprotection status for diphtheria (D), tetanus (T), HBs antigen, inactivated poliovirus (IPV) and Haemophilus influenzae type b (Hib) antigens (PRP) and in terms of vaccine or booster responses to the pertussis antigens, 1 month after the last dose of the primary vaccination or the booster dose. The MAH took the opportunity to update the posology information in the package leaflet to align it with the SmPC.

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1."

Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

### Juluca - dolutegravir / rilpivirine - EMEA/H/C/004427/II/0016

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update the safety information regarding the occurrence of neural tube defects with the dolutegravir -containing regimens based on the interim analysis from the Tsepamo study. This is a birth outcomes surveillance study being conducted in Botswana that was designed to evaluate adverse birth outcomes by HIV status and antiretroviral regimen, and to determine if there is an increased risk of neural tube defects among infants exposed to efavirenz at conception. This surveillance system captures all antiretroviral exposure including

See agenda 9.1

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 28/98

dolutegravir.

The PL is updated accordingly."

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 26.03.2020, 12.12.2019, 14.11.2019.

### Juluca - dolutegravir / rilpivirine - EMEA/H/C/004427/II/0027

ViiV Healthcare B.V., Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC in order to add new information on resistance in vivo and clinical efficacy, based on final results from studies 201636 (SWORD-1) and 201637 (SWORD-2): Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority Studies Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir plus Rilpivirine from Current INSTI-, NNRTI-, or PI-Based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed." Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

### Keytruda - pembrolizumab - EMEA/H/C/003820/II/0087/G

Merck Sharp & Dohme B.V., Rapporteur:
Daniela Melchiorri, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from three interventional efficacy studies in non-small cell lung cancer; study KEYNOTE-407 listed as a PAES in the Annex II, study KEYNOTE-189 listed as a category 3 study in the RMP and KEYNOTE-021 (cohort A, C and G1) listed as a category 3 study in the RMP."
Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

## Kisplyx - lenvatinib - EMEA/H/C/004224/II/0035

Eisai GmbH, Rapporteur: Bart Van der Schueren, "Submission of the final Clinical Study Report for Study E7080-J081-208 (Study 208), a Phase 2 Study of lenvatinib in Subjects with Advanced Thyroid Cancer." Opinion adopted on 23.07.2020. Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### Lenvima - lenvatinib - EMEA/H/C/003727/II/0035/G

Eisai GmbH, Rapporteur: Bart Van der Schueren, "-Submission of non-clinical final report from study M14014: Antiproliferative Activities of Lenvatinib Mesilate and Sorafenib Tosylate in VEGF-Stimulated Growth of HUVECs Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 29/98

(human umbilical vein endothelial cells), relevant to the license's approved indications of differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC) which were conducted since the approval of the initial Marketing Authorisation Application. -Submission of non-clinical final report from study M13015: Antiangiogenic Activity of Lenvatinib Mesilate and Sorafenib Tosylate in Human Papillary Thyroid Cancer Cell Line K1 Xenografts in Mice, relevant to the license's approved indications of differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC) which were conducted since the approval of the initial Marketing Authorisation Application.

- -Submission of non-clinical final report from study M13016: Antiangiogenic Activity of Lenvatinib Mesilate and Sorafenib Tosylate in Human Follicular Thyroid Cancer Cell Line R082-W-1 Xenografts in Mice, relevant to the license's approved indications of differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC) which were conducted since the approval of the initial Marketing Authorisation Application.
- -Submission of non-clinical final report from study W-20140845: Antiangiogenic Activity of Lenvatinib Mesilate and Sorafenib Tosylate in bFGF-Induced Matrigel Plug Assay in Athymic Mice, relevant to the license's approved indications of differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC) which were conducted since the approval of the initial Marketing Authorisation Application. -Submission of non-clinical final report from study on the Immuno-modulatory Activity of Lenvatinib Contributes to Antitumor Activity in the Hep1-6 Hepatocellular Carcinoma Model, relevant to the license's approved indications of differentiated thyroid cancer (DTC) and hepatocellular carcinoma (HCC) which were conducted since the approval of the initial Marketing Authorisation Application." Opinion adopted on 16.07.2020.

#### Lucentis - ranibizumab - EMEA/H/C/000715/II/0086

Novartis Europharm Limited, Rapporteur: Kristina Dunder, "C.I.11.b - Submission of the results of the second interim analysis (IA2) of Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 30/98

the PAES study H2301E1"
Opinion adopted on 23.07.2020.

### Mepsevii - vestronidase alfa - EMEA/H/C/004438/II/0014, Orphan

Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC following the assessment of final results from study UX003-CL202, a multicenter, multinational, open-label treatment, extension of study UX003-CL301 in subjects with MPS VII, previously submitted under Article 46 of Regulation (EC) No 1901/2006; the Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to implement minor editorial changes in the Product Information."

Opinion adopted on 16.07.2020.

Request for Supplementary Information adopted on 11.06.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Nerlynx - neratinib - EMEA/H/C/004030/II/0014/G

Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Submission of the final reports from a safety pharmacology study evaluating the potential cardiovascular toxicity of M3, a metabolite of neratinib maleate (report 20130869) and from a toxicology study evaluating the potential toxicity of M11, another metabolite of neratinib maleate (Report 20104291)."

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### Nilemdo - bempedoic acid -EMEA/H/C/004958/II/0002

Opinion adopted on 09.07.2020.

Daiichi Sankyo Europe GmbH, Rapporteur:
Johann Lodewijk Hillege, "C.I.13: Submission of the final report from phase 2 study (1002FDC-058) listed as a category 3 study in the RMP.
This is a randomized, double-blind, parallel Group Study to evaluate the efficacy and safety of the FDC (bempedoic acid 180 mg + ezetimibe 10 mg) compared to ezetimibe and placebo in subjects with type 2 diabetes and elevated LDL-Cholesterol."

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

## Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959/II/0002

Daiichi Sankyo Europe GmbH, Rapporteur: Johann Lodewijk Hillege, "C.I.13: Submission of Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

EMA/CHMP/566439/2020 Page 31/98

the final report from phase 2 study (1002FDC-058) listed as a category 3 study in the RMP. This is a randomized, double-blind, parallel Group Study to evaluate the efficacy and safety of the FDC (bempedoic acid 180 mg + ezetimibe 10 mg) compared to ezetimibe and placebo in subjects with type 2 diabetes and elevated LDL-Cholesterol."

recommendation.

Opinion adopted on 09.07.2020.

### OFEV - nintedanib - EMEA/H/C/003821/II/0033

Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, "Update of SmPC sections 4.8 and 5.1. to include additional clinical information from an open-label extension trial 1199.33 (INPULSIS-ON)" Request for Supplementary Information adopted Request for supplementary information adopted with a specific timetable.

### OFEV - nintedanib - EMEA/H/C/003821/II/0034

on 16.07.2020.

Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, "Update of section 5.1 of the SmPC to include results of a double-blind, randomised, parallel-group trial to evaluate the efficacy and safety of Ofev co-administered with oral sildenafil, compared to treatment with Ofev alone (INSTAGE Trial)." Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 16.07.2020.

#### Ovitrelle - choriogonadotropin alfa - EMEA/H/C/000320/II/0081

Merck Europe B.V., Rapporteur: Paula Boudewina van Hennik, "Changes in sections 4.1, 4.2, 4.4 and 4.6 of the SmPC in order to update the terminology, in 4.3 to amend existing contraindications and in 4.8 to delete certain adverse drug reactions (ADRs) and add gastrointestinal ADRs with frequency common, with the aim to align the Product Information with similar text provided for other gonadotropin products.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1 and performed minor linguistic changes."

Request for Supplementary Information adopted on 16.07.2020.

Request for supplementary information adopted with a specific timetable.

Pergoveris - follitropin alfa / lutropin alfa - Positive Opinion adopted by consensus on

EMA/CHMP/566439/2020 Page 32/98

#### EMEA/H/C/000714/II/0069

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "Submission of immunogenicity results on anti-drug antibodies (ADAs) against follicle stimulating hormone (FSH) and luteinizing hormone (LH), which were measured using validated assays in the bioequivalence study designed to compare the bioavailability of the liquid formulation to the previously-approved freeze-dried formulation (study EMR200061-006), as agreed during the assessment of the line extension application EMEA/H/C/714/X/47. The requested variation proposed no amendments to the Product Information." Opinion adopted on 23.07.2020.

23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Praxbind - idarucizumab - EMEA/H/C/003986/II/0020

Boehringer Ingelheim International GmbH, Rapporteur: Jan Mueller-Berghaus, "C.I.4 Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update information on paediatrics based on final results from study 1321.7. This was single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate for the treatment and secondary prevention of venous thromboembolism listed as part of PIP (P46)." Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

### Qutenza - capsaicin - EMEA/H/C/000909/II/0049

Grunenthal GmbH, Rapporteur: Bruno Sepodes, "Update of section 4.8 of the SmPC in order to update the safety information on adverse reactions frequencies based on latest clinical data pooling; the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version."

Opinion adopted on 16.07.2020.

Request for Supplementary Information adopted on 14.05.2020, 19.03.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Repatha - evolocumab - EMEA/H/C/003766/II/0043

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "C.I.4,

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 33/98

Update of section 5.1 of the SmPC based on final results from study 20167869 (EVOPACS). It was a randomised, double-blind, placebocontrolled, multicenter study assessing the superiority of evolocumab vs. placebo administered during the acute phase of ACS (within 72 hours)."

Request for Supplementary Information adopted on 23.07.2020.

### Reyataz - atazanavir - EMEA/H/C/000494/II/0129/G

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jean-Michel Race, "Grouped application:

- C.I.4 (Type IB) Update of sections 4.3 and 4.5 of the SmPC to add a new contraindication and a new drug-drug interaction related to coadministration with lomitapide, based on recommendations already approved for lomitapide; the Package Leaflet is updated accordingly.
- C.I.4 (Type II) Update of section 4.5 of the SmPC to add new drug-drug interactions related to co-administration with the direct oral anticoagulants (DOACs) apixaban, dabigatran, edoxaban and rivaroxaban, to align with wording approved for DOACs; the Package Leaflet is updated accordingly.

In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the PI in line with the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (EMA/CHMP/302620/2017 Rev.1) regarding sucrose content, remove boceprevir from section 4.5 of the SmPC and section 2 of the PL, bring the PI in line with the latest QRD template version 10.1 and update the list of local representatives in the Package Leaflet." Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Tafinlar - dabrafenib - EMEA/H/C/002604/II/0045

on 28.05.2020.

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Submission of the final report from study DRB436A2107 listed as a category 3 study in the RMP. This is a phase I, open label, multicenter, single dose study to evaluate the pharmacokinetics of dabrafenib in healthy subjects with normal hepatic function and

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 34/98

subjects with impaired hepatic function." Opinion adopted on 16.07.2020.

### Tafinlar - dabrafenib - EMEA/H/C/002604/II/0046

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Submission of the final report from study DRB436A2106 listed as a category 3 study in the RMP. This is a phase I, open label, multicenter, single dose study to evaluate the pharmacokinetics of dabrafenib in healthy subjects with normal renal function and subjects with impaired renal function."

Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

## Tecentriq - atezolizumab - EMEA/H/C/004143/II/0036

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Submission of the final report from study GO28915 (OAK) listed as a category 3 study in the RMP. This is a Phase III, open-label multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with docetaxel in patients with NSCLC after failure with platinum-containing chemotherapy. In addition, the MAH submitted integrated analyses of the potential relationship of ADA and safety were based on studies IMvigor210, IMvigor211, OAK, POPLAR, IMpower150, IMpower130, IMpower131, IMpower132, IMpower133 and IMpassion130 as recommended by the CHMP." Opinion adopted on 23.07.2020. Request for Supplementary Information adopted

#### See agenda 9.1

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Tivicay - dolutegravir - EMEA/H/C/002753/II/0052

on 12.03.2020.

ViiV Healthcare B.V., Rapporteur: Filip
Josephson, "Update of section 4.6 of the SmPC
in order to update the safety information
regarding the occurrence of neural tube defects
with the dolutegravir -containing regimens
based on the interim analysis from the Tsepamo
study. This is a birth outcomes surveillance
study being conducted in Botswana that was
designed to evaluate adverse birth outcomes by
HIV status and antiretroviral regimen, and to
determine if there is an increased risk of neural
tube defects among infants exposed to efavirenz
at conception. This surveillance system captures
all antiretroviral exposure including

#### See agenda 9.1

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 35/98

dolutegravir.

The PL is updated accordingly."

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 26.03.2020, 12.12.2019, 14.11.2019.

#### Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0069

ViiV Healthcare B.V., Rapporteur: Filip
Josephson, "Update of section 4.6 of the SmPC
in order to update the safety information
regarding the occurrence of neural tube defects
with the dolutegravir -containing regimens
based on the interim analysis from the Tsepamo
study. This is a birth outcomes surveillance
study being conducted in Botswana that was
designed to evaluate adverse birth outcomes by
HIV status and antiretroviral regimen, and to
determine if there is an increased risk of neural
tube defects among infants exposed to efavirenz
at conception. This surveillance system captures
all antiretroviral exposure including
dolutegravir.

The PL is updated accordingly."

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 26.03.2020, 12.12.2019, 14.11.2019.

#### See agenda 9.1

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0023

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on interim analysis data at Week 24 from study GS-US-320-4035. This is a Phase 2, open-label study evaluating the efficacy and safety of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B subjects with renal and/or hepatic impairment who switch from tenofovir disoproxil fumarate and/or other oral antiviral agents to TAF 25 mg once daily. Supportive safety and pharmacokinetic data are also provided from study GS-US-292-1825( phase 3b trial in which Elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide an fixed-dose TAF containing combination indicated for the treatment of HIV-1 infection, was evaluated in HIV-1 infected subjects with end stage renal disease). Study GS-US-320-4035 is included in the RMP version 4.2 under additional PhV activities." Request for Supplementary Information adopted Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 36/98

on 23.07.2020, 07.05.2020, 06.02.2020.

#### Vfend - voriconazole -EMEA/H/C/000387/II/0137/G

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Grouping of two type II variations:

-to update section 4.4 of the SmPC in order to add a new warning on adrenal events, along with editorial changes to the paragraph and the abbreviation of severe cutaneous adverse reactions (SCARs),

-to update section 4.5. of the SmPC in order to add drug-drug interaction information with naloxegol, ivacaftor and corticosteroids following PRAC request during the assessment of PSUR 18 (for corticosteroids) and the French National Agency for the Safety of Medicines and Health Products (ANSM) update of the French "Medical Interaction Thesaurus" (May 2018), where voriconazole is classified as a strong CYP3A4 inhibitor.

In addition the MAH has taken the opportunity to update the information in the SmPC in line with the EU excipient guidance from October 2017 (SANTE-2017-11668) for sodium and cyclodextrin, to introduce a correction to the amount of sodium per vial for the IV presentations in sections 2. QUALITATIVE AND "Justification for not including Braille accepted." bring the PI in line with the latest QRD template Request for supplementary information adopted with a specific timetable.

**OUANTITATIVE COMPOSITION and 4.4 Special** warnings and precautions for use of the SmPC. The Package Leaflet is updated accordingly. Following a recent discussion with EMA/EDQM; the MAH is also updating Annex IIIA Outer carton text for both iv presentations 16. INFORMATION IN BRAILLE to include: In addition, the MAH took the opportunity to version 10.1." Request for Supplementary Information adopted on 23.07.2020, 14.05.2020.

#### Zejula - niraparib -EMEA/H/C/004249/II/0020, Orphan

GlaxoSmithKline (Ireland) Limited, Rapporteur: Bjorg Bolstad, "Update of section 4.8 of the SmPC in order to add hypersensitivity, confusional state, and pneumonitis to the list of adverse drug reactions (ADRs) with the frequency "common", "uncommon" and "uncommon" respectively based on safety

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 37/98 evaluations; the Package Leaflet is updated accordingly."

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 11.06.2020.

### Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0053

Pfizer Ireland Pharmaceuticals, Rapporteur: Alar Irs, "Update of sections 4.8 and 4.9 of the SmPC in order to add eosinophilic pneumonia and encephalopathy as adverse drug reactions (ADRs), with frequencies 'not known' and 'uncommon' respectively, based on a review of the MAH global safety database and literature. The package leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) clarified in section 4.8 of the SmPC that the ADRs agranulocytosis, neutropenia and eosinophilia have been identified postmarketing. Furthermore, the PI is brought in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

#### WS1749

#### AZILECT-EMEA/H/C/000574/WS1749/ 0084

#### Rasagiline ratiopharm-EMEA/H/C/ 003957/WS1749/0016

Teva B.V., Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from study TV1030-CNS-50024 listed as a category 3 study in the RMP. This is a non-interventional retrospective cohort study which was conducted using the United States Medicare research database to assess the potential risk of melanoma associated with the use of rasagilline mesylate in patients with Parkinson's disease." Request for Supplementary Information adopted on 09.07.2020, 13.02.2020.

Request for supplementary information adopted with a specific timetable.

#### WS1790 OPDIVO-EMEA/H/C/003985/WS1790/ 0082

#### Yervoy-EMEA/H/C/002213/WS1790/0078

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.8 and 5.1 of the SmPC in order to include at least 5 years (60 months) of follow-up for all subjects from study CA209067.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 38/98

Updated efficacy data provided in this submission include overall survival (OS), progression-free survival (PFS) and objective response rate (ORR)."

Opinion adopted on 23.07.2020.

Request for Supplementary Information adopted on 05.06.2020.

#### WS1842

#### Aluvia-EMEA/H/W/000764/WS1842/0113 Kaletra-EMEA/H/C/000368/WS1842/0185 Norvir-EMEA/H/C/000127/WS1842/0158

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to update the safety information for nephrolithiasis as an adverse reaction following an update to the Kaletra and Aluvia (lopinavir/ritonavir) and Norvir (ritonavir) Company Core Data Sheets (CCDS 0220). The Package Leaflet is updated accordingly.

In addition, the MAH/SOH takes the opportunity to make additional changes in the PI in order to comply with the current QRD template and provide clarity to instructions contained in the Package Leaflet."

Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1845

#### Aluvia-EMEA/H/W/000764/WS1845/0114 Kaletra-EMEA/H/C/000368/WS1845/0186 Norvir-EMEA/H/C/000127/WS1845/0159

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Jean-Michel Race, "C.I.4: Update of section 4.5 of the SmPCs in order to add information on drug-drug interactions with fostamatinib. The Package Leaflets are updated accordingly."

Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1846

#### Vfend-EMEA/H/C/000387/WS1846/0138

Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.5 of the SmPC in order to include additional text regarding interactions between voriconazole and letermovir & tolvaptan in the interaction table. The Package Leaflet is updated accordingly." Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1848

#### DuoPlavin-EMEA/H/C/001143/WS1848/ 0057

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

EMA/CHMP/566439/2020 Page 39/98

#### Iscover-EMEA/H/C/000175/WS1848/ 0143

#### Plavix-EMEA/H/C/000174/WS1848/0141

sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, "To update section 4.4 and 4.5 of the SmPC to add drug-drug interaction information for rifampicin and clopidogrel based on a literature review and a review of the MAH pharmacovigilance database. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives and to update the SmPC for the excipient lactose in accordance with the Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal products for human use". The MAH also took the opportunity to update the product information regarding the standard term for the all aluminium unit-dose blisters." Opinion adopted on 23.07.2020.

recommendation.

#### **B.5.3. CHMP-PRAC assessed procedures**

#### Bavencio - avelumab - EMEA/H/C/004338/II/0015

Merck Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Hans Christian Siersted, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to change posology recommendations, amend an existing warning and add new ADRs with frequency uncommon regarding myasthenia gravis and myasthenic syndrome. The update results from an update of the Company Core Data Sheet (CCDS) based on the review of cases of myasthenia gravis/ myasthenic syndrome. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted to reclassify "Other immune-related events (myasthenic syndrome)" from an important potential risk to an important identified risk of "Other immune-related events (myasthenia gravis/myasthenic syndrome)"." Opinion adopted on 23.07.2020. Request for Supplementary Information adopted Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

# Bortezomib Fresenius Kabi - bortezomib - EMEA/H/C/005074/II/0001/G

on 30.04.2020.

Fresenius Kabi Deutschland GmbH, Generic, Generic of VELCADE, Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Amelia Cupelli Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 40/98

Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 28.05.2020, 26.03.2020.

### Desloratadine ratiopharm - desloratadine - EMEA/H/C/002404/II/0023/G

ratiopharm GmbH, Generic, Generic of Aerius, Rapporteur: Koenraad Norga, PRAC Rapporteur: Laurence de Fays, "C.I.5.b - Change in the legal status of desloratadine ratiopharm from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' in view of the safety profile of desloratadine ratiopharm and the postmarketing experience already available with other medicinal products containing similar long acting histamine antagonists. The RMP version 1.0 has also been submitted. In addition, the MAH also took the opportunity to bring the PI in line with the latest QRD template (version 10.1), to update the list of local representatives in the package leaflet and to make editorial changes.

C.I.6.b - To delete the therapeutic indication in adolescents aged 12 years and older for the relief of symptoms associated with allergic rhinitis and urticaria. Section 4.1 of the SmPC and section 1 of the PL are updated accordingly."

Request for Supplementary Information adopted on 23.07.2020, 26.03.2020.

Request for supplementary information adopted with a specific timetable.

# Firmagon - degarelix - EMEA/H/C/000986/II/0037

Ferring Pharmaceuticals A/S, Rapporteur:
Alexandre Moreau, PRAC Rapporteur: Tiphaine
Vaillant, "C.I.11.b Update of Annex II to revise
risk minimisation measures based on previous
and a newly submitted study. As a
consequence, the RMP is updated accordingly.
The MAH took the occasion to transfer to GVP V
revision 2 of the RMP, to aligned the PI to QRD
template v.10.1 and propose combination of
different strengths."
Opinion adopted on 09.07.2020.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0030

on 14.05.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP

EMA/CHMP/566439/2020 Page 41/98

Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "Change in the legal status of Fortacin from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription'. As a consequence, sections 4.4, 4.8, 4.9 of the SmPC are updated. The package leaflet and labelling are updated accordingly. Furthermore, the product information is being brought in line with the latest QRD template (version 10.1). The RMP is updated to version 4.0." Opinion adopted on 23.07.2020. Request for Supplementary Information adopted on 26.03.2020, 12.12.2019.

Members were in agreement with the CHMP recommendation.

### Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0026/G, Orphan

Alexion Europe SAS, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Ulla Wändel Liminga, "Grouping consisting of the following variations:

- Update of sections 4.2, 4.4, 4.8 and 5.1 of the Summary of Product Characteristics (SmPC) in order to update the clinical information based on the pooled safety and efficacy analysis of already submitted studies (Studies LAL-CL04, LAL-CL03, LAL-CL06, LAL-CL08 and LAL-CL02) and updated population PK analyses in children and adults. The Package Leaflet has been amended accordingly. The ATC code has been added to the SmPC. The RMP version 4 has also been submitted. Annex II is also updated to remove the obligation related to the provision of study LAL-CL08.
- Submission of the final report from study LAL-EA01 An open-label study with sebelipase alfa (1 mg/kg every other week for up to 78 weeks or until drug commercialization) in United States (US) patients who did not otherwise qualify for an active sebelipase alfa trial (expanded access protocol)"

Request for Supplementary Information adopted on 23.07.2020, 26.03.2020.

Request for supplementary information adopted with a specific timetable.

### Myalepta - metreleptin - EMEA/H/C/004218/II/0012, Orphan

Amryt Pharmaceuticals DAC, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Adam Przybylkowski, "Update of section 4.4 of the SmPC in order to add a new warning on the risk of autoimmune disease following exposure to Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 42/98

metreleptin; the Package Leaflet and the key elements to be included in the Guide/training material for healthcare professionals are updated accordingly. The RMP version 2.0 has also been submitted."

Request for Supplementary Information adopted on 09.07.2020.

#### Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/0049

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Rhea Fitzgerald, "Update of section 4.8 of the SmPC with the safety data and section 5.1 with the (secondary) efficacy data from the Phase 3, open-label, rollover study for study 109 and study 011 Part B designed to evaluate the long-term safety and tolerability of Orkambi treatment for 96 weeks in patients with cystic fibrosis, 6 years of age and older, homozygous for F508del. The MAH also took the opportunity to include minor changes to section 4.5 of the Granules SmPC and sections 4.8 and 5.2 of the Tablets and Granules SmPC which were considered acceptable by CHMP. In addition, the RMP version 8.0 is acceptable." Opinion adopted on 09.07.2020. Request for Supplementary Information adopted on 11.06.2020, 30.01.2020, 31.10.2019, 05.09.2019.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/0055

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Rhea Fitzgerald, "Update of section 4.8 of the SmPC with safety data in children from the Phase 3, open-label, multicentre rollover study for study 115 Part B, designed to evaluate long-term safety of Orkambi treatment for 96 weeks in patients with cystic fibrosis, 2 years of age and older, homozygous for F508del. The MAH also took the opportunity to update the SmPC in line with the latest version of the QRD template v10.1. The Package Leaflet is updated accordingly. In addition, the RMP version 8.0 is acceptable." Opinion adopted on 09.07.2020. Request for Supplementary Information adopted Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Privigen - human normal immunoglobulin -

on 17.04.2020.

Request for supplementary information adopted

EMA/CHMP/566439/2020 Page 43/98

#### EMEA/H/C/000831/II/0161/G

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "C.I.4: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to amend an existing warning on haemolytic anaemia and to update safety information based on final results from study IgPro10\_5003 listed as a category 3 study in the RMP; this is an observational hospital-based cohort study in the US to evaluate Privigen use and haemolytic anaemia in adults and children and the Privigen safety profile in children with CIDP; the Package Leaflet is updated accordingly.

C.I.4: Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions based on final results from study IgPro10\_3004; this is a Prospective Open-Label Single-Arm Study of the Pharmacokinetics and Safety of Intravenous IgPro10 in Japanese Subjects with Primary Immunodeficiency. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to align the SmPC with the EU Core SmPC for IVIG, to update the local representative for Bulgaria in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1."

Request for Supplementary Information adopted on 09.07.2020.

with a specific timetable.

#### Protopic - tacrolimus - EMEA/H/C/000374/II/0083/G

Opinion adopted on 23.07.2020.

LEO Pharma A/S, Rapporteur: Peter Kiely, PRAC Rapporteur: Rhea Fitzgerald, "Update of sections 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC following results from two non-interventional post-authorisation safety studies: JOELLE study (Joint European Longitudinal Lymphoma and skin cancer Evaluation, category 3) and APPLES study (a prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis, category 3). The Package Leaflet is updated accordingly. The RMP is updated to version 16.0. In addition, the marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1."

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 44/98

on 11.06.2020, 16.01.2020.

## RoActemra - tocilizumab - EMEA/H/C/000955/II/0097

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC for RoActemra 20 mg/mL concentrate for solution for infusion in order to amend the existing recommendations for monitoring of laboratory abnormalities in systemic juvenile idiopathic arthritis (sJIA) patients based on final results from study WA28029 (ARTHUR) listed as a category 3 study in the RMP; this is a Phase IV study to evaluate decreased dose frequency in sJIA who experience laboratory abnormalities during treatment with tocilizumab. The submission of the final study report for study WA28029 (ARTHUR) fulfils requirements of Article 46 of the paediatric regulation. The RMP is updated to version 26.0 to reflect the completion of study WA29029 (ARTHUR) and study WA22480 (ARTIS) which was assessed as part of variation EMEA/H/C/000955/II/0094." Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

## Trumenba - meningococcal group B vaccine (recombinant, adsorbed) -

EMEA/H/C/004051/II/0027/G

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné, "C.I.11.b- To update the RMP for Trumenba to version 4.0 to provide a revised protocol outline for study B1971060 in immunocompromised individuals: Although the study was originally designed to evaluate 3 doses of Trumenba administered on a 0-, 2-, and 6-month schedule, the MAH is now proposing a 2-dose regimen administered on 0-and 6-month schedule.

C.I.11.b- To submit the protocol outline for the co-administration study (C3511006). The MAH is proposing that the commitment to conduct a co-administration study with Trumenba may be met by a study of the MAH's candidate pentavalent meningococcal vaccine (which contains Trumenba) co-administered with MMR and PnC vaccines."

Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

#### WS1664

Request for supplementary information adopted

### Keppra-EMEA/H/C/000277/WS1664/0187

UCB Pharma S.A., Lead Rapporteur: Koenraad Norga, Lead PRAC Rapporteur: Laurence de Fays, "Update of section 4.2 of the SmPC to recommend the same dosing for monotherapy and adjunctive therapy based on data from modelling and simulation project.

The Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted. The MAH took the opportunity to move Braille to another box section and to review and adapt the German PI according to the current QRD template."

Request for Supplementary Information adopted on 23.07.2020, 30.04.2020.

with a specific timetable.

#### WS1844

## Edistride-EMEA/H/C/004161/WS1844/ 0039

## Forxiga-EMEA/H/C/002322/WS1844/ 0057

AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Re-categorisation of the Forxiga/Edistride PASS (D169C00011): Retrospective Cohort Study on the Risk of Diabetic Ketoacidosis (DKA) to determine the effectiveness of additional risk minimisation measures in place for DKA by assessing the impact of the risk minimisation measures on the risk of DKA in T1DM patients who are treated with dapagliflozin in Europe, from a category 1 to category 3 PASS in the RMP Version 20 and removal of the following Annex IID of the PI: Obligation to conduct the following Non-interventional PASS: In order to estimate the incidence of DKA in T1DM dapagliflozin users following implementation of RMMs in Europe, the MAH should conduct and submit the results from an observational cohort study using existing data sources in European countries where dapagliflozin will be launched for T1DM " Request for Supplementary Information adopted Request for supplementary information adopted with a specific timetable.

### **B.5.4. PRAC assessed procedures**

PRAC Led

on 23.07.2020.

Duavive - estrogens conjugated / bazedoxifene -

EMEA/H/C/002314/II/0025

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 46/98

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final clinical study report (CSR) for the Duavive Non-Interventional EU Drug Utilisation Study (DUS) - Study B2311061. This final CSR relates to the Post-Authorisation Measure MEA 003." Request for Supplementary Information adopted on 09.07.2020.

PRAC Led

## Entyvio - vedolizumab - EMEA/H/C/002782/II/0050

Takeda Pharma A/S, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Update of the RMP with regards to the measures to evaluate effectiveness of additional risk minimization measures (educational material) and addition of the completion date of the interim report for the post approval safety study (PASS) MLN00020401."

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

## Fampyra - fampridine - EMEA/H/C/002097/II/0046

Opinion adopted on 09.07.2020.

Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.2, 4.3, 4.4, 4.8, 4.9 and 5.2 of the SmPC in order to remove the contraindication for patients with mild renal impairment, add a warning for patients with mild renal impairment, update the frequency of seizure to uncommon, add vertigo with frequency common, add dizziness in section 4.9 to reflect safety information based on final results of study 218MS401 (LIBERATE) listed as category 3 study in the RMP; Study 218MS401 was a Phase IV prospective, noninterventional, multicentre, observational study in MS patients who began Fampyra treatment in the postmarketing setting. The Package Leaflet is updated accordingly. An updated RMP version 13.1 has also been submitted to align with the RMP Rev. 2 template and to remove all safety concerns; some continue to be monitored in PSUSA safety specifications."

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 47/98

Request for Supplementary Information adopted on 13.02.2020.

PRAC Led

## Forsteo - teriparatide - EMEA/H/C/000425/II/0054

Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "submission of the concluding report of the European Union (EU) component of the post-authorisation safety study (PASS): Study B3D-MC-GHBX(2.1) of Forsteo (teriparatide)." Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

PRAC Led

## Lemtrada - alemtuzumab - EMEA/H/C/003718/II/0031

Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "Submission of an update of the RMP (version 7.2) incorporating all amendments and additional activities defined in the Article 20 referral procedure (EMEA/H/A-20/1483/C/3718/0028)."

Opinion adopted on 09.07.2020.

Request for Supplementary Information adopted on 17.04.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

## Lucentis - ranibizumab - EMEA/H/C/000715/II/0085

Novartis Europharm Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the results of the noninterventional post-approval efficacy and safety study OBTAIN" Opinion adopted on 09.07.2020. Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

alfa with significant

## Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0079

Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study ALGMYC07390, Prevalence of immunology testing in patients treated with alglucosidase

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 48/98

hypersensitivity/anaphylactic reactions (MEA 053 resulting from variation EMEA/H/C/000636/II/0052 ) to test the effectiveness of the approved Safety Information Packet (SIP)." Request for Supplementary Information adopted on 09.07.2020, 12.03.2020.

PRAC Led

## Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0113

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study 20160176 listed as a category 3 study in the RMP. This is a retrospective cohort study with primary outcome the time from index date to diagnosis of MDS or AML (safety)." Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

PRAC Led

## Olumiant - baricitinib - EMEA/H/C/004085/II/0017

Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "C.I.13: Submission of the final report from Study I4V-MC-B010 "Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant" listed as a category 3 study in the RMP. This observational study was a multi-national cross-sectional survey. The RMP version 9.2 has also been submitted. In addition to the removal of this study from the RMP, three safety concerns (Use in combination with bDMARDs or with other JAK inhibitors, Use in patients with severe hepatic impairment, Effect on fertility, on pregnancy and the foetus, and use in breastfeeding) previously classified as Missing Information, have been removed from the list of safety concerns as per Procedure EMEA/H/C/004085/II/006." Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

PRAC Led

on 09.07.2020.

Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0031

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 49/98

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, PRAC-CHMP liaison: Andrea Laslop, "C.I.11.b To update the RMP for Shingrix to version 3.0 in order to present the outcome of the MAH assessment with respect to a potential increased risk of exacerbation of pre-existing pIMDs following vaccination with Shingrix. The implementation of the change is further substantiated by new additional data on posthoc analyses and spontaneous reports of potential exacerbations of pIMDS from a worldwide safety database submitted by the MAH."

Opinion adopted on 09.07.2020.

#### PRAC Led

## Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0045

Addmedica S.A.S., Rapporteur: Koenraad Norga, PRAC Rapporteur: Laurence de Fays, PRAC-CHMP liaison: Bart Van der Schueren, "Update of sections 4.2, 4.4, 4.5, 4.6, 4.8, 4.9 and 5.1 of the SmPC as a consequence of the final study results of the non-interventional cohort study ESCORT-HU (European Sickle Cell Disease Cohort - Hydroxyurea) and harmonisation with other HU products. In addition, Annex II is amended to revise the information on the physician information pack and to add that pharmacists should receive targeted communication on the risk of medication error due to the confusion between the two strengths where both are available. The PIL is updated in accordance with the changes to the SmPC. The RMP (v. 20 revision 1) is updated to reflect the finalisation of the ESCORT-HU study and modifications on the risk minimisation measures." Opinion adopted on 09.07.2020. Request for Supplementary Information adopted on 17.04.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

## Trulicity - dulaglutide - EMEA/H/C/002825/II/0048

Eli Lilly Nederland B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, "Submission of the final study report from study B010, investigating the utilisation of dulaglutide in European countries: A cross-sectional, multi-

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 50/98

country and multi-source drug utilisation study using electronic health record databases. Study B010 is listed as a category 3 study in the RMP (MEA 001). An updated RMP version 5.2 was agreed during the procedure."

Opinion adopted on 09.07.2020.

Request for Supplementary Information adopted on 12.03.2020.

PRAC Led

## Trulicity - dulaglutide - EMEA/H/C/002825/II/0051

Eli Lilly Nederland B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, "Submission of the final study report for the PASS category 3 dulaglutide drug utilisation study B009: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU (ref. PAM MEA 002-002.5). An updated RMP version 6.1 was provided as part of the application." Request for Supplementary Information adopted on 09.07.2020.

Request for supplementary information adopted with a specific timetable.

PRAC Led

## Yervoy - ipilimumab -EMEA/H/C/002213/II/0080

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 28.0 in order to propose the discontinuation of the Healthcare Professional Adverse Reaction Management Guide as an additional risk minimisation measure described in the RMP Annex 6 and in the Product Information Annex II.D. The RMP and the annex II.D are updated accordingly. The MAH also took the occasion to align the PI to the latest QRD version 10.1 and to include standard text on sodium excipient information."

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

WS1589

Incruse Ellipta-EMEA/H/C/002809/ WS1589/0029 Rolufta Ellipta-EMEA/H/C/004654/ WS1589/0014

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 51/98

Lead PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, "C.I.11.b. Submission of an updated RMP version 7.1 following completion of a category 3 study (WWE117397) "A Post-authorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting". In addition, updates are included relating to the Category 1 study 201038 "A Post Authorisation Safety Observational Cohort Study to quantify the incidence of selected cardiovascular and cerebrovascular events in COPD patients using inhaled UMEC/VI combination or inhaled UMEC versus Tiotropium" The RMP is also updated to align with the

The RMP is also updated to align with the Guidance on the Good Pharmacovigilance Practice (GVP) Module V - Risk management systems Revision 2 guidelines."

Request for Supplementary Information adopted on 09.07.2020.

PRAC Led

WS1761

Anoro Ellipta-EMEA/H/C/002751/ WS1761/0029 Incruse Ellipta-EMEA/H/C/002809/ WS1761/0028 Laventair Ellipta-EMEA/H/C/003754/ WS1761/0032 Rolufta Ellipta-EMEA/H/C/004654/ WS1761/0013

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, "Submission of the final report from study WWE117397 listed as a category 3 study in the RMP. This was a retrospective longitudinal non-interventional observational study of new users of inhaled umeclidinium/vilanterol (UMEC/VI) or new users of inhaled umeclidinium (UMEC) or new users or long-acting bronchodilators (LABD) in the primary care setting."

Opinion adopted on 09.07.2020.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

on 12.03.2020.

WS1794

Brimica Genuair-EMEA/H/C/003969/

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 52/98

### WS1794/0029

## Duaklir Genuair-EMEA/H/C/003745/ WS1794/0029

AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra, Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final report from study D6570R00002 listed as a category 3 study in the RMP. This is a descriptive, noninterventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected COPD medications. The RMP version 5.0 has also been submitted. As a consequence, the following safety concerns, listed as missing information in the RMP, are proposed to be removed: 'safety in patients with hepatic or severe renal impairment', 'safety in patients with benign hyperplasia or urinary retention' and 'use in pregnancy or lactation'." Request for Supplementary Information adopted on 09.07.2020.

PRAC Led

#### WS1795

## Bretaris Genuair-EMEA/H/C/002706/ WS1795/0043 Eklira Genuair-EMEA/H/C/002211/ WS1795/0043

AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra, Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final report from study D6570R00002 listed as a category 3 study in the RMP. This is a descriptive, noninterventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected COPD medications. The RMP version 5.0 has also been submitted. As a consequence, the following safety concerns, listed as missing information in the RMP, are proposed to be removed: 'safety in patients with hepatic or severe renal impairment', 'safety in patients with benign hyperplasia or urinary retention' and 'use in pregnancy or lactation'." Request for Supplementary Information adopted Request for supplementary information adopted with a specific timetable.

PRAC Led

on 09.07.2020.

### WS1805

### Advagraf-EMEA/H/C/000712/WS1805/

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 53/98

### 0057

## Modigraf-EMEA/H/C/000954/WS1805/ 0035

Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, Lead PRAC Rapporteur: Ronan Grimes, PRAC-CHMP liaison: Jayne Crowe, "Submission of an updated RMP version 3 in order to add a non-interventional postauthorisation safety study related to the safety concerns of use during pregnancy and use during lactation. The two important potential risks, 'Exchangeability between the granule and capsule formulations of tacrolimus' for Modigraf and 'If administered accidentally either arterially or perivascularly, the reconstituted solution may cause irritation at the injection site' for Prograf concentrate for solution for infusion, are combined into the important identified risk 'Medication errors'. The RMP is being brought to EU RMP template revision 2." Request for Supplementary Information adopted

on 09.07.2020.

PRAC Led

#### WS1850

on 23.07.2020.

## Anoro Ellipta-EMEA/H/C/002751/ WS1850/0030 Laventair Ellipta-EMEA/H/C/003754/ WS1850/0033

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Peter Kiely, Lead PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, "To update the RMP completion of study WWE117397 "A Postauthorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting." As part of the assessment of EMEA/H/C/WS1761 the MAH was requested to update the RMP.

In addition, the MAH has amendment the RMP with the study 201038 "A Post authorisation Safety Observational Cohort Study to quantify the incidence of selected cardiovascular and cerebrovascular events in COPD patients using inhaled UMEC/VI combination or inhaled UMEC versus Tiotropium" as approved during procedure EMEA/H/C/PSA/S/0032.3." Request for Supplementary Information adopted Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 54/98

### **B.5.5. CHMP-CAT assessed procedures**

# Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0025, Orphan, ATMP

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 23.07.2020, 17.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### **B.5.6. CHMP-PRAC-CAT assessed procedures**

### **B.5.7. PRAC assessed ATMP procedures**

### B.5.8. Unclassified procedures and worksharing procedures of type I variations

## WS1796/G Aflunov-EMEA/H/C/002094/WS1796/ 0059/G Foclivia-EMEA/H/C/001208/WS1796/ 0054/G

Seqirus S.r.I, Lead Rapporteur: Daniela MelchiorriRequest for Supplementary Information adopted on 02.07.2020.

Request for supplementary information adopted with a specific timetable.

#### WS1806

Juluca-EMEA/H/C/004427/WS1806/0026 Tivicay-EMEA/H/C/002753/WS1806/0060 Triumeq-EMEA/H/C/002754/WS1806/ 0081

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson

Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1809/G

Fluenz Tetra-EMEA/H/C/002617/ WS1809/0099/G Pandemic influenza vaccine H5N1

AstraZeneca-EMEA/H/C/003963/ WS1809/0033/G

AstraZeneca AB, Lead Rapporteur: Christophe Focke

Opinion adopted on 09.07.2020.

Positive Opinion adopted by consensus on 09.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1812

Infanrix hexa-EMEA/H/C/000296/ WS1812/0277

GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 23.07.2020. Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

## WS1816

Nuwiq-EMEA/H/C/002813/WS1816/0035

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP

EMA/CHMP/566439/2020 Page 55/98

## Vihuma-EMEA/H/C/004459/WS1816/ 0017

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 02.07.2020.

Request for Supplementary Information adopted on 28.05.2020.

Members were in agreement with the CHMP recommendation.

#### WS1825

## Segluromet-EMEA/H/C/004314/WS1825/ 0011

Steglatro-EMEA/H/C/004315/WS1825/ 0012

Steglujan-EMEA/H/C/004313/WS1825/ 0014

Merck Sharp & Dohme B.V., Lead Rapporteur: Kristina Dunder, "To update section 4.4 of the SmPC and section 2 of the Package Leaflet to comply with the revised Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal products for human use" for sodium."

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1827

### Keppra-EMEA/H/C/000277/WS1827/0188

UCB Pharma S.A., Lead Rapporteur: Koenraad Norga, "To update the PI following outcome of LEG-087. Section 4.4 of the SmPC: Special warnings and precautions for use was updated as follows:

- Addition of warning "seizure worsening" Section 4.8 Undesirable effects was updated as follows:
- Addition of ADR "seizures aggravated"
  The PL was also updated accordingly.
  The requested worksharing procedure proposed amendments to the Summary of Product
  Characteristics and Package Leaflet."

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1829

Aldurazyme-EMEA/H/C/000477/WS1829/ 0076

Evoltra-EMEA/H/C/000613/WS1829/0070 Fasturtec-EMEA/H/C/000331/WS1829 /0059

Rilutek-EMEA/H/C/000109/WS1829/0064 Zaltrap-EMEA/H/C/002532/WS1829/0057

sanofi-aventis groupe, Lead Rapporteur: Filip Josephson, "To update the product information with respect to the excipient Sodium in accordance with the updated annex to the European Commission guideline on `Excipients

Request for supplementary information adopted with a specific timetable.

EMA/CHMP/566439/2020 Page 56/98

in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668). The Product Information was also brought in line with the latest QRD template. Finally, the MAH took the opportunity to implement an update of the phone number for the local representative for Italy, Malta Netherlands and Slovakia in section 6 of the Package Leaflet for all products." Request for Supplementary Information adopted on 23.07.2020.

#### WS1835

### Glyxambi-EMEA/H/C/003833/WS1835/ 0030

## Jentadueto-EMEA/H/C/002279/WS1835/ 0056

### Trajenta-EMEA/H/C/002110/WS1835/ 0042

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege

Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1839/G

## Hexacima-EMEA/H/C/002702/WS1839/ 0103/G

## Hexaxim-EMEA/H/W/002495/WS1839/ 0108/G

## Hexyon-EMEA/H/C/002796/WS1839/ 0107/G

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1841

## Ryzodeg-EMEA/H/C/002499/WS1841/ 0039

## Tresiba-EMEA/H/C/002498/WS1841/0045 Xultophy-EMEA/H/C/002647/WS1841/ 0036

Novo Nordisk A/S, Lead Rapporteur: Kristina

Dunder

Dunder

Opinion adopted on 02.07.2020.

Positive Opinion adopted by consensus on 02.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1843/G

## Ebymect-EMEA/H/C/004162/WS1843/ 0048/G

## Xigduo-EMEA/H/C/002672/WS1843/ 0058/G

AstraZeneca AB, Lead Rapporteur: Kristina

Opinion adopted on 23.07.2020.

Positive Opinion adopted by consensus on 23.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 57/98

#### WS1847

## Nuwiq-EMEA/H/C/002813/WS1847/0036 Vihuma-EMEA/H/C/004459/WS1847/ 0018

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "To adapt the SmPC, labelling and package leaflet and Annex II according to the currently valid Core SmPC guideline for human plasma derived and recombinant coagulation factor VIII products rev. 3 (EMA/CHMP/BPWP/1619/1999 Rev. 3). Moreover, the MAH took the opportunity to align the PI to QRD template version 10.1. In addition, more minor linguistic amendments like editorial changes in wording, typographical errors or punctuation mistakes were performed. Finally, section 4.4 of the SmPC and the PIL were updated in relation to sodium content following the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)." Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### WS1855/G

## Bretaris Genuair-EMEA/H/C/002706/ WS1855/0044/G Eklira Genuair-EMEA/H/C/002211/

Eklira Genuair-EMEA/H/C/002211/ WS1855/0044/G

AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

## WS1856/G

## Brimica Genuair-EMEA/H/C/003969/ WS1856/0030/G Duaklir Genuair-EMEA/H/C/003745/ WS1856/0030/G

AstraZeneca AB, Lead Rapporteur: Ewa

Balkowiec Iskra

Request for Supplementary Information adopted on 23.07.2020.

Request for supplementary information adopted with a specific timetable.

#### WS1860

## Aflunov-EMEA/H/C/002094/WS1860/ 0061

## Foclivia-EMEA/H/C/001208/WS1860/ 0057

Seqirus S.r.I, Lead Rapporteur: Daniela

Melchiorri

Opinion adopted on 16.07.2020.

Positive Opinion adopted by consensus on 16.07.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMA/CHMP/566439/2020 Page 58/98

### B.5.9. Information on withdrawn type II variation / WS procedure

## IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0042, Orphan

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of section 4.2 of the SmPC to update the posology by expanding the once weekly routine prophylaxis regimen of IDELVION from 35-to 50 IU/kg to 25- to 50 IU/kg."

The MAH withdrew the procedure on 13.07.2020.

## Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0010/G

Portola Netherlands B.V., Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted

on 28.05.2020, 17.04.2020.

Withdrawal request submitted on 09.07.2020.

The MAH withdrew the procedure on 09.07.2020.

### B.5.10. Information on type II variation / WS procedure with revised timetable

#### **B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION**

## **B.6.1.** Start of procedure for New Applications: timetables for information

#### abiraterone acetate - EMEA/H/C/005649

Treatment of prostate cancer in adult men

# lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731, Orphan, ATMP

Celgene Europe BV, treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

### **Accelerated review**

### dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

### imatinib - EMEA/H/C/005595

treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), eosinophilic leukaemia (CEL), Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), and unresectable dermatofibrosarcoma

EMA/CHMP/566439/2020 Page 59/98

protuberans (DFSP)

## setmelanotide - EMEA/H/C/005089, Orphan

### **Accelerated review**

TMC Pharma (EU) Limited, Treatment of obesity and the control of hunger associated with deficiencies in the leptin-melanocortin pathway

### lenalidomide - EMEA/H/C/005734

treatment of multiple myeloma and Follicular lymphoma

### lenalidomide - EMEA/H/C/005729

treatment of multiple myeloma, myelodysplastic syndromes and follicular lymphoma.

## B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

## Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0026

Eurocept International B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "Extension application to introduce a new pharmaceutical form associated with new strength (350 mg/ml oral solution). The RMP (version 0.1) is updated in accordance."

## Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0028

Eurocept International B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "Extension application to introduce a new pharmaceutical form associated with new strength (500 mg film-coated tablets). The RMP (version 0.1) is updated in accordance."

## **B.6.3.** Restart of procedure - responses received to Day 120 List of Questions timetables: for information

### duvelisib - EMEA/H/C/005381, Orphan

Verastem Europe GmbH, Treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and relapsed or refractory follicular lymphoma (FL) List of Questions adopted on 30.04.2020.

## Cosentyx - secukinumab - EMEA/H/C/003729/X/0059

Novartis Europharm Limited, Rapporteur: Tuomo Lapveteläinen, PRAC Rapporteur: Eva A.

EMA/CHMP/566439/2020 Page 60/98

Segovia, "Extension application to add a new strength of 300 mg (in 2 ml) solution for injection (in pre-filled syringe and pre-filled pen).

The RMP (version 7.0) is updated in accordance."

List of Questions adopted on 28.05.2020.

#### inclisiran - EMEA/H/C/005333

treatment for primary hypercholesterolaemia or mixed dyslipidaemia
List of Questions adopted on 28.05.2020.
Letter from the applicant dated 12.07.2020 requesting a clock stop extension. For information.

### glucagon - EMEA/H/C/005391

for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus
List of Questions adopted on 30.04.2020.

## pemigatinib - EMEA/H/C/005266, Orphan

Incyte Biosciences Distribution B.V., treatment of locally advanced or metastatic cholangiocarcinoma
List of Questions adopted on 30.04.2020.

## Plegridy - peginterferon beta-1a - EMEA/H/C/002827/X/0056

Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a new route of administration (intramuscular use) for the 125 µg solution for injection." List of Questions adopted on 25.06.2020.

## netarsudil / latanoprost - EMEA/H/C/005107

reduction of elevated intraocular pressure List of Questions adopted on 30.04.2020.

## SIRTURO - bedaquiline - EMEA/H/C/002614/X/0036/G, Orphan

Janssen-Cilag International NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to add a new strength (20 mg tablets) grouped with a type II variation (C.I.6) to extend the existing Sirturo indication to include paediatric patients aged from 5 years to less than 18 years of age and weighing more than 15 kg, based on the results of the Week 24 analysis of Cohort 2 (paediatric

EMA/CHMP/566439/2020 Page 61/98

subjects aged ≥5 to <12 years) of study TMC207-C211. Sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 and the Product Leaflet are updated to support the extended indication. The RMP (version 4.4) is updated in accordance." List of Questions adopted on 30.04.2020.

## TEPADINA - thiotepa - EMEA/H/C/001046/X/0036

ADIENNE S.r.I., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Extension application to introduce a new pharmaceutical form associated with new strength (400 mg powder and solvent for solution for infusion)." List of Questions adopted on 26.03.2020.

# Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0008/G

Chiesi Farmaceutici S.p.A., Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser, "Extension application to introduce a new strength (172  $\mu$ g / 5  $\mu$ g / 9  $\mu$ g) grouped with a type II variation (C.I.6.a) to add a new indication (asthma). The RMP (version 6.1) is updated in accordance." List of Questions adopted on 26.03.2020. Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

### icosapent ethyl - EMEA/H/C/005398

indicated to reduce cardiovascular risk as an adjunct to statin therapy.
List of Questions adopted on 26.03.2020.

### baloxavir marboxil - EMEA/H/C/004974

Treatment of influenza in patients aged 12 and above, including patients at high risk of developing influenza-related complications and for post-exposure prophylaxis of influenza in individuals aged 12 List of Questions adopted on 26.03.2020.

### **B.6.4.** Annual Re-assessments: timetables for adoption

## Qarziba - dinutuximab beta - EMEA/H/C/003918/S/0022, Orphan

EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur:

EMA/CHMP/566439/2020 Page 62/98

## B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

### Alprolix - eftrenonacog alfa -

### EMEA/H/C/004142/R/0032, Orphan

Swedish Orphan Biovitrum AB (publ), Rapporteur: Andrea Laslop, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski

## Coagadex - human coagulation factor X - EMEA/H/C/003855/R/0031, Orphan

BPL Bioproducts Laboratory GmbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

## Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/R/0051

Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins

## Empliciti - elotuzumab -

### EMEA/H/C/003967/R/0024

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Brigitte Keller-Stanislawski

## Lonsurf - trifluridine / tipiracil - EMEA/H/C/003897/R/0020

Les Laboratoires Servier, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

## Neofordex - dexamethasone - EMEA/H/C/004071/R/0016

Laboratoires CTRS, Rapporteur: Ondřej Slanař, Co-Rapporteur: Daniela Melchiorri, PRAC

Rapporteur: Tiphaine Vaillant

## OCALIVA - obeticholic acid - EMEA/H/C/004093/R/0023, Orphan

Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan

## Polivy - polatuzumab vedotin -

### EMEA/H/C/004870/R/0003, Orphan

Roche Registration GmbH, Rapporteur:

Alexandre Moreau, Co-Rapporteur: Jan Mueller-

EMA/CHMP/566439/2020 Page 63/98

Berghaus, PRAC Rapporteur: Annika Folin

### Taltz - ixekizumab -

### EMEA/H/C/003943/R/0039

Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

### Uptravi - selexipag -

### EMEA/H/C/003774/R/0030

Janssen-Cilag International N.V., Rapporteur:

Martina Weise, Co-Rapporteur: Maria

Concepcion Prieto Yerro, PRAC Rapporteur:

Adrien Inoubli

### Wakix - pitolisant -

### EMEA/H/C/002616/R/0024, Orphan

Bioprojet Pharma, Rapporteur: Alexandre Moreau, Co-Rapporteur: Outi Mäki-Ikola, PRAC

Rapporteur: Kirsti Villikka

### **B.6.6. VARIATIONS - START OF THE PROCEDURE**

**Timetables for adoption** provided that the validation has been completed.

#### B.6.7. Type II Variations scope of the Variations: Extension of indication

## Benlysta - belimumab - EMEA/H/C/002015/II/0080

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Extension of indication to include treatment of lupus nephritis for belimumab; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38 of the RMP has also been submitted."

## BiResp Spiromax - budesonide / formoterol - EMEA/H/C/003890/II/0033/G

Teva Pharma B.V., Duplicate, Duplicate of DuoResp Spiromax, Rapporteur: John Joseph Borg, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Hans Christian Siersted, "Type II variation – C.I.6.a. - Extension of indication to include adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and longacting  $\beta 2$  adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting  $\beta 2$  adrenoceptor agonists; or in patients already adequately controlled on both

EMA/CHMP/566439/2020 Page 64/98

inhaled corticosteroids and long-acting  $\beta 2$  adrenoceptor agonists. The proposed extension to the indication is based upon data from the literature.

As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make an administrative update to the Greek, Islandic, Irish and Maltese local representatives phone numbers in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1. An updated RMP version 3.0 was submitted as part of the application.

Type IB variation - C.I.z other – updates of sections 4.2, 5.1 and 5.2 of the SmPC to update the information on paediatric data and section 4.4 of the SmPC to remove the warning regarding the risk of growth retardation in children and the guidance on how to address this risk as agreed during the assessment of the duplicate Budesonide/Formoterol Teva Pharma B.V. (EMEA/H/C/004882), which was approved in Jan 2020."

# DuoResp Spiromax - budesonide / formoterol - EMEA/H/C/002348/II/0033/G

Teva Pharma B.V., Rapporteur: John Joseph Borg, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Hans Christian Siersted, "Type II variation - C.I.6.a. - Extension of indication to include adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and longacting \( \beta \) adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting B2 adrenoceptor agonists; or in patients already adequately controlled on both inhaled corticosteroids and long-acting \( \beta \)2 adrenoceptor agonists. The proposed extension to the indication is based upon data from the literature.

As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make an administrative update to the Greek, Islandic, Irish and Maltese local representatives

EMA/CHMP/566439/2020 Page 65/98

phone numbers in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1. An updated RMP version 3.0 was submitted as part of the application.

Type IB variation - C.I.z other – updates of sections 4.2, 5.1 and 5.2 of the SmPC to update the information on paediatric data and section 4.4 of the SmPC to remove the warning regarding the risk of growth retardation in children and the guidance on how to address this risk as agreed during the assessment of the duplicate Budesonide/Formoterol Teva Pharma B.V. (EMEA/H/C/004882), which was approved in Jan 2020."

## Keytruda - pembrolizumab - EMEA/H/C/003820/II/0091

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "C.I.6 -Extension of indication to include first-line treatment of unresectable or metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda based on the results from KEYNOTE-177 (an international, randomised, open-label Phase 3 trial of pembrolizumab versus chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma). As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, a minor correction has been made in section 4.4, "Immune related endocrinopathies" subsection. Version 29.1 of the RMP has also been submitted."

## Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0047

Addmedica S.A.S., Rapporteur: Koenraad Norga, "Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional tolerance) in adults, adolescents and children older than 2 years suffering from sickle cell syndrome for Siklos; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

### Venclyxto - venetoclax -

EMA/CHMP/566439/2020 Page 66/98

### EMEA/H/C/004106/II/0030

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur:

Eva Jirsová, "Extension of indication for

Venclyxto (venetoclax) in combination with

Hypomethylating Agents (HMAs) or Low Dose

Cytarabine (LDAC) for the treatment of adult

patients with newly-diagnosed acute myeloid

leukaemia (AML) who are ineligible for intensive

chemotherapy. As a consequence, sections 4.2,

4.3, 4.4, 4.5, 4.7, 4.8, 5.1 and 5.2 of the SmPC

are updated. The Package Leaflet and RMP

version 6.1 are also updated accordingly."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation

(EC) 726/2004)

### B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

## AJOVY - fremanezumab -

EMEA/H/C/004833/II/0011

TEVA GmbH, Rapporteur: Jan Mueller-Berghaus

#### Bavencio - avelumab -

EMEA/H/C/004338/II/0020/G

Merck Europe B.V., Rapporteur: Filip Josephson

## Bemfola - follitropin alfa - EMEA/H/C/002615/II/0027

Gedeon Richter Plc., Rapporteur: Paula

Boudewina van Hennik

## Betaferon - interferon beta-1b -

EMEA/H/C/000081/II/0129

Bayer AG, Rapporteur: Martina Weise

### CRYSVITA - burosumab -

### EMEA/H/C/004275/II/0017, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Kristina

Dunder

## Dukoral - cholera vaccine (inactivated, oral) - EMEA/H/C/000476/II/0062/G

Valneva Sweden AB, Rapporteur: Kristina

Dunder

### Efavirenz/Emtricitabine/Tenofovir

disoproxil Zentiva - efavirenz /

emtricitabine / tenofovir disoproxil -

EMEA/H/C/004250/II/0019

Zentiva k.s., Generic, Generic of Atripla,

Rapporteur: Tomas Radimersky

EMA/CHMP/566439/2020 Page 67/98

## Extavia - interferon beta-1b - EMEA/H/C/000933/II/0102

Novartis Europharm Limited, Informed Consent of Betaferon, Rapporteur: Martina Weise

### Eylea - aflibercept -

### EMEA/H/C/002392/II/0062/G

Bayer AG, Rapporteur: Alexandre Moreau

# Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0002

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

## Gardasil - human papillomavirus vaccine

[types 6, 11, 16, 18] (recombinant,

adsorbed) - EMEA/H/C/000703/II/0086

MSD Vaccins, Rapporteur: Kristina Dunder

## Herzuma - trastuzumab - EMEA/H/C/002575/II/0031

Celltrion Healthcare Hungary Kft., Rapporteur:

Jan Mueller-Berghaus

## Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0117

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

### Idacio - adalimumab -

## EMEA/H/C/004475/II/0006/G

Fresenius Kabi Deutschland GmbH, Rapporteur:

Johann Lodewijk Hillege

## IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0044/G, Orphan

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

## Imraldi - adalimumab -

### EMEA/H/C/004279/II/0037/G

Samsung Bioepis NL B.V., Rapporteur: Outi

Mäki-Ikola

## IMVANEX - smallpox vaccine (live modified

vaccinia virus Ankara) -

### EMEA/H/C/002596/II/0050

Bavarian Nordic A/S, Rapporteur: Jan Mueller-

Berghaus

## Invokana - canagliflozin -

### EMEA/H/C/002649/II/0052/G

Janssen-Cilag International NV, Rapporteur:

Martina Weise

### LIBTAYO - cemiplimab -

EMA/CHMP/566439/2020 Page 68/98

### EMEA/H/C/004844/II/0010/G

Regeneron Ireland Designated Activity Company

(DAC), Rapporteur: Sinan B. Sarac

### LUTATHERA - lutetium (177Lu)

oxodotreotide -

## EMEA/H/C/004123/II/0021/G, Orphan

Advanced Accelerator Applications, Rapporteur:

Janet Koenig

#### MabThera - rituximab -

### EMEA/H/C/000165/II/0176

Roche Registration GmbH, Rapporteur: Sinan B.

Sarac

### Movymia - teriparatide -

### EMEA/H/C/004368/II/0020

STADA Arzneimittel AG, Duplicate, Duplicate of

Terrosa, Rapporteur: Milena Stain

### Nepexto - etanercept -

### EMEA/H/C/004711/II/0002

Mylan IRE Healthcare Limited, Rapporteur:

Martina Weise

### NovoMix - insulin aspart -

### EMEA/H/C/000308/II/0105

Novo Nordisk A/S, Rapporteur: Kristina Dunder

### Nucala - mepolizumab -

## EMEA/H/C/003860/II/0033

GlaxoSmithKline Trading Services Limited,

Rapporteur: Peter Kiely

## Oncaspar - pegaspargase -

### EMEA/H/C/003789/II/0035

Les Laboratoires Servier, Rapporteur: Alexandre

Moreau

### Ondexxya - andexanet alfa -

### EMEA/H/C/004108/II/0012/G

Portola Netherlands B.V., Rapporteur: Jan

Mueller-Berghaus

## Pergoveris - follitropin alfa / lutropin alfa -

### EMEA/H/C/000714/II/0071

Merck Europe B.V., Rapporteur: Kirstine Moll

Harboe

### Polivy - polatuzumab vedotin -

### EMEA/H/C/004870/II/0002/G, Orphan

Roche Registration GmbH, Rapporteur:

Alexandre Moreau

### Posaconazole Accord - posaconazole -

## EMEA/H/C/005005/II/0002

EMA/CHMP/566439/2020 Page 69/98

Accord Healthcare S.L.U., Generic, Generic of Noxafil, Rapporteur: Kolbeinn Gudmundsson

## Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0164

CSL Behring GmbH, Rapporteur: Jan Mueller-

Berghaus

## Repatha - evolocumab - EMEA/H/C/003766/II/0044

Amgen Europe B.V., Rapporteur: Johann

Lodewijk Hillege

## Simponi - golimumab - EMEA/H/C/000992/II/0095

Janssen Biologics B.V., Rapporteur: Kristina

Dunder

## Strensiq - asfotase alfa -

### EMEA/H/C/003794/II/0046, Orphan

Alexion Europe SAS, Rapporteur: Daniela

Melchiorri

### Terrosa - teriparatide -

### EMEA/H/C/003916/II/0018

Gedeon Richter Plc., Rapporteur: Milena Stain

### Trepulmix - treprostinil sodium -

### EMEA/H/C/005207/II/0002/G, Orphan

SciPharm Sarl, Rapporteur: Johann Lodewijk

Hillege

#### Trogarzo - ibalizumab -

### EMEA/H/C/004961/II/0008

Theratechnologies Europe Limited, Rapporteur:

Johann Lodewijk Hillege

### Yellox - bromfenac -

## EMEA/H/C/001198/II/0025

Bausch Health Ireland Limited, Rapporteur:

Kirstine Moll Harboe

### WS1838

#### Infanrix hexa-

### EMEA/H/C/000296/WS1838/0279

GlaxoSmithkline Biologicals SA, Lead

Rapporteur: Christophe Focke

### WS1865

Levemir-EMEA/H/C/000528/WS1865/

nnaa

Ryzodeg-EMEA/H/C/002499/WS1865/

0040

Tresiba-EMEA/H/C/002498/WS1865/0046

Xultophy-EMEA/H/C/002647/WS1865/

EMA/CHMP/566439/2020 Page 70/98

### 0037

Novo Nordisk A/S, Lead Rapporteur: Kristina

Dunder

#### WS1866

Actraphane-EMEA/H/C/000427/WS1866/

0084

Actrapid-EMEA/H/C/000424/WS1866/

0077

Insulatard-EMEA/H/C/000441/WS1866/

0082

Mixtard-EMEA/H/C/000428/WS1866/

0085

Protaphane-EMEA/H/C/000442/WS1866/

0081

Novo Nordisk A/S, Lead Rapporteur: Kirstine

Moll Harboe

### WS1884

Nuwiq-EMEA/H/C/002813/WS1884/0037

Vihuma-EMEA/H/C/004459/WS1884/

0019

Octapharma AB, Lead Rapporteur: Jan Mueller-

Berghaus

#### WS1888/G

Blitzima-EMEA/H/C/004723/WS1888/

0033/G

Ritemvia-EMEA/H/C/004725/WS1888/

0033/G

Truxima-EMEA/H/C/004112/WS1888/

0036/G

Celltrion Healthcare Hungary Kft., Lead

Rapporteur: Sol Ruiz

### WS1889/G

M-M-RVAXPRO-EMEA/H/C/000604/

WS1889/0101/G

ProQuad-EMEA/H/C/000622/WS1889/

0141/G

MSD Vaccins, Lead Rapporteur: Jan Mueller-

Berghaus

## B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

## Abilify - aripiprazole -

### EMEA/H/C/000471/II/0136/G

Otsuka Pharmaceutical Netherlands B.V.,

Rapporteur: Bruno Sepodes, "Update of the

product information and the Company Core

Data Sheet (CCDS) due to new safety data.

The applicant used the opportunity to revise the

EMA/CHMP/566439/2020 Page 71/98

wording for "Akathesia" in the package leaflet for a better differentiation between akathisia and restless leg syndrome (adaption to Abilify Maintena)."

## Abilify Maintena - aripiprazole - EMEA/H/C/002755/II/0037

Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Bruno Sepodes, "to update the product information with "DRESS" as new identified ADR in section 4.8 of the SmPC and subsequently in section 4 of the package leaflet according to the current CCDS version."

## BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0164

Pfizer Europe MA EEIG, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the SmPC to remove reference to the severity of the disease pertaining to the prophylaxis regimen. In addition, the product information is being brought in line with the most recent QRD template version 10.1 and the MAH has taken the opportunity to include in section 4.4 of the SmPC an update related to the guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' regarding the sodium content."

## Benlysta - belimumab - EMEA/H/C/002015/II/0081

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to correct the result for the other efficacy endpoint of time to first severe flare over 52 weeks for the clinical study BEL114055 conducted in paediatric patients. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

# Bevespi Aerosphere - glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004245/II/0006

AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'Urinary Tract Infection' (UTI) to the list of adverse drug reactions (ADRs) with frequency common, based on final results from study ETHOS (PT010005): A randomized, doubleblind, multi-center, parallel-group study to assess the efficacy and safety of PT010 (budesonide/glycopyrronium/formoterol fumarate) relative to PT003

EMA/CHMP/566439/2020 Page 72/98

(glycopyrronium/formoterol fumarate, Bevespi Aerosphere) and PT009 (budesonide/fomorterol fumarate) on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD; and study KRONOS (PT010006): A randomized, doubleblind, parallel-group, 24-week, chronic-dosing, multi-center study to assess the efficacy and safety of PT010, PT003, and PT009 compared with Symbicort Turbuhaler as an active control in subjects with moderate to very severe COPD. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1."

## Constella - linaclotide - EMEA/H/C/002490/II/0049

Allergan Pharmaceuticals International Limited, Rapporteur: Martina Weise, "Update of section 4.6 of the SmPC based on the final results of Lactation study 1915-7/LIN-PK-01 listed as a category 3 study in the RMP; this is an openlabel, multiple-dose, milk-only lactation study in lactating women receiving linaclotide therapeutically. The Package Leaflet is updated accordingly."

## Cresemba - isavuconazole - EMEA/H/C/002734/II/0030, Orphan

Basilea Pharmaceutica Deutschland GmbH,
Rapporteur: Johann Lodewijk Hillege, "Update of
section 5.3 of the SmPC to update the
description of non-clinical information following
REC 002.2, based on final results from study B7855, a 2-year carcinogenicity studies in mice.
In this context, the safety margins described in
section 5.3 based on PK data provided with the
initial Cresemba MAA have been recalculated,
corrected and expressed based on exposure
(AUC; including free fraction) rather than based
on body surface area (only bound fraction)."

## CRYSVITA - burosumab - EMEA/H/C/004275/II/0018, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC to include the new ADR 'blood phosphorous increased', which includes the terms blood phosphorus increased and hyperphosphataemia, with a frequency of 'not known' based on postmarketing data. In addition, the MAH took the

EMA/CHMP/566439/2020 Page 73/98

opportunity to implement some editorial changes in SmPC section 4.8 and to include an age qualifier for the paediatric population (>1 year of age) for clarity. The Package Leaflet has been updated accordingly."

## Deltyba - delamanid - EMEA/H/C/002552/II/0045, Orphan

Otsuka Novel Products GmbH, Rapporteur:
Koenraad Norga, "Submission of the revised
final study report from the Hollow Fiber System
- Tuberculosis (HFS-TB) study listed as a
Specific Obligation in the Annex II of the
Product Information. This is a PK/PD study
carried out using the HFS-TB model and
designed to obtain the pharmacodynamic target
(PDT) of delamanid in the HFS-TB, using
Mycobacterium tuberculosis (Mtb) both under
log-phase growth conditions and under low pH
conditions (pH 5.8). The Annex II is updated
accordingly. This submission addresses the
post-authorisation measure SOB 009."

## ELOCTA - efmoroctocog alfa - EMEA/H/C/003964/II/0039

Swedish Orphan Biovitrum AB (publ), Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.8 and 5.1 of the SmPC to include the results of study 997HA306 in previously untreated patients which have previously been assessed as an Article 46 paediatric submission and renewal (EMEA/H/C/003964/R/0036)."

## Erleada - apalutamide - EMEA/H/C/004452/II/0007/G

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of the SmPC in order to add toxic epidermal necrolysis and decreased appetite to the list of adverse drug reactions (ADRs) with frequency 'not known' and 'very common' respectively based on cumulative safety reviews; the Package Leaflet is updated accordingly."

## EXJADE - deferasirox - EMEA/H/C/000670/II/0073

Novartis Europharm Limited, Rapporteur: Alexandre Moreau, "Submission of the final study report from the post-authorisation pharmacovigilance measure in the Annex II and in the RMP, a single-arm interventional Phase IV, evaluating the safety of paediatric patients with transfusional hemosiderosis treated with

EMA/CHMP/566439/2020 Page 74/98

deferasirox crushed film-coated tablets. This submission also serves to comply with Article 46 of the Regulation (EC) No 1901/2006 on medicinal products for paediatric use."

# Gardasil - human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - EMEA/H/C/000703/II/0087

MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the information of the duration of immunity following a 2-dose schedule of Gardasil based on the results from extension Protocol V501-167; this was a randomized clinical trial that assessed the immunogenicity of a 2-dose schedule of the qHPV in adolescents 9 to 13 years of age compared to a 3-dose schedule in young women 16 to 26 years of age.

In addition, the MAH is taking the opportunity to implement the following guidelines/template in the Product Information: Annex to the European Commission, Volume 2C, Guidelines, Medicinal products for human use, Safety, environment and information, Excipients in the label and package leaflet of medicinal products for human use, Rev 2, Mar 2018; and the Guideline on quality aspects included in the product information for vaccines for human use EMA/CHMP/BWP/133540/2017. Furthermore, the PI is being brought in line with the latest QRD template (version 10.1) and some minor editorial changes regarding the nomenclature for excipients have been implemented."

## Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) -EMEA/H/C/003852/II/0040

MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in relation to the post-marketing safety experience information, currently based on the post-marketing safety experience for the quadrivalent HPV vaccine, based on 4 years of post-marketing experience of the 9vHPV vaccine. The package leaflet is updated accordingly.

In addition, the MAH took the opportunity to update the wording regarding sodium according to the Guideline on quality aspects included in the product information for vaccines for human

EMA/CHMP/566439/2020 Page 75/98

use EMA/CHMP/BWP/133540/2017 and to implement an editorial change in sections 5.1 and 9 of the SmPC, and the package leaflet."

## Imnovid - pomalidomide - EMEA/H/C/002682/II/0038, Orphan

Celgene Europe BV, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC with information from a paediatric study in patients aged 4 to 18 years with recurrent or progressive high-grade glioma, medulloblastoma, ependymoma or diffuse intrinsic pontine glioma (DIPG) with primary location in the CNS."

## Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0012

Bayer AG, Rapporteur: Kirstine Moll Harboe, "Update of sections 4.8 and 5.1 of the SmPC to reflect the final study results of the long-term extension study 13024 (PROTECT VIII). This extension study is a category 3 study of the Jivi RMP (MEA-005). The PL is updated to reflect a change in the contact of a local representative."

## Lemtrada - alemtuzumab - EMEA/H/C/003718/II/0032

Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Kirstine Moll Harboe, "to update sections 4.4 and 4.8 of the SmPC to amend the existing warning and adverse drug reactions on Epstein-Barr virus (EBV) infections and EBV associated hepatitis, following safety evaluation report (SER). The package leaflet is updated accordingly."

## Lorviqua - Iorlatinib - EMEA/H/C/004646/II/0008

Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.4 and 4.8 to include the new term "Psychotic effects" as an adverse drug reaction (ADR) based on the cumulative review of the data available through Clinical Databases and Safety Database. The package leaflet has been updated accordingly."

## Luminity - perflutren - EMEA/H/C/000654/II/0033

Lantheus EU Limited, Rapporteur: Peter Kiely, "To update sections 4.4 and 6.1 of the SmPC on the hypersensitivity reactions for patients with a history of allergy to polyethylene glycol (PEG), following a signal identified from a review of the

EMA/CHMP/566439/2020 Page 76/98

existing and previously submitted safety information. The Package Leaflet is updated in accordance."

## MabThera - rituximab - EMEA/H/C/000165/II/0177

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Hans Christian Siersted, "Submission of the final Clinical Study Report for study WA29330 (Pemphix) in order to fulfil the Post Authorisation Measure in the Annex IID of the MabThera PI following 48 week safety follow up period of the study."

## Nerlynx - neratinib - EMEA/H/C/004030/II/0015

Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of section 5.1 of the SmPC in order to include final OS results from study 3144A2-3004-WW, a randomised, double-blind, placebo-controlled trial of neratinib after trastuzumab in women with early-stage HER-2/neu overexpressed/ amplified breast cancer."

## Nplate - romiplostim - EMEA/H/C/000942/II/0078

Amgen Europe B.V., Rapporteur: Maria
Concepcion Prieto Yerro, "Update of sections 4.8
and 5.1 of the SmPC to reflect the main results
from study 20101221 following the assessment
performed under Article 46 of Regulation
1901/2006. Study 20101221 is an open-label
trial to evaluate safety in children from 1 year of
age to less than 18 years of age with primary
ITP regardless of splenectomy status, including
a protocol supplement to implement bone
marrow evaluations."

## Slenyto - melatonin - EMEA/H/C/004425/II/0017

RAD Neurim Pharmaceuticals EEC SARL, Rapporteur: Kristina Dunder, "The update of the product information to reflect information from children treated with Circadin during the French RTU program and the known safety profile of Circadin authorised for adults."

## SomaKit TOC - edotreotide - EMEA/H/C/004140/II/0015, Orphan

Advanced Accelerator Applications, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4, 4.5 and 4.6 of the SmPC in order to amend an existing warning extending the

EMA/CHMP/566439/2020 Page 77/98

period during which close contact with infants and pregnant women should be restricted, add information on interactions with glucocorticosteroids and extend the period during which breastfeeding should be interrupted. The Package Leaflet is updated accordingly. Additionally, the MAH took the opportunity to update the details of local representatives."

## Somavert - pegvisomant - EMEA/H/C/000409/II/0097

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to add a new warning on acromegaly control and adjustment of doses during pregnancy, include information on use during pregnancy and effects on fertility, as well as an update on the effects of the drug product on the early embryonic development and embryo-foetal development in pregnant rabbits, following international regulatory procedures outcomes and literature review. The MAH took the opportunity to make editorial changes to the Package Leaflet."

## Stocrin - efavirenz - EMEA/H/C/000250/II/0123

Merck Sharp & Dohme B.V., Duplicate, Duplicate of Sustiva, Rapporteur: Bruno Sepodes, "Update of sections 4.4 and 4.8 of the SmPC in order to add new warnings regarding late-onset neurotoxicity, including ataxia and encephalopathy, based on reviews of the published literature and MAH safety database; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial amendments."

## Sunosi - solriamfetol - EMEA/H/C/004893/II/0004

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Janet Koenig, "Submission of the results of the Environmental Risk Assessment Phase II risk assessment of solriamfetol."

## TAGRISSO - osimertinib - EMEA/H/C/004124/II/0037

AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of the SmPC in order to add cutaneous vasculitis to the list of adverse drug reactions (ADRs) with frequency ""uncommon"", based on the review of the

EMA/CHMP/566439/2020 Page 78/98

available safety data. In addition, the MAH took the opportunity of this variation to introduce minor editorial updates to the SmPC."

## Tasigna - nilotinib - EMEA/H/C/000798/II/0106

Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, "Update of the section "4.8 Undesirable effects" of the SmPC with 'Facial paralysis' with the frequency unknown. Section "4 possible side effects" of the package leaflet has been updated accordingly. The QRD template version 10.1 has been implemented as part of this PI update. The Annex III has been updated accordingly. Editorial changes have been made to the Annex II to follow the new QRD template."

## Tecentriq - atezolizumab - EMEA/H/C/004143/II/0047

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC in order to add headache, dry skin and blood creatinine increased to the list of adverse drug reactions (ADRs) for atezolizumab given as monotherapy identified in study WO29636. The MAH has taken this opportunity to update the frequencies of existing ADRs in section 4.8 subsections 'Summary of the safety profile' and 'Description of selected adverse reactions' to reflect the updated pool of patients for atezolizumab monotherapy. Other minor corrections and editorial changes are being proposed. The package leaflet is updated accordingly."

## Tresiba - insulin degludec - EMEA/H/C/002498/II/0047

Novo Nordisk A/S, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the description of day-to-day variability in glucose-lowering effect further to assessment of post-authorisation measure LEG013. In addition, the MAH took the opportunity to make editorial corrections in section 5.2 of the SmPC."

## Uptravi - selexipag - EMEA/H/C/003774/II/0029

Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update of section 5.1 of the SmPC based on interim survival and safety data from study AC-065A303 a long-term single-arm,

EMA/CHMP/566439/2020 Page 79/98

open-label study to evaluate the safety and tolerability of selexipag / ACT-293987 in patients with Pulmonary Arterial Hypertension. In addition, the MAH took the opportunity to implement minor editorial changes and update the list of local representatives in the Package Leaflet."

#### Wakix - pitolisant -

### EMEA/H/C/002616/II/0023/G, Orphan

Bioprojet Pharma, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka, "Update of the product information based on new clinical data from the open-label, long-term treatment of EDS (with or without cataplexy) in narcolepsy P09-10 HARMONY III study, and the randomised, double-blind, placebo-controlled, drug abuse potential study (P16-02). The proposed update also includes results of a post-approval network meta-analysis which compares efficacy and safety of multiple treatments, multi-arm studies, and multi-criteria treatment decisions."

## Xarelto - rivaroxaban - EMEA/H/C/000944/II/0079

Bayer AG, Rapporteur: Kristina Dunder, "Submission of the final report from the CASSINI study, an interventional phase III study comparing 10 mg rivaroxaban to placebo in the prevention of venous thromboembolism in ambulatory cancer patients."

## Xeljanz - tofacitinib - EMEA/H/C/004214/II/0025

Pfizer Europe MA EEIG, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Liana Gross-Martirosyan, "To submit the final report from study A3921092, a long term, open-label extension study of tofacitinib for the treatment of adult patients with PsA, listed as a category 3 study in the RMP. An updated RMP version 11.1 has also been submitted. The MAH took also the opportunity to update the milestones for study A3921347 (US UC active surveillance study) in the RMP."

## XOSPATA - gilteritinib - EMEA/H/C/004752/II/0003, Orphan

Astellas Pharma Europe B.V., Rapporteur: Bjorg Bolstad, "C.I.4 Update of section 5.2 of the SmPC in order to update information about Transporter drug-drug

EMA/CHMP/566439/2020 Page 80/98

interactions based on final results from in vitro transporter studies identified as recommendations by CHMP (REC003) during the initial approval. In addition, the MAH took the opportunity to perform minor corrections and editorial changes in the PI."

#### WS1780

Glyxambi-EMEA/H/C/003833/WS1780/ 0027

Jardiance-EMEA/H/C/002677/WS1780/ 0049

Synjardy-EMEA/H/C/003770/WS1780/ 0046

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4. of the SmPC for Jardiance, Synjardi and Glyxambi in the SmPC subsection `Diabetic ketoacidosis' to reflect new data from 2 phase III interventional studies (EASE-2 1245.69 and EASE-3 1245.72) from the clinical trial program of empagliflozin as an adjunct to insulin in patients with type 1 diabetes."

#### WS1874/G

### Advagraf-EMEA/H/C/000712/WS1874/ 0058/G

Modigraf-EMEA/H/C/000954/WS1874/ 0036/G

Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "C.I.4

Update of sections 4.4 and 4.5 of the SmPC on the drug-drug interaction with CYP3A4 based on a comprehensive review of available data. Section 4.5 of the SmPC is also updated to include impact of direct acting antiviral therapy. C.I.z

Update of section 4.8 of the SmPC to add posterior reversible encephalopathy syndrome as an adverse reaction. The MAH took also the opportunity to change the SOC for febrile neutropenia from General disorders and administration site conditions to Blood and lymphatic system disorders in section 4.8 of the SmPC and to update the instruction for handling of the product in section 6.6 of the SmPC. The Package Leaflet is updated accordingly."

#### WS1883

Prezista-EMEA/H/C/000707/WS1883/ 0108

Rezolsta-EMEA/H/C/002819/WS1883/

EMA/CHMP/566439/2020 Page 81/98

### 0038

### Symtuza-EMEA/H/C/004391/WS1883/ 0025

Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.5 of the SmPC for Prezista, Rezolsta and Symtuza in order to include information on the interacion with Clopidogrel.

The MAH also takes the opportunity to make several editorial changes in the SmPC to include the sodium-free statement in section 4.4 and remove simeprevir, boceprevir and nelfinavir from section 4.5 from the list of interactions, as they are no longer marketed."

#### WS1893

Blitzima-EMEA/H/C/004723/WS1893/ 0034

Ritemvia-EMEA/H/C/004725/WS1893/ 0034

### Truxima-EMEA/H/C/004112/WS1893/ 0037

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, Lead PRAC Rapporteur: Hans Christian Siersted, "To provide CT-P10 3.4 final CSR along with the updated RMP (version 10.1) in compliance with the postauthorisation measure.

CT-P10 3.4 was a Phase 3, randomised, parallel-group, active-controlled, double-blind study to compare efficacy and safety between CT-P10 and Rituxan in patients with LTBFL. Study CTP10 3.4 was designed to demonstrate similarity of efficacy of CT-P10 to Rituxan in patients with LTBFL. The patients were randomised in a 1:1 ratio in a double-blinded fashion."

#### **B.6.10. CHMP-PRAC assessed procedures**

### Bosulif - bosutinib - EMEA/H/C/002373/II/0043

Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, "C.I.4, Update of section 5.3 of the SmPC in order to update non-clinical information following the final results from the six-month transgenic rasH2 mouse carcinogenicity study, listed as a category 3 in the current approved RMP version 4.5.; the RMP version 5.0 has also been submitted. The MAH took the opportunity to

EMA/CHMP/566439/2020 Page 82/98

implement changes resulting from the revision of the SmPC guideline on excipients, applied in the SmPC section 4.4 and in the Package Leaflet section 2."

# Defitelio - defibrotide - EMEA/H/C/002393/II/0048, Orphan

Gentium S.r.I., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of the SmPC section 5.1 based on the results of Defitelio Post Authorisation Safety Study DF VOD-2013-03-REG entitled: A multi-centre, multinational, prospective observational registry to collect safety and outcome data in patients diagnosed with severe hepatic VOD following hematopoietic stem cell transplantation (HSCT) and treated with Defitelio or supportive care (control group). Additionally, the Risk Management Plan v. 8 has been updated. In addition, the Marketing Authorisation Holder took the opportunity to:

- Update Sub-section Cardiac
   Electrophysiology in section 5.1 of Annex I
   (SmPC) to correct a typographical error;
- · Introduce other minor editorial and QRD updates throughout Annexes I-III;
- Change Annex IIIB in line with the excipients warning for medicinal products containing Sodium;
- · Update the RMP in line with PRAC recommendations, following approval of PBRER 12 (EMEA/H/C/PSUSA/00010086/201910), to update section SVII 2, Safety Concerns and Reclassification for removal of the Important Potential Risks and Missing Information from the RMP: Injection site reactions/infections, including septicaemia as a serious complication of these reactions/infections; Immunogenicity (generation of anti-nuclear antibodies); Use in patients with grade B-D GvHD; Use in patients with ethnic background other than Caucasian; use in patients >65 years of age and off-label use."

# NUBEQA - darolutamide - EMEA/H/C/004790/II/0002

Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser, "Update of section 5.1 of the SmPC in order to update efficacy information based on final OS results from study 17772 (ARAMIS) listed as a PAES in the Annex II; this is a multinational, randomised, double-

EMA/CHMP/566439/2020 Page 83/98

blind, placebo-controlled, phase III efficacy and safety study of darolutamide in men with highrisk non-metastatic castration-resistant prostate cancer; the Annex II is updated accordingly. The RMP version 1.1 has also been submitted."

# Orbactiv - oritavancin - EMEA/H/C/003785/II/0030

Menarini International Operations Luxembourg S.A., Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski, "Submission of the final report from 14-TMC-01, a Surveillance study investigation, listed as a category 3 study in the RMP, part of the global SENTRY Antimicrobial Surveillance Program platform to monitor the activity of oritavancin against Gram-positive clinical isolates collected from Europe and the US.

This application addresses PAM MEA 003.4, presenting the cumulative surveillance data from 2010 to 2019 (including the first 5-year post-approval period).

The RMP version 3.0 has also been submitted."

# Rubraca - rucaparib - EMEA/H/C/004272/II/0020

Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.2 and 5.2 of the SmPC in order to update the information on the use of rucaparib in patients with hepatic impairment based on final results from Part I of Study CO-338-078 listed as a category 3 study in the RMP; this is a phase 1, open-label, parallel group study to determine the pharmacokinetics, safety and tolerability of rucaparib in patients with an advanced solid tumour and either moderate hepatic impairment or normal hepatic function; the Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to make minor corrections in the SmPC, to update the list of local representatives in the Package Leaflet, and to bring the PI in line with the latest QRD template version 10.1 and excipient guideline."

# Rydapt - midostaurin - EMEA/H/C/004095/II/0014, Orphan

Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva,

EMA/CHMP/566439/2020 Page 84/98

#### "C.I.4

Update of sections 4.2, 4.4, and 5.1 of the SmPC in order to change posology recommendations and add Special warnings and precautions for use in Paediatric population following the occurrence of severe dose limiting toxicities (DLTs) in the paediatric study CPKC412A2218 which is currently on clinical hold. The study is part of the agreed PIP (EMEA-000780-PIP01-09-M05) for which a Request for Modification was submitted on 20-Apr-2020 . Section 5.1 of the SmPC and the Package Leaflet are updated accordingly. The RMP version 5.0 has also been submitted. In addition Novartis takes this opportunity to introduce minor editorial changes to align the PI to the updated QRD template version 10.1."

# Sivextro - tedizolid phosphate - EMEA/H/C/002846/II/0037

Merck Sharp & Dohme B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "Update of section 5.1 of the SmPC in order to update the description of the potential risk of emergence of drug resistance with tedizolid phosphate, based on final results from study Surveillance of Tedizolid Activity and Resistance (STAR) listed as a category 3 study in the RMP; this is a surveillance study established in January 2014 to monitor tedizolid susceptibility activity and emergence of resistance across the US, 11 European Union countries, Russia and Turkey.

# Xtandi - enzalutamide - EMEA/H/C/002639/II/0049

Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.7, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from study MDV3100-14 (PROSPER) listed as a PAES in the Annex II; this is a phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer; the Package Leaflet and Annex II are updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet,

EMA/CHMP/566439/2020 Page 85/98

make few editorial update and bring the PI in line with the latest QRD template version 10.1."

#### **B.6.11. PRAC assessed procedures**

#### PRAC Led

# Beovu - brolucizumab - EMEA/H/C/004913/II/0002

Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "C.I.4, Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation."

#### PRAC Led

# Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0092

GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "C.I.13: Submission of the final report from study V72\_380B listed as a category 3 PASS in the RMP. This is an observational study conducted by Public Health England (PHE) to assess Bexsero effectiveness and impact in infants in the UK upon introduction on the vaccine in the infant National Immnunization Program (NIP) administered at 2, 4 and 12 months of age. An updated RMP version 8.0 has also been submitted. This version includes the changes due to this variation and those due to a separate type II variation submitted in parallel to include the final report of an additional PASS V72\_820B"

#### PRAC Led

# Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0093

GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,

PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study V72\_82OB listed as a category 3 PASS in the RMP. This is an observational study on the safety of Bexsero in pregnant women and their offspring, the objective of the study was to

EMA/CHMP/566439/2020 Page 86/98

evaluate pregnancy outcomes among women immunized with the Bexsero vaccine within 30 days prior to the last menstrual period (LMP) or at any time during pregnancy. An updated RMP version 8.0 has also been submitted. This version includes the changes due to this variation and those due to a separate type II variation submitted in parallel to include the final report of an additional PASS V72 380B"

#### PRAC Led

# Conbriza - bazedoxifene - EMEA/H/C/000913/II/0052

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final clinical study report (CSR) for the Conbriza Non-Interventional EU Post Authorisation Safety Study (EU PASS) - Protocol B1781044. This final CSR relates to the Post Approval Measure EMEA/H/C/000913/MEA 012.12."

#### PRAC Led

# DaTSCAN - ioflupane (123I) - EMEA/H/C/000266/II/0060

GE Healthcare B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau,

"Submission of the first RMP"

#### PRAC Led

# Evoltra - clofarabine - EMEA/H/C/000613/II/0069

Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of the RMP (version 9.0) to reflect updated information regarding the Evoltra European Registry Programme and to remove all safety concerns from the list of important identified and potential risks and missing information to follow revised guidance in the good pharmacovigilance practice (GVP) Module V Rev.2."

#### PRAC Led

#### Iressa - gefitinib -

#### EMEA/H/C/001016/II/0033

AstraZeneca AB, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Filip Josephson, "Submission of an updated RMP version 11 in order to provide the

EMA/CHMP/566439/2020 Page 87/98

RMP in revision 2 as per the revised `Guideline on Good Pharmacovigilance Practices: Module V - Risk management systems (Rev. 2)' together with inclusion of RMP changes as per the commitments indicated in PSUSA procedure (EMEA/H/C/PSUSA/00001518/201807)"

#### PRAC Led

### Obizur - susoctocog alfa - EMEA/H/C/002792/II/0034

Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of a final report of the survey among Health Care Professionals to Assess their Knowledge on Dosing and Administration of OBIZUR (Susoctocog alfa) in 6 European Countries."

#### PRAC Led

# Orfadin - nitisinone - EMEA/H/C/000555/II/0074

Swedish Orphan Biovitrum International AB, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Daniela Melchiorri, "Submission of the final report from study Sobi.NTBC-005 listed as a category 3 study in the RMP. This is a non-interventional Post Authorization Safety Study (PASS) to evaluate long-term safety of Orfadin treatment in hypertyrosinemia type 1 (HT-1) patients in standard clinical care.The RMP version 5.3 has also been submitted."

#### PRAC Led

# XOSPATA - gilteritinib - EMEA/H/C/004752/II/0001, Orphan

Astellas Pharma Europe B.V., Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "C.I.13: Submission of a pooled analysis report from studies 2215-CL-0101 (Phase 1/2), 2215-CL-0102 (Phase 1), 2215-CL-0301, 2215-CL-9100 (phase 3) listed as "Other forms of routine pharmacovigilance activities in section III.1 of the RMP". This is a pooled analysis to characterize gilteritinibrelated differentiation syndrome, specifically incidence, observed signs and symptoms, duration, and response to intervention based on patient-level data from on-going trials in patients with acute myeloid leukemia."

#### PRAC Led

#### WS1810

EMA/CHMP/566439/2020 Page 88/98

### Juluca-EMEA/H/C/004427/WS1810/0028 Tivicay-EMEA/H/C/002753/WS1810/0061 Triumeq-EMEA/H/C/002754/WS1810/ 0082

ViiV Healthcare B.V., Lead PRAC Rapporteur:
Martin Huber, PRAC-CHMP liaison: Martina
Weise, "Submission of the final report from
study EuroSIDA (Study 201177) listed as a
category 3 study in the RMP. This is a
prospective observational cohort study to
monitor and compare the occurrence of
hypersensitivity reaction and hepatotoxicity in
patients receiving dolutegravir (with or without
abacavir) and other integrase inhibitors (with or
without abacavir)."

#### PRAC Led

#### WS1849

### Thymanax-EMEA/H/C/000916/WS1849/ 0045

### Valdoxan-EMEA/H/C/000915/WS1849/ 0047

Les Laboratoires Servier, Lead Rapporteur:
Bjorg Bolstad, Lead PRAC Rapporteur: Pernille
Harg, PRAC-CHMP liaison: Bjorg Bolstad,
"Submission of an updated RMP version 23.1 in
order to revise the safety concerns, important
identified and potential risks in line with the new
GVP module V. In addition, the completed
studies have been deleted and, as agreed in
LEG 031, the frequency of the educational
material distribution is updated to once a year."

#### PRAC Led

#### WS1861/G

### Kisplyx-EMEA/H/C/004224/WS1861/ 0037/G

### Lenvima-EMEA/H/C/003727/WS1861/ 0037/G

Eisai GmbH, Lead Rapporteur: Bart Van der Schueren, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final clinical study report (CSR) for Study E7080-G000-201 (Study 201) - To evaluate the long-term safety of lenvatinib in Medullary and Iodine-131 Refractory, Unresectable differentiated thyroid carcinoma (DTC), Stratified by Histology (MEA 001 for Lenvima; from initial MAA for Kisplyx). Submission of the final CSR for Study E7080-G000-303 (Study 303) - To evaluate long-term safety of lenvatinib in patients with RR-DTC

EMA/CHMP/566439/2020 Page 89/98

(radioiodine refractory differentiated thyroid cancer) in a randomized, double-blind, placebo-controlled Phase 3 study (MEA 004 for Lenvima; MEA 002 for Kisplyx).

Submission of an updated integrated summary of safety (ISS) including data from DTC subjects in Studies 201, 303 and E7080-J081-208 (Study 208) - the latter study was to determine the long-term safety profile of lenvatinib in Japanese patients with advanced thyroid cancer (Kisplyx REC from Study 208 variation (procedure EMEA/H/C/003727/II/0008) for Lenvima).

The RMP version 12 has also been submitted."

#### PRAC Led

#### WS1879

Cymbalta-EMEA/H/C/000572/WS1879/ 0084

Duloxetine Lilly-EMEA/H/C/004000/ WS1879/0021

#### Yentreve-EMEA/H/C/000545/WS1879/ 0069

Eli Lilly Nederland B.V., Duplicate, Duplicate of Ariclaim, Yentreve, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Ravon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "This worksharing variation is being submitted to present and discuss the results of Study F1J-MC-B034 Pregnancy Registry to meet the commitment made during the previous procedure No. EMEA/H/C/WS1527/G which received positive CHMP opinion on 25 July 2019. As a consequence of the submission of the F1J-MC-B034 Study Report, the Risk Management Plan (RMP) for duloxetine has been updated. The RMP for all Lilly duloxetine products are combined. The changes introduced are not

#### **B.6.12. CHMP-CAT assessed procedures**

specific to one product and are therefore the

same for all products."

# Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0003/G, Orphan, ATMP

AveXis EU Limited Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Johann Lodewijk Hillege

EMA/CHMP/566439/2020 Page 90/98

#### **B.6.13. CHMP-PRAC-CAT assessed procedures**

#### **B.6.14. PRAC assessed ATMP procedures**

#### B.6.15. Unclassified procedures and worksharing procedures of type I variations

#### WS1811

Olanzapine Glenmark-EMEA/H/C/001085/WS1811/0034 Olanzapine Glenmark Europe-EMEA/H/C/001086/WS1811/0031 Olazax-EMEA/H/C/001087/WS1811/0027 Olazax Disperzi-EMEA/H/C/001088/ WS1811/0029

Glenmark Arzneimittel GmbH, Generic, Generic of Olansek (SRD), Zyprexa, Zyprexa Velotab, Lead Rapporteur: Alexandre Moreau

Lead Rapportedi. Alexandre Morec

#### WS1853/G

Ebymect-EMEA/H/C/004162/WS1853/ 0049/G

Edistride-EMEA/H/C/004161/WS1853/

0040/G

Forxiga-EMEA/H/C/002322/WS1853/

0058/G

Xigduo-EMEA/H/C/002672/WS1853/

0059/G

AstraZeneca AB, Lead Rapporteur: Kristina

Dunder

### WS1857

Adrovance-EMEA/H/C/000759/WS1857/ 0042

FOSAVANCE-EMEA/H/C/000619/WS1857/ 0045

VANTAVO-EMEA/H/C/001180/WS1857/ 0032

Merck Sharp & Dohme B.V., Lead Rapporteur: Andrea Laslop, "To update section 4.4 of the SmPC for excipients lactose and sodium and section 2 of the Package Leaflet for the excipient sodium to comply with the updated Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use" (Revised March 2018) and corresponding Annex (Rev.01, 09Oct2017; Corr.1 19Nov2018).

Minor formatting changes and editorial changes to comply with the latest QRD template are also applied in the Product Information.

In addition, the MAH took the opportunity to

EMA/CHMP/566439/2020 Page 91/98

update the list of local representatives as follows:

- o The Netherlands for the 3 products
- o Belgium and Portugal for Adrovance and

#### Vantavo

o Luxembourg for Adrovance"

#### WS1859/G

Blitzima-EMEA/H/C/004723/WS1859/ 0032/G

Ritemvia-EMEA/H/C/004725/WS1859/ 0032/G

### Truxima-EMEA/H/C/004112/WS1859/ 0035/G

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, "To update section 4.1 and related SmPC sections, to add the extension of indication to include treatment of paediatric GPA/MPA patients to align the PI with the parent product MabThera which had this indication approved with procedure II-162. The Package Leaflet was updated accordingly.

To update section 4.1 and related SmPC sections, to add the extension of indication to include treatment of paediatric NHL patients to align the PI with the parent product MabThera which had this indication approved with procedure II-168. The Package Leaflet was updated accordingly.

To update sections 4.4 and 4.8 of the SmPC to add the Post-authorisation efficacy study (PAES) randomised phase 3 study without new additional clinical data required to align the PI with the parent product Mabthera which had this change approved with procedure II-169."

#### WS1864/G

Kivexa-EMEA/H/C/000581/WS1864/ 0086/G

Trizivir-EMEA/H/C/000338/WS1864/

0118/G

Ziagen-EMEA/H/C/000252/WS1864/

0113/G

ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race

#### WS1867/G

Rivastigmine 1A Pharma-EMEA/H/C/001181/WS1867/0029/G Rivastigmine Hexal-EMEA/H/C/001182/ WS1867/0030/G

Rivastigmine Sandoz-EMEA/H/C/001183/

EMA/CHMP/566439/2020 Page 92/98

#### WS1867/0031/G

Sandoz GmbH, Informed Consent of Exelon, Lead Rapporteur: Alexandre Moreau

#### WS1873/G

Filgrastim Hexal-EMEA/H/C/000918/ WS1873/0056/G Zarzio-EMEA/H/C/000917/WS1873/ 0057/G

Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege

#### WS1875/G

0042/G

Rixathon-EMEA/H/C/003903/WS1875/ 0042/G Riximyo-EMEA/H/C/004729/WS1875/

Sandoz GmbH, Duplicate, Duplicate of Rixathon, Lead Rapporteur: Jan Mueller-Berghaus, "To update sections 4.8, 5.1 and 5.2 of the SmPC following safety changes for the parent product Mabthera adopted during procedure II-169. To update sections 1, 2, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.5 and 8 of the SmPC following adoption of extension of indication to include the induction of remission in paediatric patients (aged  $\geq$  2 to <18 years old) with severe, active granulomatosis with polyangiitis (GPA) (Wegener's) and microscopic polyangiitis (MPA) for parent product Mabthera during procedure II-162. The PL was updated accordingly. To update sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC following adoption of extension of indication to include treatment of paediatric patients (aged ≥6 months to <18 years old) with previously untreated advanced stage diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature Bcell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL) in combination with chemotherapy for parent product MabThera during procedure II-168.

The Package Leaflet is updated accordingly. The MAH also took this opportunity to introduce minor editorial changes. Amongst these the MAH included in Annex III of the Product Information the text appearing on the peel-off label recently introduced for both, Rixathon and Riximyo."

#### WS1880

#### Lixiana-EMEA/H/C/002629/WS1880/0027

EMA/CHMP/566439/2020 Page 93/98

#### Roteas-EMEA/H/C/004339/WS1880/0015

Daiichi Sankyo Europe GmbH, Lead Rapporteur:

Maria Concepcion Prieto Yerro

#### WS1885/G

Silodosin Recordati-EMEA/H/C/004964/

WS1885/0005/G

Silodyx-EMEA/H/C/001209/WS1885/

0041/G

Urorec-EMEA/H/C/001092/WS1885/

0044/G

Recordati Ireland Ltd, Generic, Generic of Urorec, Lead Rapporteur: Margareta Bego

#### WS1894/G

Incresync-EMEA/H/C/002178/WS1894/

0032/G

Vipdomet-EMEA/H/C/002654/WS1894/

0028/G

Vipidia-EMEA/H/C/002182/WS1894/

0023/G

Takeda Pharma A/S, Lead Rapporteur: Johann

Lodewijk Hillege

#### WS1899/G

Elebrato Ellipta-EMEA/H/C/004781/

WS1899/0019/G

Temybric Ellipta-EMEA/H/C/005254/

WS1899/0007/G

Trelegy Ellipta-EMEA/H/C/004363/

WS1899/0016/G

GlaxoSmithKline Trading Services Limited, Lead

Rapporteur: Peter Kiely

#### WS1903

Actraphane-EMEA/H/C/000427/WS1903/

0085

Actrapid-EMEA/H/C/000424/WS1903/

0078

Insulatard-EMEA/H/C/000441/WS1903/

0083

Mixtard-EMEA/H/C/000428/WS1903/

0086

Protaphane-EMEA/H/C/000442/WS1903/

0082

Novo Nordisk A/S, Lead Rapporteur: Kirstine

Moll Harboe

#### WS1909

Humalog-EMEA/H/C/000088/WS1909/

**0183** 

Liprolog-EMEA/H/C/000393/WS1909/

0143

EMA/CHMP/566439/2020 Page 94/98

Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder, "To update sections 4.2, 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations on "Signal assessment report on cutaneous amyloidosis with insulin human(regular and NPH), insulin degludec, insulin aspart, insulin lispro, insulin detemir, insulin glargine, insulin glulisine and insulin porcine (class effect of insulin containing products) " (EPITT no 19499) adopted at the 17/04/2020 PRAC meeting. In addition, the MAH is taking the opportunity to make some corrections to the labelling specifically the pictures in the Liprolog instructions Information For Use and some typographic issues in the Icelandic, Danish and Norway, Patient Information Leaflet and Summary of Product Characteristic."

Hexacima-EMEA/H/C/002702/WS1872/ 0104/G Hexaxim-EMEA/H/W/002495/WS1872/ 0109/G Hexyon-EMEA/H/C/002796/WS1872/ 0108/G

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

EMA/CHMP/566439/2020 Page 95/98

#### **B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

- B.7.1. Yearly Line listing for Type I and II variations
- **B.7.2.** Monthly Line listing for Type I variations
- B.7.3. Opinion on Marketing Authorisation transfer (MMD only)
- B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)
- B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)
- **B.7.6.** Notifications of Type I Variations (MMD only)
- C. Annex C Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)
- D. Annex D Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)
- E. Annex E EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

- E.1. PMF Certification Dossiers:
- E.1.1. Annual Update
- E.1.2. Variations:
- E.1.3. Initial PMF Certification:
- E.2. Timetables starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

EMA/CHMP/566439/2020 Page 96/98

#### F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

### F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

## F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

#### G. ANNEX G

#### G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### G.2. Ongoing procedures

#### G.3. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

#### G.3.1. List of procedures concluding at 20-23 July 2020 CHMP plenary:

Ophi	thalmology	
1.	Treatment of non arteritic retinal artery occlusion	The CHMP denied eligibility to PRIME and adopted the critical summary report.
2.	Treatment of X-linked Retinitis Pigmentosa (XLRP)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Vaccines		
3.	(SME); Prevention of influenza in healthy adults aged 18–60 years	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Cardiovascular Diseases		
4.	Treatment of septic shock	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Onc	rology	
5.	(SME);Consolidation treatment in patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation	The CHMP denied eligibility to PRIME and adopted the critical summary report.
6.	ADP-A2M4; ATMP; Treatment of HLA-A*02 positive patients with inoperable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumour expresses the MAGE-A4 tumour antigen	The CHMP granted eligibility to PRIME and adopted the critical summary report
Haei	matology - Hemostaseology	
7.	<b>Bomedemstat (IMG-7289)</b> , (SME); Treatment of myelofibrosis	The CHMP granted eligibility to PRIME and adopted the critical summary report

EMA/CHMP/566439/2020 Page 97/98

G.3.2. List of procedures starting in July 2020 for September 2020 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes - e-mail address

EMA/CHMP/566439/2020 Page 98/98